<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25144393</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1473-558X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neuroreport</Title>
                <ISOAbbreviation>Neuroreport</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dynamics of sodium channel Nav1.5 expression in astrocytes in mouse models of multiple sclerosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Astrocytes actively participate in the response of the central nervous system to injury, including in multiple sclerosis. Astrocytes can play both beneficial and detrimental roles in response to neuroinflammation; however, in extreme cases, astrogliosis can result in the formation of a glial scar, which can impede the regeneration of injured neurons. Although astrocytes do not express the voltage-gated sodium channel Nav1.5 in the nonpathological human brain, they exhibit robust upregulation of Nav1.5 within acute and chronic multiple sclerosis lesions. Recent work has indicated that Nav1.5 contributes to the pathways that regulate glial scar formation in vitro through modulation of intracellular Ca levels. However, the temporal dynamics of astrocytic Nav1.5 channel expression in response to neuroinflammatory pathologies has not been investigated. We examined astrocytes from mice with monophasic and chronic-relapsing (CR) experimental autoimmune encephalomyelitis (EAE) by immunohistochemical analysis to determine whether Nav1.5 is expressed in these cells, and whether the expression correlates with the severity of disease and/or phases of relapse and remission. Our results demonstrate that Nav1.5 is upregulated in astrocytes in situ in a temporal manner that correlates with disease severity in both monophasic and CR EAE. Further, in CR EAE, Nav1.5 expression is upregulated during relapses and subsequently attenuated during periods of remission. These observations are consistent with the suggestion that Nav1.5 can play a role in the response of astrocytes to inflammatory pathologies in the central nervous system and suggest Nav1.5 may be a potential therapeutic target to modulate reactive astrogliosis in vivo.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Pappalardo</LastName>
                    <ForeName>Laura W</ForeName>
                    <Initials>LW</Initials>
                    <Affiliation>aDepartment of Neurology, Center for Neuroscience and Regeneration Research, Yale University School of Medicine, New Haven bRehabilitation Research Center, VA Connecticut Healthcare System, West Haven, Connecticut, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Shujun</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Black</LastName>
                    <ForeName>Joel A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author>
                    <LastName>Waxman</LastName>
                    <ForeName>Stephen G</ForeName>
                    <Initials>SG</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neuroreport</MedlineTA>
            <NlmUniqueID>9100935</NlmUniqueID>
            <ISSNLinking>0959-4965</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WNR.0000000000000249</ArticleId>
            <ArticleId IdType="pubmed">25144393</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144390</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2041-1723</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Nature communications</Title>
                <ISOAbbreviation>Nat Commun</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High susceptibility to fatty liver disease in two-pore channel 2-deficient mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4699</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms5699</ELocationID>
            <Abstract>
                <AbstractText>Endolysosomal organelles play a key role in trafficking, breakdown and receptor-mediated recycling of different macromolecules such as low-density lipoprotein (LDL)-cholesterol, epithelial growth factor (EGF) or transferrin. Here we examine the role of two-pore channel (TPC) 2, an endolysosomal cation channel, in these processes. Embryonic mouse fibroblasts and hepatocytes lacking TPC2 display a profound impairment of LDL-cholesterol and EGF/EGF-receptor trafficking. Mechanistically, both defects can be attributed to a dysfunction of the endolysosomal degradation pathway most likely on the level of late endosome to lysosome fusion. Importantly, endolysosomal acidification or lysosomal enzyme function are normal in TPC2-deficient cells. TPC2-deficient mice are highly susceptible to hepatic cholesterol overload and liver damage consistent with non-alcoholic fatty liver hepatitis. These findings indicate reduced metabolic reserve of hepatic cholesterol handling. Our results suggest that TPC2 plays a crucial role in trafficking in the endolysosomal degradation pathway and, thus, is potentially involved in the homoeostatic control of many macromolecules and cell metabolites.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Grimm</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Holdt</LastName>
                    <ForeName>Lesca M</ForeName>
                    <Initials>LM</Initials>
                    <Affiliation>1] Institute of Laboratory Medicine-University Hospital Munich, 81377 Munich, Germany [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Cheng-Chang</ForeName>
                    <Initials>CC</Initials>
                    <Affiliation>1] Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hassan</LastName>
                    <ForeName>Sami</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>1] Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>M??ller</LastName>
                    <ForeName>Christoph</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pharmacy, Ludwig-Maximilians-Universit??t M??nchen, 81377 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>J??rs</LastName>
                    <ForeName>Simone</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>2nd Department of Internal Medicine, Klinikum rechts der Isar, Technical University of Munich, 81675 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cuny</LastName>
                    <ForeName>Hartmut</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>1] Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany [2] [3].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kissing</LastName>
                    <ForeName>Sandra</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Institute of Biochemistry, Christian-Albrechts-Universit??t Kiel, 24118 Kiel, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schr??der</LastName>
                    <ForeName>Bernd</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Institute of Biochemistry, Christian-Albrechts-Universit??t Kiel, 24118 Kiel, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Butz</LastName>
                    <ForeName>Elisabeth</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Northoff</LastName>
                    <ForeName>Bernd</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Institute of Laboratory Medicine-University Hospital Munich, 81377 Munich, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castonguay</LastName>
                    <ForeName>Jan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Albert-Ludwigs-Universit??t Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luber</LastName>
                    <ForeName>Christian A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>1] Max-Planck-Institute for Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moser</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Max-Planck-Institute for Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spahn</LastName>
                    <ForeName>Saskia</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>L??llmann-Rauch</LastName>
                    <ForeName>Renate</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Institute of Anatomy, Christian-Albrechts-Universit??t Kiel, 24098 Kiel, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fendel</LastName>
                    <ForeName>Christina</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Institute for Cell Biology, Rheinische Friedrich-Wilhelms-Universit??t Bonn, 53121 Bonn, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klugbauer</LastName>
                    <ForeName>Norbert</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Albert-Ludwigs-Universit??t Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Griesbeck</LastName>
                    <ForeName>Oliver</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Max-Planck-Institute of Neurobiology, Am Klopferspitz 18, 82152 Martinsried, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haas</LastName>
                    <ForeName>Albert</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Institute for Cell Biology, Rheinische Friedrich-Wilhelms-Universit??t Bonn, 53121 Bonn, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mann</LastName>
                    <ForeName>Matthias</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Max-Planck-Institute for Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bracher</LastName>
                    <ForeName>Franz</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Pharmacy, Ludwig-Maximilians-Universit??t M??nchen, 81377 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teupser</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Institute of Laboratory Medicine-University Hospital Munich, 81377 Munich, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saftig</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Institute of Biochemistry, Christian-Albrechts-Universit??t Kiel, 24118 Kiel, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Biel</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl-Schott</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Commun</MedlineTA>
            <NlmUniqueID>101528555</NlmUniqueID>
            <ISSNLinking>2041-1723</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ncomms5699</ArticleId>
            <ArticleId IdType="doi">10.1038/ncomms5699</ArticleId>
            <ArticleId IdType="pubmed">25144390</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144366</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1553-7374</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>PLoS pathogens</Title>
                <ISOAbbreviation>PLoS Pathog.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ly6Chi Monocyte Recruitment Is Responsible for Th2 Associated Host-Protective Macrophage Accumulation in Liver Inflammation due to Schistosomiasis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e1004282</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1004282</ELocationID>
            <Abstract>
                <AbstractText>Accumulation of M2 macrophages in the liver, within the context of a strong Th2 response, is a hallmark of infection with the parasitic helminth, Schistosoma mansoni, but the origin of these cells is unclear. To explore this, we examined the relatedness of macrophages to monocytes in this setting. Our data show that both monocyte-derived and resident macrophages are engaged in the response to infection. Infection caused CCR2-dependent increases in numbers of Ly6Chi monocytes in blood and liver and of CX3CR1+ macrophages in diseased liver. Ly6Chi monocytes recovered from liver had the potential to differentiate into macrophages when cultured with M-CSF. Using pulse chase BrdU labeling, we found that most hepatic macrophages in infected mice arose from monocytes. Consistent with this, deletion of monocytes led to the loss of a subpopulation of hepatic CD11chi macrophages that was present in infected but not na??ve mice. This was accompanied by a reduction in the size of egg-associated granulomas and significantly exacerbated disease. In addition to the involvement of monocytes and monocyte-derived macrophages in hepatic inflammation due to infection, we observed increased incorporation of BrdU and expression of Ki67 and MHC II in resident macrophages, indicating that these cells are participating in the response. Expression of both M2 and M1 marker genes was increased in liver from infected vs. naive mice. The M2 fingerprint in the liver was not accounted for by a single cell type, but rather reflected expression of M2 genes by various cells including macrophages, neutrophils, eosinophils and monocytes. Our data point to monocyte recruitment as the dominant process for increasing macrophage cell numbers in the liver during schistosomiasis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nascimento</LastName>
                    <ForeName>Marcia</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Stanley C</ForeName>
                    <Initials>SC</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>Amber</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Everts</LastName>
                    <ForeName>Bart</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lam</LastName>
                    <ForeName>Wing</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bassity</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Trudeau Institute, Saranac Lake, New York, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gautier</LastName>
                    <ForeName>Emmanuel L</ForeName>
                    <Initials>EL</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Randolph</LastName>
                    <ForeName>Gwendalyn J</ForeName>
                    <Initials>GJ</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pearce</LastName>
                    <ForeName>Edward J</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS Pathog</MedlineTA>
            <NlmUniqueID>101238921</NlmUniqueID>
            <ISSNLinking>1553-7366</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month>8</Month>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1004282</ArticleId>
            <ArticleId IdType="pii">PPATHOGENS-D-13-02087</ArticleId>
            <ArticleId IdType="pubmed">25144366</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144359</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1553-7358</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>PLoS computational biology</Title>
                <ISOAbbreviation>PLoS Comput. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tracing the evolution of lineage-specific transcription factor binding sites in a birth-death framework.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e1003771</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pcbi.1003771</ELocationID>
            <Abstract>
                <AbstractText>Changes in cis-regulatory element composition that result in novel patterns of gene expression are thought to be a major contributor to the evolution of lineage-specific traits. Although transcription factor binding events show substantial variation across species, most computational approaches to study regulatory elements focus primarily upon highly conserved sites, and rely heavily upon multiple sequence alignments. However, sequence conservation based approaches have limited ability to detect lineage-specific elements that could contribute to species-specific traits. In this paper, we describe a novel framework that utilizes a birth-death model to trace the evolution of lineage-specific binding sites without relying on detailed base-by-base cross-species alignments. Our model was applied to analyze the evolution of binding sites based on the ChIP-seq data for six transcription factors (GATA1, SOX2, CTCF, MYC, MAX, ETS1) along the lineage toward human after human-mouse common ancestor. We estimate that a substantial fraction of binding sites (???58-79% for each factor) in humans have origins since the divergence with mouse. Over 15% of all binding sites are unique to hominids. Such elements are often enriched near genes associated with specific pathways, and harbor more common SNPs than older binding sites in the human genome. These results support the ability of our method to identify lineage-specific regulatory elements and help understand their roles in shaping variation in gene regulation across species.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yokoyama</LastName>
                    <ForeName>Ken Daigoro</ForeName>
                    <Initials>KD</Initials>
                    <Affiliation>Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Jian</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America; Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS Comput Biol</MedlineTA>
            <NlmUniqueID>101238922</NlmUniqueID>
            <ISSNLinking>1553-734X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month>8</Month>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pcbi.1003771</ArticleId>
            <ArticleId IdType="pii">PCOMPBIOL-D-14-00701</ArticleId>
            <ArticleId IdType="pubmed">25144359</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144323</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2041-1723</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Nature communications</Title>
                <ISOAbbreviation>Nat Commun</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cardiac arrhythmia induced by genetic silencing of 'funny' (f) channels is rescued by GIRK4 inactivation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4664</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms5664</ELocationID>
            <Abstract>
                <AbstractText>The mechanisms underlying cardiac automaticity are still incompletely understood and controversial. Here we report the complete conditional and time-controlled silencing of the 'funny' current (If) by expression of a dominant-negative, non-conductive HCN4-channel subunit (hHCN4-AYA). Heart-specific If silencing caused altered [Ca(2+)]i release and Ca(2+) handling in the sinoatrial node, impaired pacemaker activity and symptoms reminiscent of severe human disease of pacemaking. The effects of If silencing critically depended on the activity of the autonomic nervous system. We were able to rescue the failure of impulse generation and conduction by additional genetic deletion of cardiac muscarinic G-protein-activated (GIRK4) channels in If-deficient mice without impairing heartbeat regulation. Our study establishes the role of f-channels in cardiac automaticity and indicates that arrhythmia related to HCN loss-of-function may be managed by pharmacological or genetic inhibition of GIRK4 channels, thus offering a new therapeutic strategy for the treatment of heart rhythm diseases.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mesirca</LastName>
                    <ForeName>Pietro</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alig</LastName>
                    <ForeName>Jacqueline</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Experimental Neuropediatrics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Torrente</LastName>
                    <ForeName>Angelo G</ForeName>
                    <Initials>AG</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>M??ller</LastName>
                    <ForeName>Jana Christina</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Department of Cellular and Integrative Physiology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marger</LastName>
                    <ForeName>Laurine</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rollin</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marquilly</LastName>
                    <ForeName>Claire</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vincent</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dubel</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bidaud</LastName>
                    <ForeName>Isabelle</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fernandez</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Centre national de la recherche scientifique, UPR-1142, Institut de G??n??tique Humaine, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seniuk</LastName>
                    <ForeName>Anika</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>1] Department of Cellular and Integrative Physiology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany [2] Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), University Medical Center Hamburg-Eppendorf, partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Engeland</LastName>
                    <ForeName>Birgit</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>1] Experimental Neuropediatrics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany [2] Experimental Neurophysiology, University Hospital Cologne, 50924 Cologne, Germany [3] German Center for Neurodegenerative Diseases (DZNE), 53175, Bonn, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Jasmin</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Experimental Pharmacology and Toxicology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miquerol</LastName>
                    <ForeName>Lucile</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Developmental Biology Institute of Marseille, Universit?? Aix-Marseille, CNRS UMR 7288, 13288 Marseille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ehmke</LastName>
                    <ForeName>Heimo</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>1] Department of Cellular and Integrative Physiology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany [2] Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), University Medical Center Hamburg-Eppendorf, partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eschenhagen</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>1] Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), University Medical Center Hamburg-Eppendorf, partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany [2] Department of Experimental Pharmacology and Toxicology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nargeot</LastName>
                    <ForeName>Joel</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wickman</LastName>
                    <ForeName>Kevin</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota 55455, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Isbrandt</LastName>
                    <ForeName>Dirk</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>1] Experimental Neuropediatrics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany [2] Experimental Neurophysiology, University Hospital Cologne, 50924 Cologne, Germany [3] German Center for Neurodegenerative Diseases (DZNE), 53175, Bonn, Germany [4].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mangoni</LastName>
                    <ForeName>Matteo E</ForeName>
                    <Initials>ME</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [4].</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Commun</MedlineTA>
            <NlmUniqueID>101528555</NlmUniqueID>
            <ISSNLinking>2041-1723</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ncomms5664</ArticleId>
            <ArticleId IdType="doi">10.1038/ncomms5664</ArticleId>
            <ArticleId IdType="pubmed">25144323</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25144316</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-7422</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human gene therapy</Title>
                <ISOAbbreviation>Hum. Gene Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>&lt;i&gt;In vivo&lt;/i&gt; evaluation of adeno-associated virus gene transfer in airways of mice with acute or chronic respiratory infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Patients with cystic fibrosis (CF) often suffer chronic lung infection with concomitant inflammation, a setting that may reduce the efficacy of gene transfer. While gene therapy development for CF often involves viral-based vectors, little is known about gene transfer in the context of an infected airway. In this study, three mouse models were established to evaluate adeno-associated virus (AAV) gene transfer in such an environment. &lt;i&gt;Bordetella bronchiseptica&lt;/i&gt; RB50 was used in a chronic, non-lethal respiratory infection in C57BL/6 mice. An inoculum of ~10&lt;sup&gt;5&lt;/sup&gt; CFU allowed &lt;i&gt;B.bronchiseptica&lt;/i&gt; RB50 to persist in the upper and lower respiratory tracts for at least 21 days. In this infection model administration of an AAV vector on day 2 resulted in an approximately three-fold reduction of reporter gene expression compared to that observed in uninfected controls. Postponement of AAV administration to day 14 resulted in an even greater (eight-fold) reduction of reporter gene expression, when compared to uninfected controls. In another infection model, &lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt; PAO1 was used to infect surfactant protein D (SP-D) or surfactant protein A (SP-A) knockout (KO) mice. With an inoculum of ~10&lt;sup&gt;5&lt;/sup&gt; CFU, infection persisted for two days in the nasal cavity of either mouse model. Reporter gene expression was approximately ~2.5 fold lower compared to uninfected mice. In the SP-D KO model, postponement of AAV administration to day 9 post-infection resulted in only a 2-fold reduction in reporter gene expression, when compared to expression seen in uninfected controls. These results confirm that respiratory infections, both on-going and recently resolved, decrease the efficacy of AAV-mediated gene transfer.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Myint</LastName>
                    <ForeName>Melissa</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>University of Pennsylvania, Institute for Medicine and Engineering, Department of Chemical &amp; Biomolecular Engineering, Philadelphia, Pennsylvania, United States ; mmyint@seas.upenn.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Limberis</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Bell</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author>
                    <LastName>Somanathan</LastName>
                    <ForeName>Suryanarayan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Haczku</LastName>
                    <ForeName>Angela</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Wilson</LastName>
                    <ForeName>James M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author>
                    <LastName>Diamond</LastName>
                    <ForeName>Scott L</ForeName>
                    <Initials>SL</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Hum Gene Ther</MedlineTA>
            <NlmUniqueID>9008950</NlmUniqueID>
            <ISSNLinking>1043-0342</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hum.2014.002</ArticleId>
            <ArticleId IdType="pubmed">25144316</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144310</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Assessment of mouse germinal vesicle stage oocyte quality by evaluating the cumulus layer, zona pellucida, and perivitelline space.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105812</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105812</ELocationID>
            <Abstract>
                <AbstractText>To improve the outcome of assisted reproductive technology (ART) for patients with ovulation problems, it is necessary to retrieve and select germinal vesicle (GV) stage oocytes with high developmental potential. Oocytes with high developmental potential are characterized by their ability to undergo proper maturation, fertilization, and embryo development. In this study, we analyzed morphological traits of GV stage mouse oocytes, including cumulus cell layer thickness, zona pellucida thickness, and perivitelline space width. Then, we assessed the corresponding developmental potential of each of these oocytes and found that it varies across the range measured for each morphological trait. Furthermore, by manipulating these morphological traits in vitro, we were able to determine the influence of morphological variation on oocyte developmental potential. Manually altering the thickness of the cumulus layer showed strong effects on the fertilization and embryo development potentials of oocytes, whereas manipulation of zona pellucida thickness effected the oocyte maturation potential. Our results provide a systematic detailed method for selecting GV stage oocytes based on a morphological assessment approach that would benefit for several downstream ART applications.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Hong-Xia</ForeName>
                    <Initials>HX</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Yu-Zhen</ForeName>
                    <Initials>YZ</Initials>
                    <Affiliation>Inner Mongolia People's Hospital, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Ying-Lei</ForeName>
                    <Initials>YL</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Cheng-Jie</ForeName>
                    <Initials>CJ</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Sha-Na</ForeName>
                    <Initials>SN</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Jiang-Peng</ForeName>
                    <Initials>JP</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Cheng-Guang</ForeName>
                    <Initials>CG</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105812</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-28075</ArticleId>
            <ArticleId IdType="pubmed">25144310</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144301</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hyperglycemia Promotes K-Ras-Induced Lung Tumorigenesis through BASCs Amplification.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105550</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105550</ELocationID>
            <Abstract>
                <AbstractText>Oncogenic K-Ras represents the most common molecular change in human lung adenocarcinomas, the major histologic subtype of non-small cell lung cancer (NSCLC). The presence of K-Ras mutation is associated with a poor prognosis, but no effective treatment strategies are available for K-Ras -mutant NSCLC. Epidemiological studies report higher lung cancer mortality rates in patients with type 2 diabetes. Here, we use a mouse model of K-Ras-mediated lung cancer on a background of chronic hyperglycemia to determine whether elevated circulating glycemic levels could influence oncogenic K-Ras-mediated tumor development. Inducible oncogenic K-Ras mouse model was treated with subtoxic doses of streptozotocin (STZ) to induce chronic hyperglycemia. We observed increased tumor mass and higher grade of malignancy in STZ treated diabetic mice analyzed at 4, 12 and 24 weeks, suggesting that oncogenic K-Ras increased lung tumorigenesis in hyperglycemic condition. This promoting effect is achieved by expansion of tumor-initiating lung bronchio-alveolar stem cells (BASCs) in bronchio-alveolar duct junction, indicating a role of hyperglycemia in the activity of K-Ras-transformed putative lung stem cells. Notably, after oncogene K-Ras activation, BASCs show upregulation of the glucose transporter (Glut1/Slc2a1), considered as an important player of the active control of tumor cell metabolism by oncogenic K-Ras. Our novel findings suggest that anti-hyperglycemic drugs, such as metformin, may act as therapeutic agent to restrict lung neoplasia promotion and progression.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Micucci</LastName>
                    <ForeName>Carla</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Clinical and Molecular Sciences, Polytechnic University of Marche, School of Medicine, Ancona, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Orciari</LastName>
                    <ForeName>Silvia</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Clinical and Molecular Sciences, Polytechnic University of Marche, School of Medicine, Ancona, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Catalano</LastName>
                    <ForeName>Alfonso</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Clinical and Molecular Sciences, Polytechnic University of Marche, School of Medicine, Ancona, Italy.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105550</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-14371</ArticleId>
            <ArticleId IdType="pubmed">25144301</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25144240</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-8534</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Stem cells and development</Title>
                <ISOAbbreviation>Stem Cells Dev.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Stress-Induced Enzyme Activation Primes Murine Embryonic Stem Cells to Differentiate toward the First Extraembryonic Lineage.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Extracellular stresses influence transcription factor (TF) expression and therefore lineage identity in the peri-implantation mouse embryo and its stem cells. This potentially affects pregnancy outcome. To understand the effects of stress signaling during this critical period of pregnancy, we exposed cultured murine embryonic stem cells (mESCs) to hyperosmotic stress. We then measured stress enzyme-dependent regulation of key pluripotency and lineage TFs. Hyperosmotic stress slowed mESC accumulation due to slowing of the cell cycle over 72hr, after a small apoptotic response within 12hr. PI3K enzymatic signaling was responsible for stem cell survival under stressed conditions. Stress initially triggered mESC differentiation after 4hr through MEK1, JNK, and PI3K enzymatic signaling, which led to proteasomal degradation of Oct4, Nanog, Sox2, and Rex1 TF proteins. Concurrent with this post-transcriptional effect was the decreased accumulation of potency TF mRNA transcripts. After 12-24hr of stress, cells adapted, cell cycle resumed, and Oct4 and Nanog mRNA and protein expression returned to ~normal levels. The TF protein recovery was mediated by p38MAPK and PI3K signaling, as well as by MEK2 and/or 1. However, due to JNK signaling Rex1 expression did not recover. Probing for downstream lineages revealed that although mESCs did not differentiate morphologically during 24hr of stress, they were primed to differentiate by upregulating markers of the first lineage differentiating from mESCs; extraembryonic endoderm. Thus, although 2-3 TFs which mark pluripotency recover expression by 24hr of stress, there is nonetheless sustained Rex1 suppression and a priming of mESCs for differentiation to the earliest lineage.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Slater</LastName>
                    <ForeName>Jill Drappole Med Wayne Edu</ForeName>
                    <Initials>JD</Initials>
                    <Affiliation>Wayne State University, Physiology, detroit, Michigan, United States ; jislater@umflint.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Sichang Drappole Med Wayne Edu</ForeName>
                    <Initials>SD</Initials>
                </Author>
                <Author>
                    <LastName>Puscheck</LastName>
                    <ForeName>Elizabeth Ella</ForeName>
                    <Initials>EE</Initials>
                </Author>
                <Author>
                    <LastName>Rappolee</LastName>
                    <ForeName>Daniel A</ForeName>
                    <Initials>DA</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Stem Cells Dev</MedlineTA>
            <NlmUniqueID>101197107</NlmUniqueID>
            <ISSNLinking>1547-3287</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1089/scd.2014.0157</ArticleId>
            <ArticleId IdType="pubmed">25144240</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144231</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of machado-joseph disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e100086</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0100086</ELocationID>
            <Abstract>
                <AbstractText>Machado-Joseph disease or Spinocerebellar ataxia type 3 is a progressive fatal neurodegenerative disorder caused by the polyglutamine-expanded protein ataxin-3. Recent studies demonstrate that RNA interference is a promising approach for the treatment of Machado-Joseph disease. However, whether gene silencing at an early time-point is able to prevent the appearance of motor behavior deficits typical of the disease when initiated before onset of the disease had not been explored. Here, using a lentiviral-mediated allele-specific silencing of mutant ataxin-3 in an early pre-symptomatic cerebellar mouse model of Machado-Joseph disease we show that this strategy hampers the development of the motor and neuropathological phenotypic characteristics of the disease. At the histological level, the RNA-specific silencing of mutant ataxin-3 decreased formation of mutant ataxin-3 aggregates, preserved Purkinje cell morphology and expression of neuronal markers while reducing cell death. Importantly, gene silencing prevented the development of impairments in balance, motor coordination, gait and hyperactivity observed in control mice. These data support the therapeutic potential of RNA interference for Machado-Joseph disease and constitute a proof of principle of the beneficial effects of early allele-specific silencing for therapy of this disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>N??brega</LastName>
                    <ForeName>Cl??vio</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>CNC - Center for Neuroscience &amp; Cell Biology, University of Coimbra, Coimbra, Portugal.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nascimento-Ferreira</LastName>
                    <ForeName>Isabel</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>CNC - Center for Neuroscience &amp; Cell Biology, University of Coimbra, Coimbra, Portugal; Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Onofre</LastName>
                    <ForeName>Isabel</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>CNC - Center for Neuroscience &amp; Cell Biology, University of Coimbra, Coimbra, Portugal; Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Albuquerque</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Faculty of Sciences and Technology, University of Coimbra, Coimbra, Portugal.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>D??glon</LastName>
                    <ForeName>Nicole</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Lausanne University Hospital, Department of Clinical Neurosciences, Laboratory of Cellular and Molecular Neurotherapies, Lausanne, Switzerland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pereira de Almeida</LastName>
                    <ForeName>Lu??s</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>CNC - Center for Neuroscience &amp; Cell Biology, University of Coimbra, Coimbra, Portugal; Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0100086</ArticleId>
            <ArticleId IdType="pii">PONE-D-13-47238</ArticleId>
            <ArticleId IdType="pubmed">25144231</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144228</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1553-7374</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>PLoS pathogens</Title>
                <ISOAbbreviation>PLoS Pathog.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Late Engagement of CD86 after Influenza Virus Clearance Promotes Recovery in a FoxP3+ Regulatory T Cell Dependent Manner.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e1004315</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1004315</ELocationID>
            <Abstract>
                <AbstractText>Influenza A virus (IAV) infection in the respiratory tract triggers robust innate and adaptive immune responses, resulting in both virus clearance and lung inflammation and injury. After virus clearance, resolution of ongoing inflammation and tissue repair occur during a distinct recovery period. B7 family co-stimulatory molecules such as CD80 and CD86 have important roles in modulating T cell activity during the initiation and effector stages of the host response to IAV infection, but their potential role during recovery and resolution of inflammation is unknown. We found that antibody-mediated CD86 blockade in vivo after virus clearance led to a delay in recovery, characterized by increased numbers of lung neutrophils and inflammatory cytokines in airways and lung interstitium, but no change in conventional IAV-specific T cell responses. However, CD86 blockade led to decreased numbers of FoxP3+ regulatory T cells (Tregs), and adoptive transfer of Tregs into ??CD86 treated mice rescued the effect of the blockade, supporting a role for Tregs in promoting recovery after virus clearance. Specific depletion of Tregs late after infection mimicked the CD86 blockade phenotype, confirming a role for Tregs during recovery after virus clearance. Furthermore, we identified neutrophils as a target of Treg suppression since neutrophil depletion in Treg-depleted mice reduced excess inflammatory cytokines in the airways. These results demonstrate that Tregs, in a CD86 dependent mechanism, contribute to the resolution of disease after IAV infection, in part by suppressing neutrophil-driven cytokine release into the airways.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Moser</LastName>
                    <ForeName>Emily K</ForeName>
                    <Initials>EK</Initials>
                    <Affiliation>The Beirne B. Carter Center for Immunology Research, The University of Virginia, Charlottesville, Virginia, United States of America; Department of Pharmacology, The University of Virginia, Charlottesville, Virginia, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hufford</LastName>
                    <ForeName>Matthew M</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>The Beirne B. Carter Center for Immunology Research, The University of Virginia, Charlottesville, Virginia, United States of America; Department of Microbiology, The University of Virginia, Charlottesville, Virginia, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Braciale</LastName>
                    <ForeName>Thomas J</ForeName>
                    <Initials>TJ</Initials>
                    <Affiliation>The Beirne B. Carter Center for Immunology Research, The University of Virginia, Charlottesville, Virginia, United States of America; Department of Microbiology, The University of Virginia, Charlottesville, Virginia, United States of America; Department of Pathology, The University of Virginia, Charlottesville, Virginia, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS Pathog</MedlineTA>
            <NlmUniqueID>101238921</NlmUniqueID>
            <ISSNLinking>1553-7366</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month>8</Month>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1004315</ArticleId>
            <ArticleId IdType="pii">PPATHOGENS-D-14-00685</ArticleId>
            <ArticleId IdType="pubmed">25144228</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144225</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1935-2735</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>8</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>PLoS neglected tropical diseases</Title>
                <ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Effect of (-)-Epigallocatechin 3-O - Gallate In Vitro and In Vivo in Leishmania braziliensis: Involvement of Reactive Oxygen Species as a Mechanism of Action.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e3093</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0003093</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Leishmaniasis is a parasitic disease associated with extensive mortality and morbidity. The treatment for leishmaniasis is currently based on pentavalent antimonials and amphotericin B; however, these drugs result in numerous adverse side effects. Natural compounds have been used as novel treatments for parasitic diseases. In this paper, we evaluated the effect of (-)-epigallocatechin 3-O-gallate (EGCG) on Leishmania braziliensis in vitro and in vivo and described the mechanism of EGCG action against L. braziliensis promastigotes and intracellular amastigotes.</AbstractText>
                <AbstractText Label="METHODOLOGY/PRINCIPAL FINDING" NlmCategory="RESULTS">In vitro activity and reactive oxygen species (ROS) measurements were determined during the promastigote and intracellular amastigote life stages. The effect of EGCG on mitochondrial membrane potential (????m) was assayed using JC-1, and intracellular ATP concentrations were measured using a luciferin-luciferase system. The in vivo experiments were performed in infected BALB/c mice orally treated with EGCG. EGCG reduced promastigote viability and the infection index in a time- and dose-dependent manner, with IC50 values of 278.8 ??M and 3.4 ??M, respectively, at 72 h and a selectivity index of 149.5. In addition, EGCG induced ROS production in the promastigote and intracellular amastigote, and the effects were reversed by polyethylene glycol (PEG)-catalase. Additionally, EGCG reduced ????m, thereby decreasing intracellular ATP concentrations in promastigotes. Furthermore, EGCG treatment was also effective in vivo, demonstrating oral bioavailability and reduced parasitic loads without altering serological toxicity markers.</AbstractText>
                <AbstractText Label="CONCLUSIONS/SIGNIFICANCE" NlmCategory="CONCLUSIONS">In conclusion, our study demonstrates the leishmanicidal effects of EGCG against the two forms of L. braziliensis, the promastigote and amastigote. In addition, EGCG promotes ROS production as a part of its mechanism of action, resulting in decreased ????m and reduced intracellular ATP concentrations. These actions ultimately culminate in parasite death. Furthermore, our data suggest that EGCG is orally effective in the treatment of L. braziliensis-infected BALB/c mice without altering serological toxicity markers.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Inacio</LastName>
                    <ForeName>Job D F</ForeName>
                    <Initials>JD</Initials>
                    <Affiliation>Laborat??rio de Bioqu??mica de Tripanosomatideos, Instituto Oswaldo Cruz (IOC), Funda????o Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gervazoni</LastName>
                    <ForeName>Luiza</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Laborat??rio de Bioqu??mica de Tripanosomatideos, Instituto Oswaldo Cruz (IOC), Funda????o Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Canto-Cavalheiro</LastName>
                    <ForeName>Marilene M</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>Laborat??rio de Bioqu??mica de Tripanosomatideos, Instituto Oswaldo Cruz (IOC), Funda????o Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Almeida-Amaral</LastName>
                    <ForeName>Elmo E</ForeName>
                    <Initials>EE</Initials>
                    <Affiliation>Laborat??rio de Bioqu??mica de Tripanosomatideos, Instituto Oswaldo Cruz (IOC), Funda????o Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS Negl Trop Dis</MedlineTA>
            <NlmUniqueID>101291488</NlmUniqueID>
            <ISSNLinking>1935-2727</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month>8</Month>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pntd.0003093</ArticleId>
            <ArticleId IdType="pii">PNTD-D-14-00554</ArticleId>
            <ArticleId IdType="pubmed">25144225</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144208</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2041-1723</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Nature communications</Title>
                <ISOAbbreviation>Nat Commun</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Trans-regulation of oligodendrocyte myelination by neurons through small GTPase Arf6-regulated secretion of fibroblast growth factor-2.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4744</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms5744</ELocationID>
            <Abstract>
                <AbstractText>The small G protein ADP-ribosylation factor 6 (Arf6) plays important roles in a wide variety of membrane dynamics-based cellular events such as neurite outgrowth and spine formation in vitro. However, little is known about physiological function of Arf6 in vivo. Here we generate conditional knockout mice lacking Arf6 in neurons, oligodendrocytes, or both cell lineages, and unexpectedly find that Arf6 expression in neurons, but not in oligodendrocytes, is crucial for oligodendrocyte myelination in the hippocampal fimbria and the corpus callosum during development, and that this is through the regulation of secretion of fibroblast growth factor-2, a guidance factor for migration of oligodendrocyte precursor cells (OPCs). These results suggest that Arf6 in neurons plays an important role in OPC migration through regulation of FGF-2 secretion during neuronal development.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Akiyama</LastName>
                    <ForeName>Masahiro</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>1] Faculty of Medicine, Department of Physiological Chemistry, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hasegawa</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>1] Faculty of Medicine, Department of Physiological Chemistry, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hongu</LastName>
                    <ForeName>Tsunaki</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>1] Faculty of Medicine, Department of Physiological Chemistry, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Frohman</LastName>
                    <ForeName>Michael A</ForeName>
                    <Initials>MA</Initials>
                    <Affiliation>Department of Pharmacology, Center for Developmental Genetics, Stony Brook University, Stony Brook, New York 11794-5140, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harada</LastName>
                    <ForeName>Akihiro</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Cell Biology, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sakagami</LastName>
                    <ForeName>Hiroyuki</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Anatomy, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0329, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanaho</LastName>
                    <ForeName>Yasunori</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Faculty of Medicine, Department of Physiological Chemistry, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Commun</MedlineTA>
            <NlmUniqueID>101528555</NlmUniqueID>
            <ISSNLinking>2041-1723</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ncomms5744</ArticleId>
            <ArticleId IdType="doi">10.1038/ncomms5744</ArticleId>
            <ArticleId IdType="pubmed">25144208</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144196</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ezrin Mediates Neuritogenesis via Down-Regulation of RhoA Activity in Cultured Cortical Neurons.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105435</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105435</ELocationID>
            <Abstract>
                <AbstractText>Neuronal morphogenesis is implicated in neuronal function and development with rearrangement of cytoskeletal organization. Ezrin, a member of Ezrin/Radixin/Moesin (ERM) proteins links between membrane proteins and actin cytoskeleton, and contributes to maintenance of cellular function and morphology. In cultured hippocampal neurons, suppression of both radixin and moesin showed deficits in growth cone morphology and neurite extensions. Down-regulation of ezrin using siRNA caused impairment of netrin-1-induced axon outgrowth in cultured cortical neurons. However, roles of ezrin in the neuronal morphogenesis of the cultured neurons have been poorly understood. In this report, we performed detailed studies on the roles of ezrin in the cultured cortical neurons prepared from the ezrin knockdown (Vil2kd/kd) mice embryo that showed a very small amount of ezrin expression compared with the wild-type (Vil2+/+) neurons. Ezrin was mainly expressed in cell body in the cultured cortical neurons. We demonstrated that the cultured cortical neurons prepared from the Vil2kd/kd mice embryo exhibited impairment of neuritogenesis. Moreover, we observed increased RhoA activity and phosphorylation of myosin light chain 2 (MLC2), as a downstream effector of RhoA in the Vil2kd/kd neurons. In addition, inhibition of Rho kinase and myosin II rescued the impairment of neuritogenesis in the Vil2kd/kd neurons. These data altogether suggest a novel role of ezrin in the neuritogenesis of the cultured cortical neurons through down-regulation of RhoA activity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Matsumoto</LastName>
                    <ForeName>Yosuke</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Inden</LastName>
                    <ForeName>Masatoshi</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tamura</LastName>
                    <ForeName>Atsushi</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Laboratory of Biological Science, Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hatano</LastName>
                    <ForeName>Ryo</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsukita</LastName>
                    <ForeName>Sachiko</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Laboratory of Biological Science, Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asano</LastName>
                    <ForeName>Shinji</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105435</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-26445</ArticleId>
            <ArticleId IdType="pubmed">25144196</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25144131</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1533-4287</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of strength and conditioning research / National Strength &amp; Conditioning Association</Title>
                <ISOAbbreviation>J Strength Cond Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of Intestinal Microbiota on Exercise Performance in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The antioxidant enzyme system helps protect against intense exercise-induced oxidative damage and is related to the physical status of athletes. Evidence suggests that intestinal microbiota may be an important environmental factor associated with host metabolism, physiology, and antioxidant endogenous defense. However, evidence of the effect of gut microbiota status on exercise performance and physical fatigue is limited. We investigated the association of intestinal bacteria and exercise performance in specific pathogen-free (SPF), germ-free (GF), and Bacteroides fragilis (BF) gnotobiotic mice. Endurance swimming time was longer for SPF and BF than GF mice, and the weight of liver, muscle, brown adipose, and epididymal fat pads was higher for SPF and BF than GF mice. The serum levels of glutathione peroxidase (GPx) and catalase were greater in SPF than GF mice. Serum superoxide dismutase activity was lower in BF than SPF and GF mice. In addition, hepatic GPx level was higher in SPF than GF and BF mice. Gut microbial status could be crucial for exercise performance and its potential action linked with the antioxidant enzyme system in athletes.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hsu</LastName>
                    <ForeName>Yi-Ju</ForeName>
                    <Initials>YJ</Initials>
                    <Affiliation>1Graduate Institute of Sports Science, National Taiwan Sport University, Taoyuan 33301, Taiwan 2National Laboratory Animal Center, National Applied Research Laboratories, Taipei 11529, Taiwan 3Graduate Institute of Athletics and Coaching Science, National Taiwan Sport University, Taoyuan 33301, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chiu</LastName>
                    <ForeName>Chien-Chao</ForeName>
                    <Initials>CC</Initials>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Yen-Peng</ForeName>
                    <Initials>YP</Initials>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Wen-Ching</ForeName>
                    <Initials>WC</Initials>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Yen-Te</ForeName>
                    <Initials>YT</Initials>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Chi-Chang</ForeName>
                    <Initials>CC</Initials>
                </Author>
                <Author>
                    <LastName>Chuang</LastName>
                    <ForeName>Hsiao-Li</ForeName>
                    <Initials>HL</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Strength Cond Res</MedlineTA>
            <NlmUniqueID>9415084</NlmUniqueID>
            <ISSNLinking>1064-8011</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1519/JSC.0000000000000644</ArticleId>
            <ArticleId IdType="pubmed">25144131</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedBookArticle>
    <BookDocument>
        <PMID Version="1">25144101</PMID>
        <ArticleIdList>
            <ArticleId IdType="bookaccession">NBK235149</ArticleId>
        </ArticleIdList>
        <Book>
            <Publisher>
                <PublisherName>National Academies Press (US)</PublisherName>
                <PublisherLocation>Washington (DC)</PublisherLocation>
            </Publisher>
            <BookTitle book="nap1429">Infectious Diseases of Mice and Rats</BookTitle>
            <PubDate>
                <Year>1991</Year>
            </PubDate>
            <AuthorList Type="authors">
                <Author>
                    <CollectiveName>National Research Council (US) Committee on Infectious Diseases of Mice and Rats</CollectiveName>
                </Author>
            </AuthorList>
            <CollectionTitle book="napcollect">The National Academies Collection: Reports funded by National Institutes of Health</CollectionTitle>
            <Isbn>0309063329</Isbn>
        </Book>
        <Language>eng</Language>
        <Abstract>
            <AbstractText>This new edition--a must for all researchers who use these lab animals-- provides practical suggestions for breeding, keeping, and identifying pathogen-free laboratory rodents. It contains three informative sections. The first, Principles of Rodent Disease Prevention, summarizes methods for eliminating infectious agents. It offers information on pathogen terminology; pathogen status of rodents; and breeding, transporting, isolating, testing, and diagnosing rodents. The second section, Individual Disease Agents and Their Effects on Research, describes the diagnosis and control of each infectious agent, and the last section, Diagnostic Indexes: Clinical Signs, Pathology, and Research Complications, contains informative tables covering all the diseases listed in the volume, arranged to help in the diagnosis of infected animals.</AbstractText>
            <CopyrightInformation>Copyright ?? 1991 by the National Academy of Sciences.</CopyrightInformation>
        </Abstract>
        <Sections>
            <Section>
                <SectionTitle book="nap1429" part="ddd00003">COMMITTEE ON INFECTIOUS DISEASES OF MICE AND RATS</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1429" part="ddd00005">INSTITUTE OF LABORATORY ANIMAL RESOURCES COUNCIL</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1429" part="ddd00007">COMMISSION ON LIFE SCIENCES</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1429" part="ddd00009">PREFACE</SectionTitle>
            </Section>
            <Section>
                <LocationLabel Type="part">PART I</LocationLabel>
                <SectionTitle book="nap1429" part="ddd00011">PRINCIPLES OF RODENT DISEASE PREVENTION</SectionTitle>
                <Section>
                    <LocationLabel Type="chapter">1</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00012">Objectives, Terminology, and Overview of Pathogen Status</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">2</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00017">Breeding, Transportation, and Use of Pathogen-free Rodents</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">3</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00018">Barrier Programs</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">4</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00024">Health Surveillance Programs</SectionTitle>
                </Section>
            </Section>
            <Section>
                <LocationLabel Type="part">PART II</LocationLabel>
                <SectionTitle book="nap1429" part="ddd00032">INDIVIDUAL DISEASE AGENTS AND THEIR EFFECTS ON RESEARCH</SectionTitle>
                <Section>
                    <LocationLabel Type="chapter">5</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00033">Introduction</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">6</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00034">Respiratory System</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">7</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00192">Digestive System</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">8</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00418">Skin and Joints</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">9</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00543">Hemopoietic System</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">10</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00600">Central Nervous System</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">11</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00623">Genitourinary System</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">12</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00647">Multiple Systems</SectionTitle>
                </Section>
            </Section>
            <Section>
                <LocationLabel Type="part">PART III</LocationLabel>
                <SectionTitle book="nap1429" part="ddd00704">INDEXES TO DIAGNOSIS AND RESEARCH COMPLICATIONS OF INFECTIOUS AGENTS</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1429" part="ddd007090">REFERENCES</SectionTitle>
            </Section>
        </Sections>
    </BookDocument>
    <PubmedBookData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25144101</ArticleId>
        </ArticleIdList>
    </PubmedBookData>
</PubmedBookArticle>


<PubmedBookArticle>
    <BookDocument>
        <PMID Version="1">25144008</PMID>
        <ArticleIdList>
            <ArticleId IdType="bookaccession">NBK235403</ArticleId>
        </ArticleIdList>
        <Book>
            <Publisher>
                <PublisherName>National Academies Press (US)</PublisherName>
                <PublisherLocation>Washington (DC)</PublisherLocation>
            </Publisher>
            <BookTitle book="nap1540">Companion Guide to Infectious Diseases of Mice and Rats</BookTitle>
            <PubDate>
                <Year>1991</Year>
            </PubDate>
            <AuthorList Type="authors">
                <Author>
                    <CollectiveName>National Research Council (US) Committee on Infectious Diseases of Mice and Rats</CollectiveName>
                </Author>
            </AuthorList>
            <CollectionTitle book="napcollect">The National Academies Collection: Reports funded by National Institutes of Health</CollectionTitle>
            <Isbn>0309042836</Isbn>
        </Book>
        <Language>eng</Language>
        <Abstract>
            <AbstractText>This companion to Infectious Diseases of Mice and Rats makes practical information on rodent diseases readily accessible to researchers. This volume parallels the three parts of the main volume. Part I, Principles of Rodent Disease Prevention, briefly examines the requirements for maintaining pathogen-free rodents, factors in designing health surveillance programs, and other laboratory management issues. Part II, Disease Agents, is an easy-to-use reference section, listing diagnosis and control methods, the potential for interference with research, and other factors for disease agents ranging from adenoviruses to tapeworms. It covers bacteria, viruses, fungi and common ectoparasites, and endoparasites. Part III, Diagnostic Indexes, presents alphabetical listings of clinical signs, pathology, and research complications and lists infectious agents that might be responsible for each.</AbstractText>
            <CopyrightInformation>Copyright ?? 1991 by the National Academy of Sciences CIP.</CopyrightInformation>
        </Abstract>
        <Sections>
            <Section>
                <SectionTitle book="nap1540" part="ddd00003">COMMITTEE ON INFECTIOUS DISEASES OF MICE AND RATS</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1540" part="ddd00005">INSTITUTE OF LABORATORY ANIMAL RESOURCES COUNCIL</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1540" part="ddd00007">COMMISSION ON LIFE SCIENCES</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1540" part="ddd00009">Preface</SectionTitle>
            </Section>
            <Section>
                <LocationLabel Type="part">PART I</LocationLabel>
                <SectionTitle book="nap1540" part="ddd00011">Principles of Rodent Disease Prevention</SectionTitle>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00012">SCIENTIFIC OBJECTIVES</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00013">INFECTION VERSUS DISEASE</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00014">TERMINOLOGY OF MICROBIAL AND PATHOGEN STATUS</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00015">COMMITMENT TO MAINTAINING PATHOGEN-FREE STATUS OF RODENTS</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00016">HEALTH SURVEILLANCE PROGRAMS</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00022">RODENT DIAGNOSTIC LABORATORIES</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00023">REFERENCES</SectionTitle>
                </Section>
            </Section>
            <Section>
                <LocationLabel Type="part">PART II</LocationLabel>
                <SectionTitle book="nap1540" part="ddd00024">Disease Agents</SectionTitle>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00025">BACTERIA, FUNGI, AND VIRUSES</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00094">DERMATOPHYTES</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00097">COMMON ECTOPARASITES</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00104">ENDOPARASITES</SectionTitle>
                </Section>
            </Section>
            <Section>
                <LocationLabel Type="part">PART III</LocationLabel>
                <SectionTitle book="nap1540" part="ddd00121">Diagnosis and Research Complications of Infectious Agents</SectionTitle>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00122">INTRODUCTION</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00123">CLINICAL SIGNS</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00124">PATHOLOGY</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00125">RESEARCH COMPLICATIONS</SectionTitle>
                </Section>
            </Section>
        </Sections>
    </BookDocument>
    <PubmedBookData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25144008</ArticleId>
        </ArticleIdList>
    </PubmedBookData>
</PubmedBookArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143992</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-744X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>TheScientificWorldJournal</Title>
                <ISOAbbreviation>ScientificWorldJournal</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phytoestrogen ??-Zearalanol Improves Memory Impairment and Hippocampal Neurogenesis in Ovariectomized Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>862019</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/862019</ELocationID>
            <Abstract>
                <AbstractText>Estrogen is known to provide robust protection of memory in postmenopausal women, but the fact that estrogen may increase the incidence of uterine and breast tumors has undoubtedly limited the clinical use of estrogen. In the present study, the effect of ??-zearalanol (??-ZAL), a plant-derived phytoestrogen with low side-effect on uterine and breast, on memory has been evaluated in ovariectomized (OVX) mice when using 17??-estradiol (17??-E2) as an estrogen positive control. Our findings demonstrated that OVX resulted in impaired spatial learning and memory and reduced numbers of newborn neurons in the dentate gyrus of the hippocampus, while 17??-E2 or ??-ZAL treatment significantly improved memory performance and restored hippocampal neurogenesis. We also found the reduction of brain derived neurotrophic factor (BDNF) and TrkB expression in OVX mice, which were ameliorated by 17??-E2 or ??-ZAL supplementation. These results indicated that ??-ZAL may improve memory impairments induced by OVX and modulate the expression of BDNF-TrkB benefit to neurogenesis which may be involved in the memory protection from ??-ZAL, in a manner similar to that of 17??-E2. The present findings suggested that ??-ZAL may be a plausible substitute of 17??-E2 in improving memory in postmenopausal women.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dong</LastName>
                    <ForeName>Yilong</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>School of Medicine, Yunnan University, Kunming, Yunnan 650091, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Aimei</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650031, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Hongju</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650031, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Huicheng</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>School of Medicine, Yunnan University, Kunming, Yunnan 650091, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yanmei</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650031, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>ScientificWorldJournal</MedlineTA>
            <NlmUniqueID>101131163</NlmUniqueID>
            <ISSNLinking>1537-744X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/862019</ArticleId>
            <ArticleId IdType="pubmed">25143992</ArticleId>
            <ArticleId IdType="pmc">PMC4131096</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143941</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2314-6141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>BioMed research international</Title>
                <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gene delivery potential of biofunctional carbonate apatite nanoparticles in lungs.</ArticleTitle>
            <Pagination>
                <MedlinePgn>646787</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/646787</ELocationID>
            <Abstract>
                <AbstractText>Existing nonviral gene delivery systems to lungs are inefficient and associated with dose limiting toxicity in mammalian cells. Therefore, carbonate apatite (CO3Ap) nanoparticles were examined as an alternative strategy for effective gene delivery to the lungs. This study aimed to (1) assess the gene delivery efficiency of CO3Ap in vitro and in mouse lungs, (2) evaluate the cytotoxicity effect of CO3Ap/pDNA in vitro, and (3) characterize the CO3Ap/pDNA complex formulations. A significantly high level of reporter gene expression was detected from the lung cell line transfected with CO3Ap/pDNA complex prepared in both serum and serum-free medium. Cytotoxicity analysis revealed that the percentage of the viable cells treated with CO3Ap to be almost similar to the untreated cells. Characterization analyses showed that the CO3Ap/pDNA complexes are in a nanometer range with aggregated spherical structures and tended to be more negatively charged. In the lung of mice, highest level of transgene expression was observed when CO3Ap (8?????L) was complexed with 40?????g of pDNA at day 1 after administration. Although massive reduction of gene expression was seen beyond day 1 post administration, the level of expression remained significant throughout the study period.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Alhaji</LastName>
                    <ForeName>Suleiman Yusuf</ForeName>
                    <Initials>SY</Initials>
                    <Affiliation>Medical Genetics Laboratory, Clinical Genetics Unit, Faculty of Medicine and Health Sciences, UPM, 43400 Serdang, Selangor, Malaysia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chowdhury</LastName>
                    <ForeName>Ezharul Houque</ForeName>
                    <Initials>EH</Initials>
                    <Affiliation>Jeffry Cheah School of Medicine and Health Sciences, Monash University Malaysia, 46150 Bandar Sunway, Selangor, Malaysia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosli</LastName>
                    <ForeName>Rozita</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Medical Genetics Laboratory, Clinical Genetics Unit, Faculty of Medicine and Health Sciences, UPM, 43400 Serdang, Selangor, Malaysia ; UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, UPM, 43400 Serdang, Selangor, Malaysia ; Genetics &amp; Regenerative Medicine Research Centre, Faculty of Medicine &amp; Health Sciences, Universiti Putra Malaysia, UPM, 43400 Serdang, Selangor, Malaysia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hassan</LastName>
                    <ForeName>Fatma</ForeName>
                    <Initials>F</Initials>
                    <Identifier Source="ORCID">0000-0003-4419-0064</Identifier>
                    <Affiliation>Molecular Pathology Research Group, Faculty of Pharmacy and Biotechnology, German University, New Cairo 11835, Egypt.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abdullah</LastName>
                    <ForeName>Syahril</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">0000-0003-2718-6266</Identifier>
                    <Affiliation>Medical Genetics Laboratory, Clinical Genetics Unit, Faculty of Medicine and Health Sciences, UPM, 43400 Serdang, Selangor, Malaysia ; UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, UPM, 43400 Serdang, Selangor, Malaysia ; Genetics &amp; Regenerative Medicine Research Centre, Faculty of Medicine &amp; Health Sciences, Universiti Putra Malaysia, UPM, 43400 Serdang, Selangor, Malaysia.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biomed Res Int</MedlineTA>
            <NlmUniqueID>101600173</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/646787</ArticleId>
            <ArticleId IdType="pubmed">25143941</ArticleId>
            <ArticleId IdType="pmc">PMC4131073</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143871</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">2167-0846</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>Suppl 3</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of pain &amp; relief</Title>
                <ISOAbbreviation>J Pain Relief</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phenotypic Identification of Spinal Cord-Infiltrating CD4(+) T Lymphocytes in a Murine Model of Neuropathic Pain.</ArticleTitle>
            <Pagination>
                <MedlinePgn>003</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neuropathic pain is one of the most devastating kinds of chronic pain. Neuroinflammation has been shown to contribute to the development of neuropathic pain. We have previously demonstrated that lumbar spinal cord-infiltrating CD4(+) T lymphocytes contribute to the maintenance of mechanical hypersensitivity in spinal nerve L5 transection (L5Tx), a murine model of neuropathic pain. Here, we further examined the phenotype of the CD4(+) T lymphocytes involved in the maintenance of neuropathic pain-like behavior via intracellular flow cytometric analysis and explored potential interactions between infiltrating CD4(+) T lymphocytes and spinal cord glial cells.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We consistently observed significantly higher numbers of T-Bet(+), IFN-??(+), TNF-??(+), and GM-CSF(+), but not GATA3(+) or IL-4(+), lumbar spinal cord-infiltrating CD4(+) T lymphocytes in the L5Tx group compared to the sham group at day 7 post-L5Tx. This suggests that the infiltrating CD4(+) T lymphocytes expressed a pro-inflammatory type 1 phenotype (Th1). Despite the observation of CD4(+) CD40 ligand (CD154)(+) T lymphocytes in the lumbar spinal cord post-L5Tx, CD154 knockout (KO) mice did not display significant changes in L5Tx-induced mechanical hypersensitivity, indicating that T lymphocyte-microglial interaction through the CD154-CD40 pathway is not necessary for L5Tx-induced hypersensitivity. In addition, spinal cord astrocytic activation, represented by glial fibillary acidic protein (GFAP) expression, was significantly lower in CD4 KO mice compared to wild type (WT) mice at day 14 post-L5Tx, suggesting the involvement of astrocytes in the pronociceptive effects mediated by infiltrating CD4(+) T lymphocytes.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In all, these data indicate that the maintenance of L5Tx-induced neuropathic pain is mostly mediated by Th1 cells in a CD154-independent manner via a mechanism that could involve multiple Th1 cytokines and astrocytic activation.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Draleau</LastName>
                    <ForeName>Ks</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Biomedical Sciences, College of Osteopathic Medicine, University of New England, Biddeford, ME, 04005, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Maddula</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Biomedical Sciences, College of Osteopathic Medicine, University of New England, Biddeford, ME, 04005, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Slaiby</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Biomedical Sciences, College of Osteopathic Medicine, University of New England, Biddeford, ME, 04005, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nutile-McMenemy</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Anesthesiology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>De Leo</LastName>
                    <ForeName>Ja</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Anesthesiology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA ; Vice President of Academic Affairs, Professor of Biology, Emmanuel College, 400 The Fenway, Boston, MA 02215, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cao</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Biomedical Sciences, College of Osteopathic Medicine, University of New England, Biddeford, ME, 04005, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <GrantList>
                <Grant>
                    <GrantID>K01 DA023503</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Pain Relief</MedlineTA>
            <NlmUniqueID>101610026</NlmUniqueID>
            <ISSNLinking>2167-0846</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Astrocytes</Keyword>
            <Keyword MajorTopicYN="N">CD154 knockout mice</Keyword>
            <Keyword MajorTopicYN="N">CD4+ T lymphocytes</Keyword>
            <Keyword MajorTopicYN="N">Type 1 helper T cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4172/2167-0846.S3-003</ArticleId>
            <ArticleId IdType="pubmed">25143871</ArticleId>
            <ArticleId IdType="pmc">PMC4136538</ArticleId>
            <ArticleId IdType="mid">NIHMS611217</ArticleId>
        </ArticleIdList>
        <?nihms?>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143862</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">2160-8407</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>4</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of nuclear medicine and molecular imaging</Title>
                <ISOAbbreviation>Am J Nucl Med Mol Imaging</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>435-47</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Personalized medicine is at the forefront of cancer diagnosis and therapy. Molecularly targeted therapies such as trastuzumab and tamoxifen have enhanced prognosis of patients with cancers expressing ERBB2 and the estrogen receptor, respectively. One obstacle to targeted therapy is the development of resistance. A targeted peptide that could distinguish resistance-susceptible cancer would aid in treatment. BT-474 human breast cancer cells can be resistant to both tamoxifen and trastuzumab, and may serve as a model for malignancies in which targeted therapy may not work. Bacteriophage (phage) display is a combinatorial technology that has been used to isolate peptides that target a specific cancer subtype. It was hypothesized that in vivo phage display could be used to select a peptide for SPECT imaging of BT-474 human breast cancer xenografts. A phage library displaying random 15 amino acid peptides was subjected to four rounds of selection, after which 14 clones were analyzed for BT-474 binding and specificity. One phage clone, 51, demonstrated superior binding and specificity, and the displayed peptide was synthesized for in vitro characterization. Peptide 51 bound specifically to BT-474 cells with an EC50 = 2.33 ??M and was synthesized as a DOTA-conjugated peptide and radiolabeled with (111)In for in vitro and in vivo analysis. The radiolabeled peptide exhibited an IC50 = 16.1 nM to BT-474 cells and its biodistribution and SPECT imaging in BT-474 xenografted mice was analyzed. Although tumor uptake was moderate at 0.11% ID/g, SPECT imaging revealed a distinct tumor vasculature binding pattern. It was discovered that peptide 51 had an identical 5 amino acid N-terminal sequence to a peptide, V1, which bound to Nrp1, a tumor vasculature protein. Peptide 51 and V1 were examined for binding to target cells, and 51 bound both target and endothelial cells, while V1 only bound endothelial cells. Truncated versions of 51 did not bind BT-474 cells, demonstrating that the targeting ability of 51 was independent of the homologous V1 sequence. These results demonstrate that in vivo phage display can effectively identify a peptide that specifically targets a breast cancer cell line that is susceptible to targeted therapy resistance.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Larimer</LastName>
                    <ForeName>Benjamin M</ForeName>
                    <Initials>BM</Initials>
                    <Affiliation>Research Services, Harry S. Truman Veterans Affairs Hospital Columbia, MO ; Department of Biochemistry, University of Missouri Columbia, MO.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deutscher</LastName>
                    <ForeName>Susan L</ForeName>
                    <Initials>SL</Initials>
                    <Affiliation>Research Services, Harry S. Truman Veterans Affairs Hospital Columbia, MO ; Department of Biochemistry, University of Missouri Columbia, MO.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Nucl Med Mol Imaging</MedlineTA>
            <NlmUniqueID>101564121</NlmUniqueID>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Peptide</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">molecular imaging</Keyword>
            <Keyword MajorTopicYN="N">phage display</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25143862</ArticleId>
            <ArticleId IdType="pmc">PMC4138138</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143818</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">2001-0001</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>4</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Pathobiology of aging &amp; age related diseases</Title>
                <ISOAbbreviation>Pathobiol Aging Age Relat Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Investigation and identification of etiologies involved in the development of acquired hydronephrosis in aged laboratory mice with the use of high-frequency ultrasound imaging.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3402/pba.v4.24932</ELocationID>
            <Abstract>
                <AbstractText>Laboratory mice develop naturally occurring lesions that affect biomedical research. Hydronephrosis is a recognized pathologic abnormality of the mouse kidney. Acquired hydronephrosis can affect any mouse, as it is caused by any naturally occurring disease that impairs free urine flow. Many etiologies leading to this condition are of particular significance to aging mice. Non-invasive ultrasound imaging detects renal pelvic dilation, renal enlargement, and parenchymal loss for pre-mortem identification of this condition. High-frequency ultrasound transducers produce high-resolution images of small structures, ideal for detecting organ pathology in mice. Using a 40 MHz linear array transducer, we obtained high-resolution images of a diversity of pathologic lesions occurring within the abdomen of seven geriatric mice with acquired hydronephrosis that enabled a determination of the underlying etiology. Etiologies diagnosed from the imaging results include pyelonephritis, neoplasia, urolithiasis, mouse urologic syndrome, and spontaneous hydronephrosis, and were confirmed at necropsy. A retrospective review of abdominal scans from an additional 149 aging mice shows that the most common etiologies associated with acquired hydronephrosis are mouse urologic syndrome and abdominal neoplasia. This report highlights the utility of high-frequency ultrasound for surveying research mice for age-related pathology, and is the first comprehensive report of multiple cases of acquired hydronephrosis in mice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Springer</LastName>
                    <ForeName>Danielle A</ForeName>
                    <Initials>DA</Initials>
                    <Affiliation>Murine Phenotyping Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Allen</LastName>
                    <ForeName>Michele</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Murine Phenotyping Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoffman</LastName>
                    <ForeName>Victoria</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Office of Research Services, Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brinster</LastName>
                    <ForeName>Lauren</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Office of Research Services, Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Starost</LastName>
                    <ForeName>Matthew F</ForeName>
                    <Initials>MF</Initials>
                    <Affiliation>Office of Research Services, Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bryant</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Office of Research Services, Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eckhaus</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Office of Research Services, Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Sweden</Country>
            <MedlineTA>Pathobiol Aging Age Relat Dis</MedlineTA>
            <NlmUniqueID>101575310</NlmUniqueID>
            <ISSNLinking>2001-0001</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">abdominal imaging</Keyword>
            <Keyword MajorTopicYN="N">abdominal neoplasia</Keyword>
            <Keyword MajorTopicYN="N">hydronephrosis</Keyword>
            <Keyword MajorTopicYN="N">kidney</Keyword>
            <Keyword MajorTopicYN="N">mice</Keyword>
            <Keyword MajorTopicYN="N">mouse urologic syndrome</Keyword>
            <Keyword MajorTopicYN="N">pathology</Keyword>
            <Keyword MajorTopicYN="N">renal pelvic dilation</Keyword>
            <Keyword MajorTopicYN="N">ultrasound</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3402/pba.v4.24932</ArticleId>
            <ArticleId IdType="pii">24932</ArticleId>
            <ArticleId IdType="pubmed">25143818</ArticleId>
            <ArticleId IdType="pmc">PMC4119937</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143817</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1976-9148</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomolecules &amp; therapeutics</Title>
                <ISOAbbreviation>Biomol Ther (Seoul)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dependence Potential of the Synthetic Cannabinoids JWH-073, JWH-081, and JWH-210: In Vivo and In Vitro Approaches.</ArticleTitle>
            <Pagination>
                <MedlinePgn>363-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4062/biomolther.2014.039</ELocationID>
            <Abstract>
                <AbstractText>Synthetic cannabinoids (CBs) such as the JWH series have caused social problems concerning their abuse liability. Because the JWH series produces euphoric and hallucinogenic effects, they have been distributed illegally under street names such as &quot;Spice&quot; and &quot;Smoke&quot;. Many countries including Korea have started to schedule some of the JWH series compounds as controlled substances, but there are a number of JWH series chemicals that remain uncontrolled by law. In this study, three synthetic CBs with different binding affinities to the CB1 receptor (JWH-073, 081, and 210) and ??(9)-tetrahydrocannabinol (??(9)-THC) were evaluated for their potential for psychological dependence. The conditioned place preference test (unbiased method) and self-administration test (fixed ratio of 1) using rodents were conducted. Ki values of the three synthetic cannabinoids were calculated as supplementary data using a receptor binding assay and overexpressed CB1 protein membranes to compare dependence potential with CB1 receptor binding affinity. All mice administered JWH-073, 081, or 210 showed significantly increased time spent at unpreferred space in a dose-dependence manner in the conditioned place preference test. In contrast, all tested substances except ??(9)-THC showed aversion phenomenon at high doses in the conditioned place preference test. The order of affinity to the CB1 receptor in the receptor binding assay was JWH-210 &gt; JWH-081 &gt; JWH-073, which was in agreement with the results from the conditioned place preference test. However, no change in self-administration was observed. These findings suggest the possibility to predict dependence potential of synthetic CBs through a receptor binding assay at the screening level.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cha</LastName>
                    <ForeName>Hye Jin</ForeName>
                    <Initials>HJ</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700 ; Department of Infectious Diseases, College of Veterinary Medicine, Seoul National University, Seoul 151-742, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Kwang-Wook</ForeName>
                    <Initials>KW</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Min-Ji</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hyeon</LastName>
                    <ForeName>Yang-Jin</ForeName>
                    <Initials>YJ</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hwang</LastName>
                    <ForeName>Ji-Young</ForeName>
                    <Initials>JY</Initials>
                    <Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon 440-746.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jang</LastName>
                    <ForeName>Choon-Gon</ForeName>
                    <Initials>CG</Initials>
                    <Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon 440-746.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahn</LastName>
                    <ForeName>Joon-Ik</ForeName>
                    <Initials>JI</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeon</LastName>
                    <ForeName>Seol-Hee</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Hyun-Uk</ForeName>
                    <Initials>HU</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Young-Hoon</ForeName>
                    <Initials>YH</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seong</LastName>
                    <ForeName>Won-Keun</ForeName>
                    <Initials>WK</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kang</LastName>
                    <ForeName>Hoil</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoo</LastName>
                    <ForeName>Han Sang</ForeName>
                    <Initials>HS</Initials>
                    <Affiliation>Department of Infectious Diseases, College of Veterinary Medicine, Seoul National University, Seoul 151-742, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeong</LastName>
                    <ForeName>Ho-Sang</ForeName>
                    <Initials>HS</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Biomol Ther (Seoul)</MedlineTA>
            <NlmUniqueID>101472832</NlmUniqueID>
            <ISSNLinking>1976-9148</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Binding affinity</Keyword>
            <Keyword MajorTopicYN="N">CB1 receptor</Keyword>
            <Keyword MajorTopicYN="N">Psychological dependence</Keyword>
            <Keyword MajorTopicYN="N">Synthetic cannabinoid</Keyword>
            <Keyword MajorTopicYN="N">??9-Tetrahydrocannabinol (??9-THC)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2014.039</ArticleId>
            <ArticleId IdType="pii">bt-22-363</ArticleId>
            <ArticleId IdType="pubmed">25143817</ArticleId>
            <ArticleId IdType="pmc">PMC4131522</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143814</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1976-9148</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomolecules &amp; therapeutics</Title>
                <ISOAbbreviation>Biomol Ther (Seoul)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Antitumor and Apoptosis Induction Effects of Paeonol on Mice Bearing EMT6 Breast Carcinoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>341-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4062/biomolther.2013.106</ELocationID>
            <Abstract>
                <AbstractText>Paeonol is a major phenolic micromolecular component of Moutan cortex Radicis, a traditional Chinese Medicine. It has shown antitumor effects in previous studies; however, the underlying mechanisms remain unknown. This study investigated the mechanism by giving treatments of placebo, cyclophosphamide, paeonol of 150 and 300 mg/kg to 4 groups of mice bearing EMT6 breast cancer. Apoptosis in tumor cells were confirmed by morphology analysis, including hematoxylin, eosin staining and TUNEL staining. The results showed that the weight of EMT6 breast tumor was significantly reduced in the groups treated with both 150 and 300 mg/kg of paeonol. Immunohistochemical and Western blot results showed that the expression of Bcl-2 was down-regulated while the expression of Bax, caspase 8 and caspase 3 was up-regulated respectively. These results suggest that paeonol exhibits antitumor effects and the mechanism of the inhibition is via induction of apoptosis, regulation of Bcl-2 and Bax expression, and activation of caspase 8 and caspase 3.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ou</LastName>
                    <ForeName>Yetao</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Biological Engineering, College of Environment and Chemical Engineering, Yanshan University, Qinghuangdao 066004 ; College of Basic Medicine, Jiamusi University, Jiamusi 154007, P. R China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Qingwang</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Department of Biological Engineering, College of Environment and Chemical Engineering, Yanshan University, Qinghuangdao 066004 ; College of Animal Science, Northwest A&amp;F University, Yangling 712100.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jianjie</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>College of Basic Medicine, Jiamusi University, Jiamusi 154007, P. R China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Kun</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Biological Engineering, College of Environment and Chemical Engineering, Yanshan University, Qinghuangdao 066004.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Shaobo</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Life Science, Institute of Biomedical and Environmental Science and Technology, University of Bedfordshire, Luton, LU1 3JU, UK.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Biomol Ther (Seoul)</MedlineTA>
            <NlmUniqueID>101472832</NlmUniqueID>
            <ISSNLinking>1976-9148</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apoptosis</Keyword>
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Paeonol</Keyword>
            <Keyword MajorTopicYN="N">Pathway</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2013.106</ArticleId>
            <ArticleId IdType="pii">bt-22-341</ArticleId>
            <ArticleId IdType="pubmed">25143814</ArticleId>
            <ArticleId IdType="pmc">PMC4131527</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143812</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1976-9148</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomolecules &amp; therapeutics</Title>
                <ISOAbbreviation>Biomol Ther (Seoul)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Adipose-derived stem cells improve efficacy of melanocyte transplantation in animal skin.</ArticleTitle>
            <Pagination>
                <MedlinePgn>328-33</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4062/biomolther.2014.065</ELocationID>
            <Abstract>
                <AbstractText>Vitiligo is a pigmentary disorder induced by a loss of melanocytes. In addition to replacement of pure melanocytes, cocultures of melanocytes with keratinocytes have been used to improve the repigmentation outcome in vitiligo treatment. We previously identified by in vitro studies, that adipose-derived stem cells (ADSCs) could be a potential substitute for keratinocytes in cocultures with melanocytes. In this study, the efficacy of pigmentation including durability of grafted melanocytes and short-term safety was examined in the nude mouse and Sprague-Dawley rat after grafting of primary cultured human melanocytes, with or without different ratios of primary cultured human ADSCs. Simultaneous grafting of melanocytes and ADSCs, which were separately cultured and mixed on grafting at the ratios of 1:1, 1:2, or 1:3, showed better efficacy than that of pure melanocytes. Grafting of melanocytes cocultured with ADSCs resulted in a similar outcome as the grafting of cell mixtures. Skin pigmentation by melanocytes : ADSCs at the ratios of 1:1 and 1:2 was better than at 1:3. No significant difference was observed between the 1-week and 2-week durations in coculturing. Time-course microscopic examination showed that the grafted melanocytes remained a little longer than 6-week post-grafting. No inflammatory cell infiltration was observed in the grafted skin and no melanocytes were detectable in other organs. Collectively, grafting of melanocytes and ADSCs was equally safe and more effective than grafting of melanocytes alone. Despite the absence of significant differences in efficacy between the group of 1:1 and that of 1:2 ratio, 1:2 ratio for 1-week coculturing may be better for clinical use from the cost-benefit viewpoint.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Won-Suk</ForeName>
                    <Initials>WS</Initials>
                    <Affiliation>Departments of Dermatology, Dongguk University Ilsan Hospital, Goyang 410-773.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Chang-Hyun</ForeName>
                    <Initials>CH</Initials>
                    <Affiliation>Departments of Dermatology, Dongguk University Ilsan Hospital, Goyang 410-773.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Ji-Young</ForeName>
                    <Initials>JY</Initials>
                    <Affiliation>Departments of Dermatology, Dongguk University Ilsan Hospital, Goyang 410-773.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Do</LastName>
                    <ForeName>Byung-Rok</ForeName>
                    <Initials>BR</Initials>
                    <Affiliation>Biotechnology Research Institute, Hurim BioCell Inc., Seoul 157-793, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Eo Jin</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Pathology, Dongguk University Ilsan Hospital, Goyang 410-773.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Ai-Young</ForeName>
                    <Initials>AY</Initials>
                    <Affiliation>Departments of Dermatology, Dongguk University Ilsan Hospital, Goyang 410-773.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Biomol Ther (Seoul)</MedlineTA>
            <NlmUniqueID>101472832</NlmUniqueID>
            <ISSNLinking>1976-9148</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adipose-derived stem cells</Keyword>
            <Keyword MajorTopicYN="N">Animal</Keyword>
            <Keyword MajorTopicYN="N">Efficacy</Keyword>
            <Keyword MajorTopicYN="N">Grafting</Keyword>
            <Keyword MajorTopicYN="N">Melanocytes</Keyword>
            <Keyword MajorTopicYN="N">Short-term safety</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2014.065</ArticleId>
            <ArticleId IdType="pii">bt-22-328</ArticleId>
            <ArticleId IdType="pubmed">25143812</ArticleId>
            <ArticleId IdType="pmc">PMC4131530</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143811</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1976-9148</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomolecules &amp; therapeutics</Title>
                <ISOAbbreviation>Biomol Ther (Seoul)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS).</ArticleTitle>
            <Pagination>
                <MedlinePgn>321-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4062/biomolther.2014.053</ELocationID>
            <Abstract>
                <AbstractText>Collagen pentapeptide (Lys-Thr-Thr-Lys-Ser, KTTKS) and its palmitoylated derivative (pal-KTTKS) have received a great deal of attention as cosmeceutical ingredients for their anti-wrinkle effects. The objective of this study was to evaluate stability and permeability of KTTKS and pal-KTTKS in hairless mouse skin. In this study, a liquid chromatography-tandem mass spectrometric method was developed for the quantification of pal-KTTKS, and used for stability and permeability studies. Stability studies were performed using skin extracts and homogenates. Both KTTKS and pal-KTTKS were rapidly degraded, but pal-KTTKS was more stable than KTTKS. When protease inhibitors were added, the stability of both compounds (KTTKS and pal-KTTKS) improved significantly. In the skin permeation study, neither KTTKS nor pal-KTTKS was detected in the receptor solution, which indicates that neither compound could permeate through the full-thickness hairless mouse skin in the experimental conditions of this study. While KTTKS was not detected in any of the skin layers (the stratum corneum, epidermis, and dermis), pal-KTTKS was observed in all skin layers: 4.2 ?? 0.7 ??g/cm(2) in the stratum corneum, 2.8 ?? 0.5 ??g/cm(2) in the epidermis, and 0.3 ?? 0.1 ??g/cm(2) in the dermis. In conclusion, this study indicated that pal-KTTKS had greater stability and permeability than that of un-modified KTTKS, and may be a useful anti-wrinkle and anti-aging cosmeceutical agent.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Yun Lim</ForeName>
                    <Initials>YL</Initials>
                    <Affiliation>College of Pharmacy, Kyungsung University, Busan 608-736.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Eun Ji</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu 702-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Eunje</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>College of Pharmacy, Kyungsung University, Busan 608-736.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Na</LastName>
                    <ForeName>Dong Hee</ForeName>
                    <Initials>DH</Initials>
                    <Affiliation>Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu 702-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shin</LastName>
                    <ForeName>Young-Hee</ForeName>
                    <Initials>YH</Initials>
                    <Affiliation>College of Pharmacy, Kyungsung University, Busan 608-736.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Biomol Ther (Seoul)</MedlineTA>
            <NlmUniqueID>101472832</NlmUniqueID>
            <ISSNLinking>1976-9148</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Collagen pentapeptide</Keyword>
            <Keyword MajorTopicYN="N">KTTKS</Keyword>
            <Keyword MajorTopicYN="N">Palmitoyl-KTTKS</Keyword>
            <Keyword MajorTopicYN="N">Permeability</Keyword>
            <Keyword MajorTopicYN="N">Stability</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2014.053</ArticleId>
            <ArticleId IdType="pii">bt-22-321</ArticleId>
            <ArticleId IdType="pubmed">25143811</ArticleId>
            <ArticleId IdType="pmc">PMC4131521</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143810</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1976-9148</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomolecules &amp; therapeutics</Title>
                <ISOAbbreviation>Biomol Ther (Seoul)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pachymic Acid Enhances Pentobarbital-Induced Sleeping Behaviors via GABAA-ergic Systems in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>314-20</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4062/biomolther.2014.045</ELocationID>
            <Abstract>
                <AbstractText>This study was investigated to know whether pachymic acid (PA), one of the predominant triterpenoids in Poria cocos (Hoelen) has the sedative-hypnotic effects, and underlying mechanisms are mediated via ??-aminobutyric acid (GABA)-ergic systems. Oral administration of PA markedly suppressed locomotion activity in mice. This compound also prolonged sleeping time, and reduced sleep latency showing synergic effects with muscimol (0.2 mg/kg) in shortening sleep onset and enhancing sleep time induced by pentobarbital, both at the hypnotic (40 mg/kg) and sub-hypnotic (28 mg/kg) doses. Additionally, PA elevated intracellular chloride levels in hypothalamic primary cultured neuronal cells of rats. Moreover, Western blotting quantitative results showed that PA increased the amount of protein level expression of GAD65/67 over a broader range of doses. PA increased ??- and ??-subunits protein levels, but decreased ??-subunit protein levels in GABAA receptors. The present experiment provides evidence for the hypnotic effects as PA enhanced pentobarbital-induced sleeping behaviors via GABAA-ergic mechanisms in rodents. Taken together, it is proposed that PA may be useful for the treatment of sleep disturbed subjects with insomnia.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shah</LastName>
                    <ForeName>Vikash Kumar</ForeName>
                    <Initials>VK</Initials>
                    <Affiliation>College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Jae Joon</ForeName>
                    <Initials>JJ</Initials>
                    <Affiliation>College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Jin-Yi</ForeName>
                    <Initials>JY</Initials>
                    <Affiliation>Institute of Veterinary Medicine, Chungbuk National University, Cheongju 361-763, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Mi Kyeong</ForeName>
                    <Initials>MK</Initials>
                    <Affiliation>College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hong</LastName>
                    <ForeName>Jin Tae</ForeName>
                    <Initials>JT</Initials>
                    <Affiliation>College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oh</LastName>
                    <ForeName>Ki-Wan</ForeName>
                    <Initials>KW</Initials>
                    <Affiliation>College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Biomol Ther (Seoul)</MedlineTA>
            <NlmUniqueID>101472832</NlmUniqueID>
            <ISSNLinking>1976-9148</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">GABAA receptors</Keyword>
            <Keyword MajorTopicYN="N">Glutamic acid decarboxylase (GAD)</Keyword>
            <Keyword MajorTopicYN="N">Insomnia</Keyword>
            <Keyword MajorTopicYN="N">Pachymic acid (PA)</Keyword>
            <Keyword MajorTopicYN="N">Pentobarbital (PENT)</Keyword>
            <Keyword MajorTopicYN="N">Poria cocos (Hoelen)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2014.045</ArticleId>
            <ArticleId IdType="pii">bt-22-314</ArticleId>
            <ArticleId IdType="pubmed">25143810</ArticleId>
            <ArticleId IdType="pmc">PMC4131518</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143803</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1976-9148</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomolecules &amp; therapeutics</Title>
                <ISOAbbreviation>Biomol Ther (Seoul)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genetically engineered mouse models for drug development and preclinical trials.</ArticleTitle>
            <Pagination>
                <MedlinePgn>267-74</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4062/biomolther.2014.074</ELocationID>
            <Abstract>
                <AbstractText>Drug development and preclinical trials are challenging processes and more than 80% to 90% of drug candidates fail to gain approval from the United States Food and Drug Administration. Predictive and efficient tools are required to discover high quality targets and increase the probability of success in the process of new drug development. One such solution to the challenges faced in the development of new drugs and combination therapies is the use of low-cost and experimentally manageable in vivo animal models. Since the 1980's, scientists have been able to genetically modify the mouse genome by removing or replacing a specific gene, which has improved the identification and validation of target genes of interest. Now genetically engineered mouse models (GEMMs) are widely used and have proved to be a powerful tool in drug discovery processes. This review particularly covers recent fascinating technologies for drug discovery and preclinical trials, targeted transgenesis and RNAi mouse, including application and combination of inducible system. Improvements in technologies and the development of new GEMMs are expected to guide future applications of these models to drug discovery and preclinical trials.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Ho</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Division of Convergence Technology, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 410-769, Republic of Korea.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Biomol Ther (Seoul)</MedlineTA>
            <NlmUniqueID>101472832</NlmUniqueID>
            <ISSNLinking>1976-9148</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Drug discovery</Keyword>
            <Keyword MajorTopicYN="N">Genetically engineered mouse models</Keyword>
            <Keyword MajorTopicYN="N">Preclinical trials</Keyword>
            <Keyword MajorTopicYN="N">RNAi mouse</Keyword>
            <Keyword MajorTopicYN="N">Targeted transgenesis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2014.074</ArticleId>
            <ArticleId IdType="pii">bt-22-267</ArticleId>
            <ArticleId IdType="pubmed">25143803</ArticleId>
            <ArticleId IdType="pmc">PMC4131519</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143786</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1758-5996</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Diabetology &amp; metabolic syndrome</Title>
                <ISOAbbreviation>Diabetol Metab Syndr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models.</ArticleTitle>
            <Pagination>
                <MedlinePgn>83</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/1758-5996-6-83</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In addition to their role in growth, cellular differentiation and homeostasis Retinoid X Receptors (RXR) regulate multiple physiological and metabolic pathways in various organs that have beneficial glucose and lipid (cholesterol) lowering, insulin sensitizing and anti-obesity effects. Rexinoids, compounds that specifically binds and activate RXR, are therefore considered as potential therapeutics for treating metabolic syndrome. Apparently many of the rexinoids developed in the past increased triglycerides, caused hepatomegaly and also suppressed the thyroid hormone axis. The aim of this study is to evaluate CNX-013-B2, a potent and highly selective rexinoid, for its potential to treat multiple risk factors of the metabolic syndrome.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">CNX-013-B2 was selected in a screening system designed to identify compounds that selectively activated only a chosen sub-set of heterodimer partners of RXR of importance to treat insulin resistance. Male C57BL/6j mice (n???=???10) on high fat diet (HFD) and 16 week old ob/ob mice (n???=???8) were treated orally with CNX-013-B2 (10 mg/kg twice daily) or vehicle for 10 weeks and 4 weeks respectively. Measurement of plasma glucose, triglyceride, cholesterol including LDL-C, glycerol, free fatty acids, feed intake, body weight, oral glucose tolerance and non-shivering thermogenesis were performed at selected time points. After study termination such measurements as organ weight, triglyceride content, mRNA levels, protein phosphorylation along with histological analysis were performed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">CNX-013-B2 selectively activates PPARs- ??, ??/?? and ?? and modulates activity of LXR, THR and FXR. In ob/ob mice a significant reduction of 25% in fed glucose (p???&lt;???0.001 ), a 14% (p???&lt;???0.05) reduction in serum total cholesterol and 18% decrease (p???&lt;???0.01) in LDL-C and in DIO mice a reduction of 12% (p???&lt;???0.01 ) in fasting glucose, 20% in fed triglyceride (p???&lt;???0.01) and total cholesterol (p???&lt;???0.001) levels, coupled with enhanced insulin sensitivity, cold induced thermogenesis and 7% reduction in body weight were observed.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CNX-013-B2 is an orally bio available selective rexinoid that can be used as a novel therapeutic agent for management of multiple risk factors of the metabolic syndrome without the risk of side effects reported to be associated with rexinoids.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sadasivuni</LastName>
                    <ForeName>Manoj Kumar</ForeName>
                    <Initials>MK</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reddy</LastName>
                    <ForeName>Bobbili Madhusudhan</ForeName>
                    <Initials>BM</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Jaideep</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Anup</LastName>
                    <ForeName>Mammen O</ForeName>
                    <Initials>MO</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sunil</LastName>
                    <ForeName>Venkategowda</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lakshmi</LastName>
                    <ForeName>Mudigere N</ForeName>
                    <Initials>MN</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yogeshwari</LastName>
                    <ForeName>Sivakumaran</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chacko</LastName>
                    <ForeName>Suni K</ForeName>
                    <Initials>SK</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pooja</LastName>
                    <ForeName>Talanki Lokesh</ForeName>
                    <Initials>TL</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dandu</LastName>
                    <ForeName>Anilkumar</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harish</LastName>
                    <ForeName>Chandrashekaran</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gopala</LastName>
                    <ForeName>Aralakuppe S</ForeName>
                    <Initials>AS</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pratibha</LastName>
                    <ForeName>Shivakumar</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naveenkumar</LastName>
                    <ForeName>Baisani S</ForeName>
                    <Initials>BS</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pallavi</LastName>
                    <ForeName>Puttrevana M</ForeName>
                    <Initials>PM</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Verma</LastName>
                    <ForeName>Mahesh Kumar</ForeName>
                    <Initials>MK</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moolemath</LastName>
                    <ForeName>Yoganand</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Somesh</LastName>
                    <ForeName>Baggavalli P</ForeName>
                    <Initials>BP</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Venkataranganna</LastName>
                    <ForeName>Marikunte V</ForeName>
                    <Initials>MV</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jagannath</LastName>
                    <ForeName>Madanahalli R</ForeName>
                    <Initials>MR</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Diabetol Metab Syndr</MedlineTA>
            <NlmUniqueID>101488958</NlmUniqueID>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CHF</Keyword>
            <Keyword MajorTopicYN="N">Diabetes</Keyword>
            <Keyword MajorTopicYN="N">Dyslipidemia</Keyword>
            <Keyword MajorTopicYN="N">Exercise mimetic</Keyword>
            <Keyword MajorTopicYN="N">Insulin sensitizer</Keyword>
            <Keyword MajorTopicYN="N">PPAR pan-activator</Keyword>
            <Keyword MajorTopicYN="N">Steatosis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1758-5996-6-83</ArticleId>
            <ArticleId IdType="pii">348</ArticleId>
            <ArticleId IdType="pubmed">25143786</ArticleId>
            <ArticleId IdType="pmc">PMC4138375</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143767</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1735-4668</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Season>Summer</Season>
                    </PubDate>
                </JournalIssue>
                <Title>Iranian journal of child neurology</Title>
                <ISOAbbreviation>Iran J Child Neurol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Familial hemiplegic migraine and spreading depression.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6-11</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Familial hemiplegic migraine (FHM) is an autosomal dominantly inherited subtype of migraine with aura, characterized by transient neurological signs and symptoms. Typical hemiplegic migraine attacks start in the first or second decade of life. Some patients with FHM suffer from daily recurrent attacks since childhood. Results from extensive studies of cellular and animal models have indicated that gene mutations in FHM increase neuronal excitability and reduce the threshold for spreading depression (SD). SD is a transient wave of profound neuronal and glial depolarization that slowly propagates throughout the brain tissue and is characterized by a high amplitude negative DC shift. After induction of SD, S218L mutant mice exhibited neurological signs highly reminiscent of clinical attacks in FHM type 1 patients carrying this mutation. FHM1 with ataxia is attributable to specific mutations that differ from mutations that cause pure FHM1 and have peculiar consequences on cerebellar Cav2.1 currents that lead to profound Purkinje cell dysfunction and neuronal loss with atrophy. SD in juvenile rats produced neuronal injury and death. Hormonal factors involved in FHM affect SD initiation and propagation. The data identify SD as a possible target of treatment of FHM. In addition, FHM is a useful model to explore the mechanisms of more common types of migraine.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kazemi</LastName>
                    <ForeName>Hadi</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Pediatric, Shahed University, Tehran, Iran ; Shefa Neuroscience Research Center, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Speckmann</LastName>
                    <ForeName>Erwin-Josef</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Epilepsy Research Center, Westf??lische Wilhelms-Universit??t M??nster, Germany ; Institut f??r Physiologie I, Westf??lische Wilhelms-Universit??t M??nster, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gorji</LastName>
                    <ForeName>Ali</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Shefa Neuroscience Research Center, Tehran, Iran ; Epilepsy Research Center, Westf??lische Wilhelms-Universit??t M??nster, Germany ; Institut f??r Physiologie I, Westf??lische Wilhelms-Universit??t M??nster, Germany ; Klinik und Poliklinik f??r Neurochirurgie, Westf??lische Wilhelms-Universit??t M??nster, Germany ; Department ofNeurology, Westf??lische Wilhelms-Universit??t M??nster, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Iran</Country>
            <MedlineTA>Iran J Child Neurol</MedlineTA>
            <NlmUniqueID>101463836</NlmUniqueID>
            <ISSNLinking>1735-4668</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cerebrovascular diseases</Keyword>
            <Keyword MajorTopicYN="N">Children</Keyword>
            <Keyword MajorTopicYN="N">Headache</Keyword>
            <Keyword MajorTopicYN="N">Spreading depolarization</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25143767</ArticleId>
            <ArticleId IdType="pmc">PMC4135274</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143734</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1178-2013</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of nanomedicine</Title>
                <ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3865-74</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S62630</ELocationID>
            <Abstract>
                <AbstractText>Primaquine (PQ) is one of the most widely used antimalarial drugs and is the only available drug that combats the relapsing form of malaria. PQ use in higher doses is limited by severe tissue toxicity including hematological- and gastrointestinal-related side effects. Nanoformulation of drugs in an appropriate drug carrier system has been extensively studied and shown to have the potential to improve bioavailability, thereby enhancing activity, reducing dose frequency, and subsequently reducing toxicity. The aim of this work was to design, synthesize, and characterize PQ-loaded solid lipid nanoparticles (SLNs) (PQ-SLNs) as a potential drug-delivery system. SLNs were prepared by a modified solvent emulsification evaporation method based on a water-in-oil-in-water (w/o/w) double emulsion. The mean particle size, zeta potential, drug loading, and encapsulation efficiency of the PQ-SLNs were 236 nm, +23 mV, 14%, and 75%, respectively. The zeta potential of the SLNs changed dramatically, from -6.54 mV to +23.0 mV, by binding positively charged chitosan as surface modifier. A spherical morphology of PQ-SLNs was seen by scanning electron microscope. In vitro, release profile depicted a steady drug release over 72 hours. Differential scanning calorimeter thermograms demonstrated presence of drug in drug-loaded nanoparticles along with disappearance of decomposition exotherms, suggesting increased physical stability of drug in prepared formulations. Negligible changes in characteristic peaks of drug in Fourier transform infrared spectra indicated absence of any interaction among the various components entrapped in the nanoparticle formulation. The nanoformulated PQ was 20% more effective as compared with conventional oral dose when tested in Plasmodium berghei-infected Swiss albino mice. This study demonstrated an efficient method of forming a nanomedicine delivery system for antimalarial drugs.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Omwoyo</LastName>
                    <ForeName>Wesley Nyaigoti</ForeName>
                    <Initials>WN</Initials>
                    <Affiliation>Department of Chemistry, Maasai Mara University, Narok, Kenya ; Department of Chemistry, Jaramogi Oginga Odinga University of Science and Technology, Bondo, Kenya.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ogutu</LastName>
                    <ForeName>Bernhards</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Center for Research in Therapeutic Sciences, Strathmore University, Nairobi, Kenya ; Kenya Medical Research Institute, Nairobi, Kenya.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oloo</LastName>
                    <ForeName>Florence</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Center for Research in Therapeutic Sciences, Strathmore University, Nairobi, Kenya ; Department of Chemical Sciences and Technology, Technical University of Kenya, Nairobi, Kenya.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swai</LastName>
                    <ForeName>Hulda</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Polymers and Composites, Council for Scientific and Industrial Research, Pretoria, South Africa.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kalombo</LastName>
                    <ForeName>Lonji</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Polymers and Composites, Council for Scientific and Industrial Research, Pretoria, South Africa.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Melariri</LastName>
                    <ForeName>Paula</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Polymers and Composites, Council for Scientific and Industrial Research, Pretoria, South Africa.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mahanga</LastName>
                    <ForeName>Geoffrey Maroa</ForeName>
                    <Initials>GM</Initials>
                    <Affiliation>Department of Chemistry, Jaramogi Oginga Odinga University of Science and Technology, Bondo, Kenya.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gathirwa</LastName>
                    <ForeName>Jeremiah Waweru</ForeName>
                    <Initials>JW</Initials>
                    <Affiliation>Center for Research in Therapeutic Sciences, Strathmore University, Nairobi, Kenya ; Kenya Medical Research Institute, Nairobi, Kenya.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Int J Nanomedicine</MedlineTA>
            <NlmUniqueID>101263847</NlmUniqueID>
            <ISSNLinking>1176-9114</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">antimalarial</Keyword>
            <Keyword MajorTopicYN="N">double emulsion</Keyword>
            <Keyword MajorTopicYN="N">nanomedicine drug-delivery system</Keyword>
            <Keyword MajorTopicYN="N">nanotechnology</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S62630</ArticleId>
            <ArticleId IdType="pii">ijn-9-3865</ArticleId>
            <ArticleId IdType="pubmed">25143734</ArticleId>
            <ArticleId IdType="pmc">PMC4137995</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143732</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1178-2013</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of nanomedicine</Title>
                <ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3841-53</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S64630</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Currently approved therapies for multiple sclerosis (MS) at best only slow down its progression. Therefore, it is necessary to utilize novel technologies in order to synthesize smart multifunctional structures. In the present study, for the first time we evaluated the therapeutic potential of MSc1 nanocomplex, which was designed based on novel nanochelating technology.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">MSc1 cell-protection capacity, with and without iron bond, was evaluated against hydrogen peroxide (H2O2)-induced oxidative stress in cultured rat pheochromocytoma-12 cells. The ability of MSc1 to maintain iron bond at pH ranges of 1-7 was evaluated. Nanocomplex toxicity was examined by estimating the intraperitoneal median lethal dose (LD50). Experimental autoimmune encephalomyelitic mice were injected with MSc1 14 days after disease induction, when the clinical symptoms appeared. The clinical score, body weight, and disease-induced mortality were monitored until day 54. In the end, after collecting blood samples for assessing hemoglobin and red blood cell count, the brains and livers of the mice were isolated for hematoxylin and eosin staining and analysis of iron content, respectively.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The results showed that MSc1 prevented H2O2-induced cell death even after binding with iron, and it preserved its bond with iron constant at pH ranges 1-7. The nanocomplex intraperitoneal LD50 was 1,776.59 mg/kg. MSc1 prompted therapeutic behavior and improved the disabling features of experimental autoimmune encephalomyelitis, which was confirmed by decreased clinical scores versus increased body mass and 100% survival probability. It did not cause any adverse effects on hemoglobin or red blood cell count. Histopathological studies showed no neural loss or lymphocyte infiltration in MSc1-treated mice, while the hepatic iron content was also normal.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results demonstrate that MSc1 could be a promising beneficial novel agent and has the capacity to be evaluated in further studies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fakharzadeh</LastName>
                    <ForeName>Saideh</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sahraian</LastName>
                    <ForeName>Mohammad Ali</ForeName>
                    <Initials>MA</Initials>
                    <Affiliation>MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hafizi</LastName>
                    <ForeName>Maryam</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kalanaky</LastName>
                    <ForeName>Somayeh</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Masoumi</LastName>
                    <ForeName>Zahra</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mahdavi</LastName>
                    <ForeName>Mehdi</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kamalian</LastName>
                    <ForeName>Nasser</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Pathology, Medical School of Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Minagar</LastName>
                    <ForeName>Alireza</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Neurology, LSU Health Sciences Centre, Shreveport, LA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nazaran</LastName>
                    <ForeName>Mohammad Hassan</ForeName>
                    <Initials>MH</Initials>
                    <Affiliation>Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Int J Nanomedicine</MedlineTA>
            <NlmUniqueID>101263847</NlmUniqueID>
            <ISSNLinking>1176-9114</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">EAE</Keyword>
            <Keyword MajorTopicYN="N">MSc1</Keyword>
            <Keyword MajorTopicYN="N">multiple sclerosis</Keyword>
            <Keyword MajorTopicYN="N">nanochelating technology</Keyword>
            <Keyword MajorTopicYN="N">nanocomplex</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S64630</ArticleId>
            <ArticleId IdType="pii">ijn-9-3841</ArticleId>
            <ArticleId IdType="pubmed">25143732</ArticleId>
            <ArticleId IdType="pmc">PMC4137990</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25143731</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1178-2013</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of nanomedicine</Title>
                <ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3825-39</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S65990</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We have previously demonstrated the epidermal growth factor receptor (EGFR)-targeted hybrid plasmonic magnetic nanoparticles (225-NP) produce a therapeutic effect in human lung cancer cell lines in vitro. In the present study, we investigated the molecular mechanism of 225-NP-mediated antitumor activity both in vitro and in vivo using the EGFR-mutant HCC827 cell line.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The growth inhibitory effect of 225-NP on lung tumor cells was determined by cell viability and cell-cycle analysis. Protein expression related to autophagy, apoptosis, and DNA-damage were determined by Western blotting and immunofluorescence. An in vivo efficacy study was conducted using a human lung tumor xenograft mouse model.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The 225-NP treatment markedly reduced tumor cell viability at 72 hours compared with the cell viability in control treatment groups. Cell-cycle analysis showed the percentage of cells in the G2/M phase was reduced when treated with 225-NP, with a concomitant increase in the number of cells in Sub-G1 phase, indicative of cell death. Western blotting showed LC3B and PARP cleavage, indicating 225-NP-treatment activated both autophagy- and apoptosis-mediated cell death. The 225-NP strongly induced ??H2AX and phosphorylated histone H3, markers indicative of DNA damage and mitosis, respectively. Additionally, significant ??H2AX foci formation was observed in 225-NP-treated cells compared with control treatment groups, suggesting 225-NP induced cell death by triggering DNA damage. The 225-NP-mediated DNA damage involved abrogation of the G2/M checkpoint by inhibiting BRCA1, Chk1, and phospho-Cdc2/CDK1 protein expression. In vivo therapy studies showed 225-NP treatment reduced EGFR phosphorylation, increased ??H2AX foci, and induced tumor cell apoptosis, resulting in suppression of tumor growth.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The 225-NP treatment induces DNA damage and abrogates G2/M phase of the cell cycle, leading to cellular apoptosis and suppression of lung tumor growth both in vitro and in vivo. Our findings provide a rationale for combining 225-NP with other DNA-damaging agents for achieving enhanced anticancer activity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kuroda</LastName>
                    <ForeName>Shinji</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tam</LastName>
                    <ForeName>Justina</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roth</LastName>
                    <ForeName>Jack A</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sokolov</LastName>
                    <ForeName>Konstantin</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramesh</LastName>
                    <ForeName>Rajagopal</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA ; Graduate Program in Biomedical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA ; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P50CA070907</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA103830</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R03EB009182</GrantID>
                    <Acronym>EB</Acronym>
                    <Agency>NIBIB NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Int J Nanomedicine</MedlineTA>
            <NlmUniqueID>101263847</NlmUniqueID>
            <ISSNLinking>1176-9114</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">autophagy</Keyword>
            <Keyword MajorTopicYN="N">epidermal growth factor receptor</Keyword>
            <Keyword MajorTopicYN="N">lung cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S65990</ArticleId>
            <ArticleId IdType="pii">ijn-9-3825</ArticleId>
            <ArticleId IdType="pubmed">25143731</ArticleId>
            <ArticleId IdType="pmc">PMC4134185</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25143665</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1875-8630</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Disease markers</Title>
                <ISOAbbreviation>Dis. Markers</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Recipients with in utero induction of tolerance upregulated MHC class I in the engrafted donor skin.</ArticleTitle>
            <Pagination>
                <MedlinePgn>531092</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/531092</ELocationID>
            <Abstract>
                <AbstractText>The alterations in MHC class I expression play a crucial step in immune evasion of cancer or virus-infected cells. This study aimed to examine whether tolerized grafts modified MHC class I expression. FVB/N mice were rendered tolerant of C57BL/6 alloantigens by in utero transplantation of C57BL/6 marrows. Postnatally, engrafted donor skins and leukocytes were examined for their MHC expression by quantitative real-time PCR and flow cytometry. Engrafted donor skins upregulated their MHC class I related gene transcripts after short-term (1~2 weeks) or long-term (&gt;1 month) engraftment. This biological phenomenon was simultaneously associated with upregulation of TAP1 gene transcripts, suggesting an important role of TAP1 in the regulation of MHC class I pathway. The surface MHC class I molecules of H-2K(b) in engrafted donor leukocytes consistently showed overexpression. Conclusively, the induction of allograft tolerance involved biological modifications of donor transplants. The overexpression of MHC class I within engrafted transplants of tolerant mice might be used as the tolerance biomarkers for identifying a state of graft tolerance.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jeng-Chang</ForeName>
                    <Initials>JC</Initials>
                    <Identifier Source="ORCID">0000-0002-7776-4338</Identifier>
                    <Affiliation>Department of Surgery, Chang Gung Children's Hospital, College of Medicine, Chang Gung University, 5 Fu-Shin Street, Kweishan, Taoyuan 333, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ou</LastName>
                    <ForeName>Liang-Shiou</ForeName>
                    <Initials>LS</Initials>
                    <Affiliation>Department of Allergy, Asthma and Rheumatology, Chang Gung Children's Hospital, College of Medicine, Chang Gung University, 5 Fu-Shin Street, Kweishan, Taoyuan 333, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Hsiu-Yueh</ForeName>
                    <Initials>HY</Initials>
                    <Affiliation>Pediatric Research Center, Chang Gung Children's Hospital, 5 Fu-Shin Street, Kweishan, Taoyuan 333, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuo</LastName>
                    <ForeName>Ming-Ling</ForeName>
                    <Initials>ML</Initials>
                    <Affiliation>Department of Microbiology and Immunology, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, 259 Wen-Hwa 1st Road, Kweishan, Taoyuan 333, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Pei-Yeh</ForeName>
                    <Initials>PY</Initials>
                    <Affiliation>Department of Surgery, Chang Gung Children's Hospital, College of Medicine, Chang Gung University, 5 Fu-Shin Street, Kweishan, Taoyuan 333, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Hsueh-Ling</ForeName>
                    <Initials>HL</Initials>
                    <Affiliation>Pediatric Research Center, Chang Gung Children's Hospital, 5 Fu-Shin Street, Kweishan, Taoyuan 333, Taiwan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Dis Markers</MedlineTA>
            <NlmUniqueID>8604127</NlmUniqueID>
            <ISSNLinking>0278-0240</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/531092</ArticleId>
            <ArticleId IdType="pubmed">25143665</ArticleId>
            <ArticleId IdType="pmc">PMC4131087</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143632</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1479-6805</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of endocrinology</Title>
                <ISOAbbreviation>J. Endocrinol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>20 YEARS OF LEPTIN: What we know and what the future holds.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">JOE-14-0506</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">This special issue of the Journal of Endocrinology celebrates the twentieth anniversary of the discovery of leptin, a hormone produced by adipose tissue which provides critical signals to the organism regarding the status of its energy stores. The discovery of leptin not only revolutionised our understanding of endocrine physiology but has also resulted in a registered medicinal product which is already improving the health of patients with serious metabolic diseases. In this issue we have gathered together a group of essays by some of the world leaders in leptin research, including an overview by Dr Jeffrey Friedman who, in his seminal article in December 1994, described the adipocyte-derived hormone, the lack of which was responsible for the severe obesity of ob/ob mice and suggested that it be named leptin.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>O'Rahilly</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>S O'Rahilly, University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Universty of Cambridge, Cambridge , United Kingdom so104@medschl.cam.ac.uk.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Endocrinol</MedlineTA>
            <NlmUniqueID>0375363</NlmUniqueID>
            <ISSNLinking>0022-0795</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">JOE-14-0506</ArticleId>
            <ArticleId IdType="doi">10.1530/JOE-14-0506</ArticleId>
            <ArticleId IdType="pubmed">25143632</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143627</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Activation of TRPML1 Clears Intraneuronal A?? in Preclinical Models of HIV Infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11485-503</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0210-14.2014</ELocationID>
            <Abstract>
                <AbstractText>Antiretroviral therapy extends the lifespan of human immunodeficiency virus (HIV)-infected patients, but many survivors develop premature impairments in cognition. These residual cognitive impairments may involve aberrant deposition of amyloid ??-peptides (A??). By unknown mechanisms, A?? accumulates in the lysosomal and autophagic compartments of neurons in the HIV-infected brain. Here we identify the molecular events evoked by the HIV coat protein gp120 that facilitate the intraneuronal accumulation of A??. We created a triple transgenic gp120/APP/PS1 mouse that recapitulates intraneuronal deposition of A?? in a manner reminiscent of the HIV-infected brain. In cultured neurons, we found that the HIV coat protein gp120 increased the transcriptional expression of BACE1 through repression of PPAR??, and increased APP expression by promoting interaction of the translation-activating RBP heterogeneous nuclear ribonucleoprotein C with APP mRNA. APP and BACE1 were colocalized into stabilized membrane microdomains, where the ??-cleavage of APP and A?? formation were enhanced. A??-peptides became localized to lysosomes that were engorged with sphingomyelin and calcium. Stimulating calcium efflux from lysosomes with a TRPM1 agonist promoted calcium efflux, luminal acidification, and cleared both sphingomyelin and A?? from lysosomes. These findings suggest that therapeutics targeted to reduce lysosomal pH in neurodegenerative conditions may protect neurons by facilitating the clearance of accumulated sphingolipids and A??-peptides.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411485-19$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bae</LastName>
                    <ForeName>Mihyun</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Johns Hopkins University School of Medicine, Department of Neurology, Division of Neuroimmunology and Neurological Infections, Baltimore, Maryland 21287.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>Neha</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Johns Hopkins University School of Medicine, Department of Neurology, Division of Neuroimmunology and Neurological Infections, Baltimore, Maryland 21287.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Haoxing</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Mingwaoh</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Section of Infections of the Nervous Systems, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tominaga-Yamanaka</LastName>
                    <ForeName>Kumiko</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Laboratories of Genetics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nath</LastName>
                    <ForeName>Avindra</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Section of Infections of the Nervous Systems, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Geiger</LastName>
                    <ForeName>Jonathan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota, School of Medicine and Health Sciences, Grand Forks, North Dakota 58202-9037, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gorospe</LastName>
                    <ForeName>Myriam</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Laboratories of Genetics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mattson</LastName>
                    <ForeName>Mark P</ForeName>
                    <Initials>MP</Initials>
                    <Affiliation>Neurosciences, National Institute on Aging-IRP, National Institutes of Health, Baltimore, Maryland 21224-6825.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haughey</LastName>
                    <ForeName>Norman J</ForeName>
                    <Initials>NJ</Initials>
                    <Affiliation>Johns Hopkins University School of Medicine, Department of Neurology, Division of Neuroimmunology and Neurological Infections, Baltimore, Maryland 21287, nhaughe1@jhmi.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">HIV</Keyword>
            <Keyword MajorTopicYN="N">amyloid</Keyword>
            <Keyword MajorTopicYN="N">dementia</Keyword>
            <Keyword MajorTopicYN="N">endosome</Keyword>
            <Keyword MajorTopicYN="N">lysosome</Keyword>
            <Keyword MajorTopicYN="N">neuron</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11485</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0210-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143627</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143625</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Threonine 149 Phosphorylation Enhances ??FosB Transcriptional Activity to Control Psychomotor Responses to Cocaine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11461-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1611-14.2014</ELocationID>
            <Abstract>
                <AbstractText>Stable changes in neuronal gene expression have been studied as mediators of addicted states. Of particular interest is the transcription factor ??FosB, a truncated and stable FosB gene product whose expression in nucleus accumbens (NAc), a key reward region, is induced by chronic exposure to virtually all drugs of abuse and regulates their psychomotor and rewarding effects. Phosphorylation at Ser(27) contributes to ??FosB's stability and accumulation following repeated exposure to drugs, and our recent work demonstrates that the protein kinase CaMKII?? phosphorylates ??FosB at Ser(27) and regulates its stability in vivo. Here, we identify two additional sites on ??FosB that are phosphorylated in vitro by CaMKII??, Thr(149) and Thr(180), and demonstrate their regulation in vivo by chronic cocaine. We show that phosphomimetic mutation of Thr(149) (T149D) dramatically increases AP-1 transcriptional activity while alanine mutation does not affect transcriptional activity when compared with wild-type (WT) ??FosB. Using in vivo viral-mediated gene transfer of ??FosB-T149D or ??FosB-T149A in mouse NAc, we determined that overexpression of ??FosB-T149D in NAc leads to greater locomotor activity in response to an initial low dose of cocaine than does WT ??FosB, while overexpression of ??FosB-T149A does not produce the psychomotor sensitization to chronic low-dose cocaine seen after overexpression of WT ??FosB and abrogates the sensitization seen in control animals at higher cocaine doses. We further demonstrate that mutation of Thr(149) does not affect the stability of ??FosB overexpressed in mouse NAc, suggesting that the behavioral effects of these mutations are driven by their altered transcriptional properties.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411461-09$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cates</LastName>
                    <ForeName>Hannah M</ForeName>
                    <Initials>HM</Initials>
                    <Affiliation>Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thibault</LastName>
                    <ForeName>Mackenzie</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Physiology, Michigan State University, Lansing, Michigan 48824.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pfau</LastName>
                    <ForeName>Madeline</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heller</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2984-8705</Identifier>
                    <Affiliation>Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eagle</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7879-5996</Identifier>
                    <Affiliation>Department of Physiology, Michigan State University, Lansing, Michigan 48824.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gajewski</LastName>
                    <ForeName>Paula</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Physiology, Michigan State University, Lansing, Michigan 48824.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bagot</LastName>
                    <ForeName>Rosemary</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Colangelo</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Molecular Biophysics and Biochemistry/Keck Biotechnology Services, New Haven, Connecticut 06511, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abbott</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Molecular Biophysics and Biochemistry/Keck Biotechnology Services, New Haven, Connecticut 06511, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rudenko</LastName>
                    <ForeName>Gabby</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Pharmacology/Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, Texas 77555.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neve</LastName>
                    <ForeName>Rachael</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nestler</LastName>
                    <ForeName>Eric J</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robison</LastName>
                    <ForeName>Alfred J</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>Department of Physiology, Michigan State University, Lansing, Michigan 48824, robiso45@msu.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CaMKII</Keyword>
            <Keyword MajorTopicYN="N">accumbens</Keyword>
            <Keyword MajorTopicYN="N">cocaine</Keyword>
            <Keyword MajorTopicYN="N">phosphorylation</Keyword>
            <Keyword MajorTopicYN="N">transcription</Keyword>
            <Keyword MajorTopicYN="N">??FosB</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11461</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1611-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143625</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143621</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Amyloid-??-Induced Action Potential Desynchronization and Degradation of Hippocampal Gamma Oscillations Is Prevented by Interference with Peptide Conformation Change and Aggregation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11416-25</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1195-14.2014</ELocationID>
            <Abstract>
                <AbstractText>The amyloid-?? hypothesis of Alzheimer's Disease (AD) focuses on accumulation of amyloid-?? peptide (A??) as the main culprit for the myriad physiological changes seen during development and progression of AD including desynchronization of neuronal action potentials, consequent development of aberrant brain rhythms relevant for cognition, and final emergence of cognitive deficits. The aim of this study was to elucidate the cellular and synaptic mechanisms underlying the A??-induced degradation of gamma oscillations in AD, to identify aggregation state(s) of A?? that mediate the peptides neurotoxicity, and to test ways to prevent the neurotoxic A?? effect. We show that A??1-42 in physiological concentrations acutely degrades mouse hippocampal gamma oscillations in a concentration- and time-dependent manner. The underlying cause is an A??-induced desynchronization of action potential generation in pyramidal cells and a shift of the excitatory/inhibitory equilibrium in the hippocampal network. Using purified preparations containing different aggregation states of A??, as well as a designed ligand and a BRICHOS chaperone domain, we provide evidence that the severity of A?? neurotoxicity increases with increasing concentration of fibrillar over monomeric A?? forms, and that A??-induced degradation of gamma oscillations and excitatory/inhibitory equilibrium is prevented by compounds that interfere with A?? aggregation. Our study provides correlative evidence for a link between A??-induced effects on synaptic currents and AD-relevant neuronal network oscillations, identifies the responsible aggregation state of A?? and proofs that strategies preventing peptide aggregation are able to prevent the deleterious action of A?? on the excitatory/inhibitory equilibrium and on the gamma rhythm.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411416-10$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kurudenkandy</LastName>
                    <ForeName>Firoz Roshan</ForeName>
                    <Initials>FR</Initials>
                    <Affiliation>Neuronal Oscillations Laboratory, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zilberter</LastName>
                    <ForeName>Misha</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Neuronal Oscillations Laboratory, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Biverst??l</LastName>
                    <ForeName>Henrik</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Presto</LastName>
                    <ForeName>Jenny</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Honcharenko</LastName>
                    <ForeName>Dmytro</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Biosciences and Nutrition, Karolinska Institutet, 17177 Stockholm, Sweden.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Str??mberg</LastName>
                    <ForeName>Roger</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Biosciences and Nutrition, Karolinska Institutet, 17177 Stockholm, Sweden.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johansson</LastName>
                    <ForeName>Jan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, The Biomedical Centre, 75123 Uppsala, Sweden, and Institute of Mathematics and Natural Sciences, Tallinn University, 10120 Tallinn, Estonia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Winblad</LastName>
                    <ForeName>Bengt</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fisahn</LastName>
                    <ForeName>Andr??</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Neuronal Oscillations Laboratory, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and andre.fisahn@ki.se.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alzheimer's disease</Keyword>
            <Keyword MajorTopicYN="N">BRICHOS domain</Keyword>
            <Keyword MajorTopicYN="N">amyloid-?? peptide</Keyword>
            <Keyword MajorTopicYN="N">gamma oscillations</Keyword>
            <Keyword MajorTopicYN="N">hippocampus</Keyword>
            <Keyword MajorTopicYN="N">neuronal synchronization</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11416</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1195-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143621</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143620</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Leptin Acts via Lateral Hypothalamic Area Neurotensin Neurons to Inhibit Orexin Neurons by Multiple GABA-Independent Mechanisms.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11405-15</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5167-13.2014</ELocationID>
            <Abstract>
                <AbstractText>The adipocyte-derived hormone leptin modulates neural systems appropriately for the status of body energy stores. Leptin inhibits lateral hypothalamic area (LHA) orexin (OX; also known as hypocretin)-producing neurons, which control feeding, activity, and energy expenditure, among other parameters. Our previous results suggest that GABAergic LHA leptin receptor (LepRb)-containing and neurotensin (Nts)-containing (LepRb(Nts)) neurons lie in close apposition with OX neurons and control Ox mRNA expression. Here, we show that, similar to leptin, activation of LHA Nts neurons by the excitatory hM3Dq DREADD (designer receptor exclusively activated by designer drugs) hyperpolarizes membrane potential and suppresses action potential firing in OX neurons in mouse hypothalamic slices. Furthermore, ablation of LepRb from Nts neurons abrogated the leptin-mediated inhibition, demonstrating that LepRb(Nts) neurons mediate the inhibition of OX neurons by leptin. Leptin did not significantly enhance GABAA-mediated inhibitory synaptic transmission, and GABA receptor antagonists did not block leptin-mediated inhibition of OX neuron activity. Rather, leptin diminished the frequency of spontaneous EPSCs onto OX neurons. Furthermore, leptin indirectly activated an ATP-sensitive potassium (KATP) channel in OX neurons, which was required for the hyperpolarization of OX neurons by leptin. Although Nts did not alter OX activity, galanin, which is coexpressed in LepRb(Nts) neurons, inhibited OX neurons, whereas the galanin receptor antagonist M40 (galanin-(1-12)-Pro3-(Ala-Leu)2-Ala amide) prevented the leptin-induced hyperpolarization of OX cells. These findings demonstrate that leptin indirectly inhibits OX neurons by acting on LHA LepRb(Nts) neurons to mediate two distinct GABA-independent mechanisms of inhibition: the presynaptic inhibition of excitatory neurotransmission and the opening of KATP channels.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411405-11$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Goforth</LastName>
                    <ForeName>Paulette B</ForeName>
                    <Initials>PB</Initials>
                    <Affiliation>Departments of Pharmacology and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leinninger</LastName>
                    <ForeName>Gina M</ForeName>
                    <Initials>GM</Initials>
                    <Affiliation>Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, and Department of Physiology, Michigan State University, East Lansing, Michigan 48824.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patterson</LastName>
                    <ForeName>Christa M</ForeName>
                    <Initials>CM</Initials>
                    <Affiliation>Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Satin</LastName>
                    <ForeName>Leslie S</ForeName>
                    <Initials>LS</Initials>
                    <Affiliation>Departments of Pharmacology and mgmyers@umich.edu lsatin@umich.edu.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Myers</LastName>
                    <ForeName>Martin G</ForeName>
                    <Initials>MG</Initials>
                    <Suffix>Jr</Suffix>
                    <Affiliation>Molecular and Integrative Physiology, and Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, and mgmyers@umich.edu lsatin@umich.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">EPSC</Keyword>
            <Keyword MajorTopicYN="N">GABA</Keyword>
            <Keyword MajorTopicYN="N">LHA</Keyword>
            <Keyword MajorTopicYN="N">leptin</Keyword>
            <Keyword MajorTopicYN="N">neurotensin</Keyword>
            <Keyword MajorTopicYN="N">orexin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11405</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.5167-13.2014</ArticleId>
            <ArticleId IdType="pubmed">25143620</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143618</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mechanisms of sharp wave initiation and ripple generation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11385-98</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0867-14.2014</ELocationID>
            <Abstract>
                <AbstractText>Replay of neuronal activity during hippocampal sharp wave-ripples (SWRs) is essential in memory formation. To understand the mechanisms underlying the initiation of irregularly occurring SWRs and the generation of periodic ripples, we selectively manipulated different components of the CA3 network in mouse hippocampal slices. We recorded EPSCs and IPSCs to examine the buildup of neuronal activity preceding SWRs and analyzed the distribution of time intervals between subsequent SWR events. Our results suggest that SWRs are initiated through a combined refractory and stochastic mechanism. SWRs initiate when firing in a set of spontaneously active pyramidal cells triggers a gradual, exponential buildup of activity in the recurrent CA3 network. We showed that this tonic excitatory envelope drives reciprocally connected parvalbumin-positive basket cells, which start ripple-frequency spiking that is phase-locked through reciprocal inhibition. The synchronized GABAA receptor-mediated currents give rise to a major component of the ripple-frequency oscillation in the local field potential and organize the phase-locked spiking of pyramidal cells. Optogenetic stimulation of parvalbumin-positive cells evoked full SWRs and EPSC sequences in pyramidal cells. Even with excitation blocked, tonic driving of parvalbumin-positive cells evoked ripple oscillations. Conversely, optogenetic silencing of parvalbumin-positive cells interrupted the SWRs or inhibited their occurrence. Local drug applications and modeling experiments confirmed that the activity of parvalbumin-positive perisomatic inhibitory neurons is both necessary and sufficient for ripple-frequency current and rhythm generation. These interneurons are thus essential in organizing pyramidal cell activity not only during gamma oscillation, but, in a different configuration, during SWRs.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411385-14$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Schlingloff</LastName>
                    <ForeName>D??niel</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Institute of Experimental Medicine, Hungarian Academy of Sciences, H-1083 Budapest, Hungary, J??nos Szent??gothai PhD Program of Semmelweis University, H-1085 Budapest, Hungary.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>K??li</LastName>
                    <ForeName>Szabolcs</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2740-6057</Identifier>
                    <Affiliation>Institute of Experimental Medicine, Hungarian Academy of Sciences, H-1083 Budapest, Hungary, Faculty of Information Technology, P??zm??ny P??ter Catholic University, H-1083 Budapest, Hungary, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Freund</LastName>
                    <ForeName>Tam??s F</ForeName>
                    <Initials>TF</Initials>
                    <Affiliation>Institute of Experimental Medicine, Hungarian Academy of Sciences, H-1083 Budapest, Hungary, Faculty of Information Technology, P??zm??ny P??ter Catholic University, H-1083 Budapest, Hungary, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>H??jos</LastName>
                    <ForeName>Norbert</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Institute of Experimental Medicine, Hungarian Academy of Sciences, H-1083 Budapest, Hungary.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guly??s</LastName>
                    <ForeName>Attila I</ForeName>
                    <Initials>AI</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4961-636X</Identifier>
                    <Affiliation>Institute of Experimental Medicine, Hungarian Academy of Sciences, H-1083 Budapest, Hungary, gulyas@koki.hu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">basket cell</Keyword>
            <Keyword MajorTopicYN="N">current generator</Keyword>
            <Keyword MajorTopicYN="N">hippocampus</Keyword>
            <Keyword MajorTopicYN="N">inhibition</Keyword>
            <Keyword MajorTopicYN="N">oscillation</Keyword>
            <Keyword MajorTopicYN="N">rhythm</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11385</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0867-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143618</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143617</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Role of the dorsal medial habenula in the regulation of voluntary activity, motor function, hedonic state, and primary reinforcement.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11366-84</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1861-14.2014</ELocationID>
            <Abstract>
                <AbstractText>The habenular complex in the epithalamus consists of distinct regions with diverse neuronal populations. Past studies have suggested a role for the habenula in voluntary exercise motivation and reinforcement of intracranial self-stimulation but have not assigned these effects to specific habenula subnuclei. Here, we have developed a genetic model in which neurons of the dorsal medial habenula (dMHb) are developmentally eliminated, via tissue-specific deletion of the transcription factor Pou4f1 (Brn3a). Mice with dMHb lesions perform poorly in motivation-based locomotor behaviors, such as voluntary wheel running and the accelerating rotarod, but show only minor abnormalities in gait and balance and exhibit normal levels of basal locomotion. These mice also show deficits in sucrose preference, but not in the forced swim test, two measures of depression-related phenotypes in rodents. We have also used Cre recombinase-mediated expression of channelrhodopsin-2 and halorhodopsin to activate dMHb neurons or silence their output in freely moving mice, respectively. Optical activation of the dMHb in vivo supports intracranial self-stimulation, showing that dMHb activity is intrinsically reinforcing, whereas optical silencing of dMHb outputs is aversive. Together, our findings demonstrate that the dMHb is involved in exercise motivation and the regulation of hedonic state, and is part of an intrinsic reinforcement circuit.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411366-19$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hsu</LastName>
                    <ForeName>Yun-Wei A</ForeName>
                    <Initials>YW</Initials>
                    <Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington 98101.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Si D</ForeName>
                    <Initials>SD</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8251-1450</Identifier>
                    <Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington 98101.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Shirong</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Sanford-Burnham Medical Research Institute, La Jolla, California 92037.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morton</LastName>
                    <ForeName>Glenn</ForeName>
                    <Initials>G</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-4823-3116</Identifier>
                    <Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington 98101.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zariwala</LastName>
                    <ForeName>Hatim A</ForeName>
                    <Initials>HA</Initials>
                    <Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington 98101.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de la Iglesia</LastName>
                    <ForeName>Horacio O</ForeName>
                    <Initials>HO</Initials>
                    <Affiliation>Department of Biology, University of Washington, Seattle, Washington 98195-1800.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Turner</LastName>
                    <ForeName>Eric E</ForeName>
                    <Initials>EE</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5499-6788</Identifier>
                    <Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington 98101, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98195, and Center on Human Development and Disability, University of Washington, Seattle, Washington 98195 eric.turner@seattlechildrens.org.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">exercise motivation</Keyword>
            <Keyword MajorTopicYN="N">interpeduncular nucleus</Keyword>
            <Keyword MajorTopicYN="N">intracranial self-stimulation</Keyword>
            <Keyword MajorTopicYN="N">medial habenula</Keyword>
            <Keyword MajorTopicYN="N">optogenetics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11366</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1861-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143617</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143608</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neural Cell Adhesion Molecule NrCAM Regulates Semaphorin 3F-Induced Dendritic Spine Remodeling.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11274-87</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1774-14.2014</ELocationID>
            <Abstract>
                <AbstractText>Neuron-glial related cell adhesion molecule (NrCAM) is a regulator of axon growth and repellent guidance, and has been implicated in autism spectrum disorders. Here a novel postsynaptic role for NrCAM in Semaphorin3F (Sema3F)-induced dendritic spine remodeling was identified in pyramidal neurons of the primary visual cortex (V1). NrCAM localized to dendritic spines of star pyramidal cells in postnatal V1, where it was coexpressed with Sema3F. NrCAM deletion in mice resulted in elevated spine densities on apical dendrites of star pyramidal cells at both postnatal and adult stages, and electron microscopy revealed increased numbers of asymmetric synapses in layer 4 of V1. Whole-cell recordings in cortical slices from NrCAM-null mice revealed increased frequency of mEPSCs in star pyramidal neurons. Recombinant Sema3F-Fc protein induced spine retraction on apical dendrites of wild-type, but not NrCAM-null cortical neurons in culture, while re-expression of NrCAM rescued the spine retraction response. NrCAM formed a complex in brain with Sema3F receptor subunits Neuropilin-2 (Npn-2) and PlexinA3 (PlexA3) through an Npn-2-binding sequence (TARNER) in the extracellular Ig1 domain. A trans heterozygous genetic interaction test demonstrated that Sema3F and NrCAM pathways interacted in vivo to regulate spine density in star pyramidal neurons. These findings reveal NrCAM as a novel postnatal regulator of dendritic spine density in cortical pyramidal neurons, and an integral component of the Sema3F receptor complex. The results implicate NrCAM as a contributor to excitatory/inhibitory balance in neocortical circuits.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411274-14$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Demyanenko</LastName>
                    <ForeName>Galina P</ForeName>
                    <Initials>GP</Initials>
                    <Affiliation>Departments of Biochemistry and Biophysics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mohan</LastName>
                    <ForeName>Vishwa</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Departments of Biochemistry and Biophysics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xuying</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Departments of Biochemistry and Biophysics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brennaman</LastName>
                    <ForeName>Leann H</ForeName>
                    <Initials>LH</Initials>
                    <Affiliation>Departments of Biochemistry and Biophysics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dharbal</LastName>
                    <ForeName>Katherine E S</ForeName>
                    <Initials>KE</Initials>
                    <Affiliation>Departments of Biochemistry and Biophysics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tran</LastName>
                    <ForeName>Tracy S</ForeName>
                    <Initials>TS</Initials>
                    <Affiliation>Department of Biological Sciences, Rutgers University, Newark, New Jersey 07102.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Manis</LastName>
                    <ForeName>Paul B</ForeName>
                    <Initials>PB</Initials>
                    <Affiliation>Departments of Otolaryngology/Head and Neck Surgery and Cell and Molecular Physiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maness</LastName>
                    <ForeName>Patricia F</ForeName>
                    <Initials>PF</Initials>
                    <Affiliation>Departments of Biochemistry and Biophysics and srclab@med.unc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">NrCAM</Keyword>
            <Keyword MajorTopicYN="N">cell adhesion</Keyword>
            <Keyword MajorTopicYN="N">cortical pyramidal neurons</Keyword>
            <Keyword MajorTopicYN="N">semaphorin</Keyword>
            <Keyword MajorTopicYN="N">spine morphogenesis</Keyword>
            <Keyword MajorTopicYN="N">visual cortex</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11274</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1774-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143608</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143604</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Astroglial connexin43 hemichannels tune Basal excitatory synaptic transmission.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11228-32</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0015-14.2014</ELocationID>
            <Abstract>
                <AbstractText>Fast exchange of extracellular signals between neurons and astrocytes is crucial for synaptic function. Over the last few decades, different pathways of astroglial release of neuroactive substances have been proposed to modulate neurotransmission. However, their involvement in physiological conditions is highly debated. Connexins, the gap junction forming proteins, are highly expressed in astrocytes and have recently been shown to scale synaptic transmission and plasticity. Interestingly, in addition to gap junction channels, the most abundant connexin (Cx) in astrocytes, Cx43, also forms hemichannels. While such channels are mostly active in pathological conditions, they have recently been shown to regulate cognitive function. However, whether astroglial Cx43 hemichannels are active in resting conditions and regulate basal synaptic transmission is unknown. Here we show that in basal conditions Cx43 forms functional hemichannels in astrocytes from mouse hippocampal slices. We furthermore demonstrate that the activity of astroglial Cx43 hemichannels in resting states regulates basal excitatory synaptic transmission of hippocampal CA1 pyramidal cells through ATP signaling. These data reveal Cx43 hemichannels as a novel astroglial release pathway at play in basal conditions, which tunes the moment-to-moment glutamatergic synaptic transmission.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411228-05$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chever</LastName>
                    <ForeName>Oana</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Neuroglial Interactions in Cerebral Physiopathology, Center for Interdisciplinary Research in Biology, Coll??ge de France, Centre National de la Recherche Scientifique, Unit?? Mixte de Recherche 7241, Institut National de la Sant?? et de la Recherche M??dicale U1050, 75005 Paris, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Chun-Yao</ForeName>
                    <Initials>CY</Initials>
                    <Affiliation>Neuroglial Interactions in Cerebral Physiopathology, Center for Interdisciplinary Research in Biology, Coll??ge de France, Centre National de la Recherche Scientifique, Unit?? Mixte de Recherche 7241, Institut National de la Sant?? et de la Recherche M??dicale U1050, 75005 Paris, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rouach</LastName>
                    <ForeName>Nathalie</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Neuroglial Interactions in Cerebral Physiopathology, Center for Interdisciplinary Research in Biology, Coll??ge de France, Centre National de la Recherche Scientifique, Unit?? Mixte de Recherche 7241, Institut National de la Sant?? et de la Recherche M??dicale U1050, 75005 Paris, France nathalie.rouach@college-de-france.fr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">astrocytes</Keyword>
            <Keyword MajorTopicYN="N">basal synaptic transmission</Keyword>
            <Keyword MajorTopicYN="N">connexin43</Keyword>
            <Keyword MajorTopicYN="N">hemichannel</Keyword>
            <Keyword MajorTopicYN="N">hippocampus</Keyword>
            <Keyword MajorTopicYN="N">physiology</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11228</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0015-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143604</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143602</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Chromophore supply rate-limits Mammalian photoreceptor dark adaptation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11212-21</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1245-14.2014</ELocationID>
            <Abstract>
                <AbstractText>Efficient regeneration of visual pigment following its destruction by light is critical for the function of mammalian photoreceptors. Here, we show that misexpression of a subset of cone genes in the rd7 mouse hybrid rods enables them to access the normally cone-specific retina visual cycle. The rapid supply of chromophore by the retina visual cycle dramatically accelerated the mouse rod dark adaptation. At the same time, the competition between rods and cones for retina-derived chromophore slowed cone dark adaptation, indicating that the cone specificity of the retina visual cycle is key for rapid cone dark adaptation. Our findings demonstrate that mammalian photoreceptor dark adaptation is dominated by the supply of chromophore. Misexpression of cone genes in rods may represent a novel approach to treating visual disorders associated with mutations of visual cycle proteins or with reduced retinal pigment epithelium function due to aging.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411212-10$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jin-Shan</ForeName>
                    <Initials>JS</Initials>
                    <Affiliation>Departments of Ophthalmology and Visual Sciences and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nymark</LastName>
                    <ForeName>Soile</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Departments of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts 02118, Department of Electronics and Communications Engineering, Tampere University of Technology and BioMediTech, FI-33014 Tampere, Finland, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Frederiksen</LastName>
                    <ForeName>Rikard</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Departments of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts 02118.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Estevez</LastName>
                    <ForeName>Maureen E</ForeName>
                    <Initials>ME</Initials>
                    <Affiliation>Departments of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts 02118, Department of Neuroscience, Brown University, Providence, Rhode Island 02912.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Susan Q</ForeName>
                    <Initials>SQ</Initials>
                    <Affiliation>Departments of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Corbo</LastName>
                    <ForeName>Joseph C</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Departments of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cornwall</LastName>
                    <ForeName>M Carter</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>Departments of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts 02118.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kefalov</LastName>
                    <ForeName>Vladimir J</ForeName>
                    <Initials>VJ</Initials>
                    <Affiliation>Departments of Ophthalmology and Visual Sciences and kefalov@wustl.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">dark adaptation</Keyword>
            <Keyword MajorTopicYN="N">photoreceptors</Keyword>
            <Keyword MajorTopicYN="N">pigment regeneration</Keyword>
            <Keyword MajorTopicYN="N">retina</Keyword>
            <Keyword MajorTopicYN="N">retinol dehydrogenase</Keyword>
            <Keyword MajorTopicYN="N">visual cycle</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11212</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1245-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143602</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143599</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Temporal and Region-Specific Requirements of ??CaMKII in Spatial and Contextual Learning.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11180-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0640-14.2014</ELocationID>
            <Abstract>
                <AbstractText>The ?? isoform of the calcium/calmodulin-dependent protein kinase II (??CaMKII) has been implicated extensively in molecular and cellular mechanisms underlying spatial and contextual learning in a wide variety of species. Germline deletion of Camk2a leads to severe deficits in spatial and contextual learning in mice. However, the temporal and region-specific requirements for ??CaMKII have remained largely unexplored. Here, we generated conditional Camk2a mutants to examine the influence of spatially restricted and temporally controlled expression of ??CaMKII. Forebrain-specific deletion of the Camk2a gene resulted in severe deficits in water maze and contextual fear learning, whereas mice with deletion restricted to the cerebellum learned normally. Furthermore, we found that temporally controlled deletion of the Camk2a gene in adult mice is as detrimental as germline deletion for learning and synaptic plasticity. Together, we confirm the requirement for ??CaMKII in the forebrain, but not the cerebellum, in spatial and contextual learning. Moreover, we highlight the absolute requirement for intact ??CaMKII expression at the time of learning.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411180-08$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Achterberg</LastName>
                    <ForeName>Katharina G</ForeName>
                    <Initials>KG</Initials>
                    <Affiliation>Department of Psychiatry.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buitendijk</LastName>
                    <ForeName>Gabri??lle H S</ForeName>
                    <Initials>GH</Initials>
                    <Affiliation>Department of Neuroscience, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kool</LastName>
                    <ForeName>Martijn J</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>Department of Neuroscience, and ENCORE Expertise Center for Neurodevelopmental Disorders, Erasmus University Medical Center, 3015 GE, Rotterdam, The Netherlands, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goorden</LastName>
                    <ForeName>Susanna M I</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Department of Neuroscience, and ENCORE Expertise Center for Neurodevelopmental Disorders, Erasmus University Medical Center, 3015 GE, Rotterdam, The Netherlands, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Post</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Neuroscience, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Slump</LastName>
                    <ForeName>Denise E</ForeName>
                    <Initials>DE</Initials>
                    <Affiliation>Department of Psychiatry.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silva</LastName>
                    <ForeName>Alcino J</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>Departments of Neurobiology, Psychiatry, Psychology, and Brain Research Institute, University of California, Los Angeles, California 90095.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Woerden</LastName>
                    <ForeName>Geeske M</ForeName>
                    <Initials>GM</Initials>
                    <Affiliation>Department of Neuroscience, and ENCORE Expertise Center for Neurodevelopmental Disorders, Erasmus University Medical Center, 3015 GE, Rotterdam, The Netherlands, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kushner</LastName>
                    <ForeName>Steven A</ForeName>
                    <Initials>SA</Initials>
                    <Affiliation>Department of Psychiatry, s.kushner@erasmusmc.nl y.elgersma@erasmusmc.nl.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elgersma</LastName>
                    <ForeName>Ype</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Neuroscience, and ENCORE Expertise Center for Neurodevelopmental Disorders, Erasmus University Medical Center, 3015 GE, Rotterdam, The Netherlands, and s.kushner@erasmusmc.nl y.elgersma@erasmusmc.nl.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CaMKII</Keyword>
            <Keyword MajorTopicYN="N">cerebellum</Keyword>
            <Keyword MajorTopicYN="N">fear conditioning</Keyword>
            <Keyword MajorTopicYN="N">hippocampus</Keyword>
            <Keyword MajorTopicYN="N">learning</Keyword>
            <Keyword MajorTopicYN="N">spatial learning</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11180</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0640-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143599</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143588</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1091-6490</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
                <ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Primary cilia signaling mediates intraocular pressure sensation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">201323292</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Lowe syndrome is a rare X-linked congenital disease that presents with congenital cataracts and glaucoma, as well as renal and cerebral dysfunction. OCRL, an inositol polyphosphate 5-phosphatase, is mutated in Lowe syndrome. We previously showed that OCRL is involved in vesicular trafficking to the primary cilium. Primary cilia are sensory organelles on the surface of eukaryotic cells that mediate mechanotransduction in the kidney, brain, and bone. However, their potential role in the trabecular meshwork (TM) in the eye, which regulates intraocular pressure, is unknown. Here, we show that TM cells, which are defective in glaucoma, have primary cilia that are critical for response to pressure changes. Primary cilia in TM cells shorten in response to fluid flow and elevated hydrostatic pressure, and promote increased transcription of TNF-??, TGF-??, and GLI1 genes. Furthermore, OCRL is found to be required for primary cilia to respond to pressure stimulation. The interaction of OCRL with transient receptor potential vanilloid 4 (TRPV4), a ciliary mechanosensory channel, suggests that OCRL may act through regulation of this channel. A novel disease-causing OCRL allele prevents TRPV4-mediated calcium signaling. In addition, TRPV4 agonist GSK 1016790A treatment reduced intraocular pressure in mice; TRPV4 knockout animals exhibited elevated intraocular pressure and shortened cilia. Thus, mechanotransduction by primary cilia in TM cells is implicated in how the eye senses pressure changes and highlights OCRL and TRPV4 as attractive therapeutic targets for the treatment of glaucoma. Implications of OCRL and TRPV4 in primary cilia function may also shed light on mechanosensation in other organ systems.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Luo</LastName>
                    <ForeName>Na</ForeName>
                    <Initials>N</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8046-9372</Identifier>
                    <Affiliation>Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN 46202; Department of Ophthalmology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Conwell</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                    <Affiliation>Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN 46202; Department of Ophthalmology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Xingjuan</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Cellular and Integrative Physiology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kettenhofen</LastName>
                    <ForeName>Christine Insinna</ForeName>
                    <Initials>CI</Initials>
                    <Affiliation>Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201;</Affiliation>
                </Author>
                <Author>
                    <LastName>Westlake</LastName>
                    <ForeName>Christopher J</ForeName>
                    <Initials>CJ</Initials>
                    <Affiliation>Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201;</Affiliation>
                </Author>
                <Author>
                    <LastName>Cantor</LastName>
                    <ForeName>Louis B</ForeName>
                    <Initials>LB</Initials>
                    <Affiliation>Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN 46202; Department of Ophthalmology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wells</LastName>
                    <ForeName>Clark D</ForeName>
                    <Initials>CD</Initials>
                    <Affiliation>Department of Biochemistry and Molecular Biology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Weinreb</LastName>
                    <ForeName>Robert N</ForeName>
                    <Initials>RN</Initials>
                    <Affiliation>Department of Ophthalmology, University of California, San Diego, La Jolla, CA 92037;</Affiliation>
                </Author>
                <Author>
                    <LastName>Corson</LastName>
                    <ForeName>Timothy W</ForeName>
                    <Initials>TW</Initials>
                    <Affiliation>Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN 46202; Department of Ophthalmology, Department of Biochemistry and Molecular Biology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Spandau</LastName>
                    <ForeName>Dan F</ForeName>
                    <Initials>DF</Initials>
                    <Affiliation>Department of Dermatology, and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Joos</LastName>
                    <ForeName>Karen M</ForeName>
                    <Initials>KM</Initials>
                    <Affiliation>Vanderbilt Eye Institute, Nashville, TN 37212; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Iomini</LastName>
                    <ForeName>Carlo</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY 10029.</Affiliation>
                </Author>
                <Author>
                    <LastName>Obukhov</LastName>
                    <ForeName>Alexander G</ForeName>
                    <Initials>AG</Initials>
                    <Affiliation>Department of Cellular and Integrative Physiology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN 46202; Department of Ophthalmology, Department of Biochemistry and Molecular Biology, Department of Dermatology, and sunyo@iupui.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
            <NlmUniqueID>7505876</NlmUniqueID>
            <ISSNLinking>0027-8424</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1323292111</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.1323292111</ArticleId>
            <ArticleId IdType="pubmed">25143588</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143538</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1598</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of neurophysiology</Title>
                <ISOAbbreviation>J. Neurophysiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Flocculus Purkinje Cell Signals in Mouse Cacna1a Calcium Channel Mutants of Escalating Severity; An Investigation of the Role of Firing Irregularity in Ataxia.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jn.00129.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Mutation of the Cacna1a gene for the P/Q (CaV2.1) calcium channel invariably leads to cerebellar dysfunction. The dysfunction has been attributed to disrupted rhythmicity of cerebellar Purkinje cells, but the hypothesis remains unproven. If irregular firing rates cause cerebellar dysfunction, then the irregularity and behavioral deficits should co-vary in a series of mutant strains of escalating severity. We compared firing irregularity in floccular and anterior vermis Purkinje cells in the mildly affected rocker and moderately affected tottering Cacna1a mutants, and normal C57BL/6 mice. We also measured the amplitude and timing of modulations of floccular Purkinje cell firing rate during the horizontal vestibulo-ocular reflex (VOR, 0.25-1 Hz) and the horizontal and vertical optokinetic reflex (OKR, 0.125-1 Hz). We recorded Purkinje cells selective for rotational stimulation about the vertical axis (VAPCs) and a horizontal axis (HAPCs). In the flocculus, irregularity scaled with behavioral deficit severity, but failed to do so in the vermis, challenging the irregularity hypothesis. Mutant VAPCs exhibited unusually strong modulation during VOR and OKR, the response augmentation scaling with phenotypic severity. HAPCs exhibited increased OKR modulation, but in tottering only. The data contradict prior claims that modulation amplitude is unaffected in tottering, but support the idea that attenuated compensatory eye movements in Cacna1a mutants arise from defective transfer of Purkinje cell signals to downstream circuitry, rather than attenuated synaptic transmission within the cerebellar cortex. Shifts in the relative sizes of the VAPC and HAPC populations raise the possibility that Cacna1a mutations influence the development of floccular zone architecture.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, Journal of Neurophysiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Stahl</LastName>
                    <ForeName>John S</ForeName>
                    <Initials>JS</Initials>
                    <Affiliation>Louis Stokes Cleveland Dept. of Veterans Affairs Medical Center jss6@case.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Thumser</LastName>
                    <ForeName>Zachary C</ForeName>
                    <Initials>ZC</Initials>
                    <Affiliation>Louis Stokes Cleveland Dept. of Veterans Affairs Medical Center.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Neurophysiol</MedlineTA>
            <NlmUniqueID>0375404</NlmUniqueID>
            <ISSNLinking>0022-3077</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Purkinje cell</Keyword>
            <Keyword MajorTopicYN="N">ataxia</Keyword>
            <Keyword MajorTopicYN="N">flocculus</Keyword>
            <Keyword MajorTopicYN="N">optokinetic</Keyword>
            <Keyword MajorTopicYN="N">vestibulo-ocular</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jn.00129.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/jn.00129.2014</ArticleId>
            <ArticleId IdType="pubmed">25143538</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143535</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1362-4962</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nucleic acids research</Title>
                <ISOAbbreviation>Nucleic Acids Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Retinoid acid-related orphan receptor ??, ROR??, participates in diurnal transcriptional regulation of lipid metabolic genes.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">gku766</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The hepatic circadian clock plays a pivotal role in regulating major aspects of energy homeostasis and lipid metabolism. In this study, we show that ROR?? robustly regulates the rhythmic expression of several lipid metabolic genes, including the insulin-induced gene 2a, Insig2a, elongation of very long chain fatty acids-like 3, Elovl3 and sterol 12??-hydroxylase, Cyp8b1, by enhancing their expression at ZT20-4. The time-dependent increase in their expression correlates with the rhythmic expression pattern of ROR??. The enhanced recruitment of ROR?? to ROREs in their promoter region, increased histone acetylation, and reporter and mutation analysis support the concept that ROR?? regulates the transcription of several lipid metabolic genes directly by binding ROREs in their promoter regulatory region. Consistent with the disrupted expression of a number of lipid metabolic genes, loss of ROR?? reduced the level of several lipids in liver and blood in a ZT-preferred manner. Particularly the whole-body bile acid pool size was considerably reduced in ROR??(-/-) mice in part through its regulation of several Cyp genes. Similar observations were made in liver-specific ROR??-deficient mice. Altogether, our study indicates that ROR?? functions as an important link between the circadian clock and the transcriptional regulation of several metabolic genes.</AbstractText>
                <CopyrightInformation>Published by Oxford University Press on behalf of Nucleic Acids Research 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Takeda</LastName>
                    <ForeName>Yukimasa</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Cell Biology Section, Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kang</LastName>
                    <ForeName>Hong Soon</ForeName>
                    <Initials>HS</Initials>
                    <Affiliation>Cell Biology Section, Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lih</LastName>
                    <ForeName>Fred B</ForeName>
                    <Initials>FB</Initials>
                    <Affiliation>Collaborative Mass Spectrometry Group, Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jiang</LastName>
                    <ForeName>Hongfeng</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Medicine, Colombia University, New York, NY 10032, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Blaner</LastName>
                    <ForeName>William S</ForeName>
                    <Initials>WS</Initials>
                    <Affiliation>Department of Medicine, Colombia University, New York, NY 10032, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jetten</LastName>
                    <ForeName>Anton M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Cell Biology Section, Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA jetten@niehs.nih.gov.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Nucleic Acids Res</MedlineTA>
            <NlmUniqueID>0411011</NlmUniqueID>
            <ISSNLinking>0305-1048</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">gku766</ArticleId>
            <ArticleId IdType="doi">10.1093/nar/gku766</ArticleId>
            <ArticleId IdType="pubmed">25143535</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143486</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0020</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Blood</Title>
                <ISOAbbreviation>Blood</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">blood-2014-03-562876</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Evidence is emerging that platelets are major contributors to innate immune responses in conditions such as acute lung injury (ALI). Platelets form heterotypic aggregates with neutrophils, and we hypothesized that lipoxin mediators regulate formation of neutrophil-platelet aggregates (NPA), and that NPA significantly contribute to ALI. LPS-induced lung injury was accompanied by platelet sequestration, activation, and intra-alveolar accumulation, and NPA formation within both blood and alveolar compartments. Using lung intravital microscopy, we observed the dynamic formation of NPA during physiologic conditions, which sharply increased with ALI. Aspirin treatment significantly reduced lung platelet sequestration and activation, NPA formation, and lung injury. Aspirin treatment increased levels of aspirin-triggered lipoxin (ATL, 15-epi-LXA4) and blocking the lipoxin A4 receptor (ALX) with a peptide antagonist (Boc2) or using ALX knockouts (Fpr2/3(-/-)) reversed this protection. LPS increased NPA formation in vitro, which was reduced by ATL, and engagement of ALX by ATL on both neutrophils and platelets was necessary to prevent aggregation. In a model of transfusion-related acute lung injury (TRALI), Boc2 also reversed aspirin protection, and treatment with ATL in both LPS and TRALI models protected from ALI. We conclude that ATL regulates neutrophil-platelet aggregation, and that platelet-neutrophil interactions are a therapeutic target in lung injury.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Society of Hematology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ortiz-Mu??oz</LastName>
                    <ForeName>Guadalupe</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Medicine, University of California, San Francisco, San Francisco, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Mallavia</LastName>
                    <ForeName>Be??at</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Medicine, University of California, San Francisco, San Francisco, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Bins</LastName>
                    <ForeName>Adriaan</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands;</Affiliation>
                </Author>
                <Author>
                    <LastName>Headley</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Krummel</LastName>
                    <ForeName>Matthew F</ForeName>
                    <Initials>MF</Initials>
                    <Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Looney</LastName>
                    <ForeName>Mark R</ForeName>
                    <Initials>MR</Initials>
                    <Affiliation>Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, United States mark.looney@ucsf.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Blood</MedlineTA>
            <NlmUniqueID>7603509</NlmUniqueID>
            <ISSNLinking>0006-4971</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">blood-2014-03-562876</ArticleId>
            <ArticleId IdType="doi">10.1182/blood-2014-03-562876</ArticleId>
            <ArticleId IdType="pubmed">25143486</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143484</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0020</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Blood</Title>
                <ISOAbbreviation>Blood</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Myc-induced SUMOylation is a therapeutic vulnerability for B cell lymphoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">blood-2014-06-584524</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Myc oncogenic transcription factors (c-Myc, N-Myc and L-Myc) coordinate the control of cell growth, division and metabolism. In cancer Myc overexpression is often associated with aggressive disease, which is in part due to the destruction of select targets by the ubiquitin-proteasome system, for example Skp2(SCF)-directed destruction of the Cdk inhibitior p27(Kip1). We reasoned that Myc would also regulate SUMOylation, a related means of post-translational modification of proteins, and that this circuit would play essential roles in Myc-dependent tumorigenesis. Here we report marked increases in the expression of genes that encode regulators and components of the SUMOylation machinery in mouse and human Myc-driven lymphomas, resulting in hyperSUMOylation in these tumors. Further, inhibition of SUMOylation by genetic means disables Myc-induced proliferation, triggering G2/M cell cycle arrest, polyploidy and apoptosis. Using genetically defined cell models and conditional expression systems this response was shown to be Myc-specific. Finally, in vivo loss-of-function and pharmacologic studies demonstrated that inhibition of SUMOylation provokes rapid regression of Myc-driven lymphoma. Thus, targeting SUMOylation represents an attractive therapeutic option for lymphomas with MYC involvement.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Society of Hematology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hoellein</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>III. Medical Department, Technische Universitaet Muenchen, Munich, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Fallahi</LastName>
                    <ForeName>Mohammad</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Cancer Biology, The Scripps Research Institute, Scripps Florida, Jupiter, FL, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Schoeffmann</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>III. Medical Department, Technische Universitaet Muenchen, Munich, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Steidle</LastName>
                    <ForeName>Sabine</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>III. Medical Department, Technische Universitaet Muenchen, Munich, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Schaub</LastName>
                    <ForeName>Franz X</ForeName>
                    <Initials>FX</Initials>
                    <Affiliation>Department of Cancer Biology, The Scripps Research Institute, Scripps Florida, Jupiter, FL, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Rudelius</LastName>
                    <ForeName>Martina</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Institute of Pathology and Clinical Cancer Center Mainfranke, Universitaet Wuerzburg, Wuerzburg, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Laitinen</LastName>
                    <ForeName>Iina</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Department of Nuclear Medicine, Technische Universitaet Muenchen, Munich, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Nilsson</LastName>
                    <ForeName>Lisa</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Sahlgrenska Cancer Center, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Sweden;</Affiliation>
                </Author>
                <Author>
                    <LastName>Goga</LastName>
                    <ForeName>Andrei</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Cell/Tissue Biology, University of California, San Francisco, CA, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Peschel</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>III. Medical Department, Technische Universitaet Muenchen, Munich, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Nilsson</LastName>
                    <ForeName>Jonas A</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>Sahlgrenska Cancer Center, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Sweden;</Affiliation>
                </Author>
                <Author>
                    <LastName>Cleveland</LastName>
                    <ForeName>John L</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Department of Cancer Biology, The Scripps Research Institute, Scripps Florida, Jupiter, FL, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Keller</LastName>
                    <ForeName>Ulrich</ForeName>
                    <Initials>U</Initials>
                    <Affiliation>III. Medical Department, Technische Universitaet Muenchen, Munich, Germany; ulrich.keller@lrz.tum.de.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Blood</MedlineTA>
            <NlmUniqueID>7603509</NlmUniqueID>
            <ISSNLinking>0006-4971</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">blood-2014-06-584524</ArticleId>
            <ArticleId IdType="doi">10.1182/blood-2014-06-584524</ArticleId>
            <ArticleId IdType="pubmed">25143484</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143463</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">0022-2275</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of lipid research</Title>
                <ISOAbbreviation>J. Lipid Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High-resolution imaging of dietary lipids in cells and tissues by NanoSIMS analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jlr.M053363</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Nanoscale secondary ion mass spectrometry (NanoSIMS) imaging makes it possible to visualize stable isotope-labeled lipids in cells and tissues at 50-nm lateral resolution. Here we report the use of NanoSIMS imaging to visualize lipids in mouse cells and tissues. After administering stable isotope-labeled fatty acids to mice by gavage, NanoSIMS imaging allowed us to visualize neutral lipids in cytosolic lipid droplets in intestinal enterocytes, chylomicrons at the basolateral surface of enterocytes, and lipid droplets in cardiomyocytes and adipocytes. After an injection of stable isotope-enriched triglyceride-rich lipoproteins (TRLs), NanoSIMS imaging documented delivery of lipids to cytosolic lipid droplets in parenchymal cells. Using a combination of backscattered electron (BSE) and NanoSIMS imaging, it was possible to correlate the chemical data provided by NanoSIMS with high-resolution BSE images of cell morphology. This combined imaging approach allowed us to visualize stable isotope-enriched TRLs along the luminal face of heart capillaries and the lipids within heart capillary endothelial cells. We also observed examples of TRLs within the subendothelial spaces of heart capillaries. NanoSIMS imaging provided evidence of defective transport of lipids from the plasma lipoproteins to adipocytes and cardiomyocytes in GPIHBP1-deficient mice.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, The American Society for Biochemistry and Molecular Biology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Jiang</LastName>
                    <ForeName>Haibo</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Oxford University, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Goulbourne</LastName>
                    <ForeName>Chris N</ForeName>
                    <Initials>CN</Initials>
                    <Affiliation>UCLA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Tatar</LastName>
                    <ForeName>Angelica</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>UCLA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Turlo</LastName>
                    <ForeName>Kirsten</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>UCLA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>UCLA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Beigneux</LastName>
                    <ForeName>Anne P</ForeName>
                    <Initials>AP</Initials>
                    <Affiliation>University of California, Los Angeles, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Grovenor</LastName>
                    <ForeName>Chris R M</ForeName>
                    <Initials>CR</Initials>
                    <Affiliation>Oxford University, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Fong</LastName>
                    <ForeName>Loren G</ForeName>
                    <Initials>LG</Initials>
                    <Affiliation>UCLA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Young</LastName>
                    <ForeName>Stephen G</ForeName>
                    <Initials>SG</Initials>
                    <Affiliation>University of California, Los Angeles, United States sgyoung@mednet.ucla.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Lipid Res</MedlineTA>
            <NlmUniqueID>0376606</NlmUniqueID>
            <ISSNLinking>0022-2275</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Antibodies</Keyword>
            <Keyword MajorTopicYN="N">Dyslipidemias</Keyword>
            <Keyword MajorTopicYN="N">Fatty acid</Keyword>
            <Keyword MajorTopicYN="N">GPIHBP1</Keyword>
            <Keyword MajorTopicYN="N">Inborn errors of metabolism</Keyword>
            <Keyword MajorTopicYN="N">NanoSIMS imaging</Keyword>
            <Keyword MajorTopicYN="N">Triglycerides</Keyword>
            <Keyword MajorTopicYN="N">backscattered electron imaging</Keyword>
            <Keyword MajorTopicYN="N">chylomicrons</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jlr.M053363</ArticleId>
            <ArticleId IdType="doi">10.1194/jlr.M053363</ArticleId>
            <ArticleId IdType="pubmed">25143463</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143459</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1466</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Renal physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Renal Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajprenal.00698.2013</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Semicarbazide-sensitive amine oxidase (SSAO) is an enzyme known for its dual function in mediating inflammation and reactive oxygen species production. However, the role of SSAO inhibitors in limiting kidney fibrosis is unclear. We aimed to determine the effectiveness of a SSAO inhibitor (PXS-4728A) as an antifibrotic agent using a 7-day unilateral ureteric obstruction (UUO) model of acute kidney fibrosis in 6-8 week old mice. The experimental groups were: (i) Sham operated; (ii) UUO; (iii) UUO+SSAOi (2mg/kg); (iv) UUO +Telmisartan, an angiotensin receptor blocker (3mg/kg); and (v) UUO + SSAOi + Telmisartan. Kidney tissue was analysed for histological evidence of tubulointerstitial fibrosis, nitrotyrosine staining and mRNA expression of markers associated with fibrosis and inflammation. Kidney SSAO activity was determined by radiometric [(14)C]-benzylamine methodology. Our results show that SSAOi effectively suppresses UUO-mediated SSAO activity. Extracellular matrix markers, namely fibronectin, collagen IV protein and nitrotyrosine staining, were lower in UUO+SSAOi mice compared to untreated UUO mice. This was consistent with the attenuated mRNA expression of collagen-IV and fibronectin. SSAOi effectively inhibited transforming growth factor-beta1 (TGF-??1) and monocyte chemoattractant protein - 1 (MCP-1) expression to a similar extent to that observed with Telmisartan. Individually, SSAOi and Telmistartan induced a reduction in interstitial leukocyte and macrophage accumulation. However, the combination of SSAOi and Telmisartan was more effective at reducing inflammatory cell infiltration. These results demonstrate that SSAO inhibition significantly suppresses profibrotic and proinflammatory cytokine secretion, reduces oxidative stress and limits inflammatory cell accumulation and extracellular matrix expression in an acute model of renal fibrosis.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology - Renal Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Wong</LastName>
                    <ForeName>May Yw</ForeName>
                    <Initials>MY</Initials>
                    <Affiliation>Kolling Institute of Medical Research.</Affiliation>
                </Author>
                <Author>
                    <LastName>Saad</LastName>
                    <ForeName>Sonia</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Kolling Institute of Medical Research.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Kolling Institute of Medical Research.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gross</LastName>
                    <ForeName>Simon</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Kolling Institute of Medical Research.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jarolimek</LastName>
                    <ForeName>Wolfgang</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Drug Discovery.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schilter</LastName>
                    <ForeName>Heidi Campos</ForeName>
                    <Initials>HC</Initials>
                    <Affiliation>Pharmaxis.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Jason A</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>Royal North Shore Hospital.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gill</LastName>
                    <ForeName>Anthony J</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>Royal North Shore Hospital.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pollock</LastName>
                    <ForeName>Carol A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital carol.pollock@sydney.edu.au.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wong</LastName>
                    <ForeName>Muh Geot</ForeName>
                    <Initials>MG</Initials>
                    <Affiliation>Kolling Institute of Medical Research.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Renal Physiol</MedlineTA>
            <NlmUniqueID>100901990</NlmUniqueID>
            <ISSNLinking>1522-1466</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">anti-inflammatory</Keyword>
            <Keyword MajorTopicYN="N">semicarbazide-sensitive amine oxidase</Keyword>
            <Keyword MajorTopicYN="N">tubulointerstitial fibrosis</Keyword>
            <Keyword MajorTopicYN="N">unilateral ureteral obstruction murine model</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajprenal.00698.2013</ArticleId>
            <ArticleId IdType="doi">10.1152/ajprenal.00698.2013</ArticleId>
            <ArticleId IdType="pubmed">25143459</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143457</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1466</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Renal physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Renal Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comparison of serum creatinine and serum cystatin C as biomarkers to detect sepsis- induced acute kidney injury and to predict mortality in CD-1 mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajprenal.00025.2013</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Acute kidney injury (AKI) dramatically increases sepsis mortality, but AKI diagnosis is delayed when based on serum creatinine (Scr) changes, due in part, to decreased creatinine production. During experimental sepsis we compared serum Cystatin C (sCysC), Scr, and BUN to inulin GFR (iGFR) before or 3-18h after cecal ligation and puncture (CLP)-induced sepsis in CD-1 mice. sCysC had a faster increase and reached peak levels more rapidly than Scr in both sepsis and bilateral nephrectomy (BiNx) models. sCysC was a better surrogate of iGFR than Scr during sepsis. Combining sCysC with Scr values into a composite biomarker improved correlation with iGFR better than any biomarker alone, or any other combination. We determined the renal contribution to sCysC handling with BiNx. sCysC and Scr were lower post-BiNx/CLP than post-BiNx alone, despite increased inflammatory and non-renal organ damage biomarkers. Sepsis decreased CysC production in nephrectomized mice, without changing body weight or CysC space. Sepsis decreased sCysC production and increased non-renal clearance, similar to effects of sepsis on Scr. sCysC, Scr and BUN were measured 6h post-sepsis to link AKI with mortality. Mice with above-median sCysC, BUN, or Scr values 6h post-sepsis died earlier than mice with below-median values, corresponding to a substantial AKI association with sepsis mortality in this model. sCysC performs similarly to Scr in classifying mice at risk for early mortality. We conclude that sCysC detects AKI early and better reflects iGFR in CLP sepsis. This study shows that renal biomarkers need to be evaluated in specific contexts.</AbstractText>
                <CopyrightInformation>Copyright ?? 2013, American Journal of Physiology - Renal Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Leelahavanichkul</LastName>
                    <ForeName>Asada</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>NIH.</Affiliation>
                </Author>
                <Author>
                    <LastName>Souza</LastName>
                    <ForeName>Ana Carolina P</ForeName>
                    <Initials>AC</Initials>
                    <Affiliation>NIH.</Affiliation>
                </Author>
                <Author>
                    <LastName>Street</LastName>
                    <ForeName>Jonathan M</ForeName>
                    <Initials>JM</Initials>
                    <Affiliation>NIH.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hsu</LastName>
                    <ForeName>Victor</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>NIH.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tsuji</LastName>
                    <ForeName>Takayuki</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>NIH.</Affiliation>
                </Author>
                <Author>
                    <LastName>Doi</LastName>
                    <ForeName>Kent</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>The Univ. of TOKYO.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Lingli</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>NIH.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Xuzhen</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>NIH.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Hua</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>NIH.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kumar</LastName>
                    <ForeName>Parag</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>NIH.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schnermann</LastName>
                    <ForeName>Jurgen B</ForeName>
                    <Initials>JB</Initials>
                    <Affiliation>NIH.</Affiliation>
                </Author>
                <Author>
                    <LastName>Star</LastName>
                    <ForeName>Robert A</ForeName>
                    <Initials>RA</Initials>
                    <Affiliation>NIH - NIDDK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yuen</LastName>
                    <ForeName>Peter S T</ForeName>
                    <Initials>PS</Initials>
                    <Affiliation>NIH py@nih.gov.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Renal Physiol</MedlineTA>
            <NlmUniqueID>100901990</NlmUniqueID>
            <ISSNLinking>1522-1466</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cystatin C</Keyword>
            <Keyword MajorTopicYN="N">acute kidney injury</Keyword>
            <Keyword MajorTopicYN="N">bilateral nephrectomy</Keyword>
            <Keyword MajorTopicYN="N">creatinine</Keyword>
            <Keyword MajorTopicYN="N">sepsis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajprenal.00025.2013</ArticleId>
            <ArticleId IdType="doi">10.1152/ajprenal.00025.2013</ArticleId>
            <ArticleId IdType="pubmed">25143457</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143454</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1466</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Renal physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Renal Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Restoring multidrug-resistance associated protein 3 attenuates cell proliferation in polycystic kidney.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajprenal.00159.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Autosomal dominant polycystic kidney disease (ADPKD) is characterized by abnormal proliferation of renal tubular epithelial cells resulting in loss of renal function. Despite identification of the genes responsible for ADPKD, few effective drugs are currently available for the disease. Thus, finding additional effective drug targets is necessary. The functions of MRP3 have been reported only in the field of drug-resistance, and the renal functions of multidrug-resistance associated protein 3 (MRP) are mostly unknown. In this study, we found that MRP3 was significantly downregulated in kidneys of human patients with ADPKD and polycystic kidney disease (PKD) mouse models. Our results suggest that downregulated MRP3 stimulated renal epithelial cell proliferation through the B-Raf/MEK/ERK signaling pathway. In contrast, we found that restoring MRP3 reduced cell proliferation and cystogenesis in vitro. These results suggest that the renal function of MRP3 is related to renal cell proliferation and cyst formation and that restoring MRP3 may be an effective therapeutic approach for PKD.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology - Renal Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chang</LastName>
                    <ForeName>EunSun</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Sookmyung Women's University.</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Eun Young</ForeName>
                    <Initials>EY</Initials>
                    <Affiliation>Sookmyung Women's University.</Affiliation>
                </Author>
                <Author>
                    <LastName>Woo</LastName>
                    <ForeName>Yu Mi</ForeName>
                    <Initials>YM</Initials>
                </Author>
                <Author>
                    <LastName>Kang</LastName>
                    <ForeName>Duk-Hee</ForeName>
                    <Initials>DH</Initials>
                    <Affiliation>Ewha Womans University School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hwang</LastName>
                    <ForeName>Young-Hwan</ForeName>
                    <Initials>YH</Initials>
                    <Affiliation>Eulji General Hospital.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ahn</LastName>
                    <ForeName>Curie</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Seoul National University Hospital.</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Jong Hoon</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>Sookmyung Women's University parkjh@sookmyung.ac.kr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Renal Physiol</MedlineTA>
            <NlmUniqueID>100901990</NlmUniqueID>
            <ISSNLinking>1522-1466</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cell proliferation</Keyword>
            <Keyword MajorTopicYN="N">Cystogenesi</Keyword>
            <Keyword MajorTopicYN="N">Multidrug resistance-associated protein 3 (MRP3)</Keyword>
            <Keyword MajorTopicYN="N">Polycystic kidney</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajprenal.00159.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/ajprenal.00159.2014</ArticleId>
            <ArticleId IdType="pubmed">25143454</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143453</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1466</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Renal physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Renal Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Carbonic anhydrase 2 deficiency leads to increased pyelonephritis susceptibility.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajprenal.00344.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Carbonic anhydrase 2 regulates acid-base homeostasis and recent findings indicate a correlation between cellular control of acid-base status and the innate defense of the kidney. Mice deficient in carbonic anhydrase 2 (Car2(-/-)) have metabolic acidosis, impaired urine acidification and are deficient in normal intercalated cells. The objective of this study is to evaluate the biological consequences of carbonic anhydrase 2 deficiency in a murine model of pyelonephritis. Infection susceptibility and transcription of bacterial response components Car2(-/-) mice were compared to wild-type littermate controls. Car2(-/-) mice had increased kidney bacterial burdens along with decreased renal bacterial clearance following inoculation compared to wild-type mice. Standardization of the urine pH and serum bicarbonate levels did not substantially alter kidney infection susceptibility between wild-type and Car2(-/-), thus factors other than acid base status are responsible. Car2(-/-),have significantly increased neutrophil-gelatinase-associated lipocalin mRNA and protein and expression at baseline and a marked decreased ability to upregulate key bacterial response genes during pyelonephritis. Our findings provide in vivo evidence that supports a role for carbonic anhydrase 2 and intercalated cells in promoting renal bacterial clearance. Decreased carbonic anhydrase expression results in increased antimicrobial peptide production by cells other than renal intercalated cells, which is not sufficient to prevent infection after a bacterial challenge.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology - Renal Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hains</LastName>
                    <ForeName>David S</ForeName>
                    <Initials>DS</Initials>
                    <Affiliation>Le Bonheur Children's Hospital.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Xi</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>The Research Institute at Nationwide Children's Hospital.</Affiliation>
                </Author>
                <Author>
                    <LastName>Saxena</LastName>
                    <ForeName>Vijay</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>The Research Institute at Nationwide Children's Hospital.</Affiliation>
                </Author>
                <Author>
                    <LastName>Barr-Beare</LastName>
                    <ForeName>Evan</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>The Research Institute at Nationwide Children's Hospital.</Affiliation>
                </Author>
                <Author>
                    <LastName>Flemming</LastName>
                    <ForeName>Weisi</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>The Research Institute at Nationwide Children's Hospital.</Affiliation>
                </Author>
                <Author>
                    <LastName>Easterling</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>The Research Institute at Nationwide Children's Hospital.</Affiliation>
                </Author>
                <Author>
                    <LastName>Becknell</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Nationwide Children's Hospital.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schwartz</LastName>
                    <ForeName>George J</ForeName>
                    <Initials>GJ</Initials>
                    <Affiliation>University of Rochester Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schwaderer</LastName>
                    <ForeName>Andrew L</ForeName>
                    <Initials>AL</Initials>
                    <Affiliation>Nationwide Children's Hospital schwaderer.5@osu.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Renal Physiol</MedlineTA>
            <NlmUniqueID>100901990</NlmUniqueID>
            <ISSNLinking>1522-1466</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">acid-base</Keyword>
            <Keyword MajorTopicYN="N">inflammation</Keyword>
            <Keyword MajorTopicYN="N">intercalated cell</Keyword>
            <Keyword MajorTopicYN="N">urinary tract infection</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajprenal.00344.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/ajprenal.00344.2014</ArticleId>
            <ArticleId IdType="pubmed">25143453</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143451</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1466</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Renal physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Renal Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of preemptive treatment with human umbilical cord blood-derived mesenchymal stem cells on the development of renal ischemia-reperfusion injury in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajprenal.00555.2013</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Human umbilical cord blood-derived stem cells (HUCB-MSCs) have been studied in several models of immune-mediated disease because of their unique immunomodulatory properties. We hypothesized that HUCB-MSCs could suppress the inflammatory response in postischemic kidneys and attenuate early renal injury. In 8-10-week-old male C57BL/6 mice, bilateral ischemia-reperfusion injury (IRI) surgery was performed and 1x106 HUCB-MSCs were injected intraperitoneally 24 h prior to surgery and during reperfusion. Renal functional and histological changes, HUCB-MSC trafficking, leukocyte infiltration, and cytokine expression were analyzed. Renal functional decline and tubular injury following IRI were attenuated by HUCB-MSC treatment. PKH26-labeled HUCB-MSCs trafficked into the postischemic kidney. Although numbers of CD45-positive leukocytes in the postischemic kidney were comparable between groups, the expression of interferon-?? in the postischemic kidney was suppressed by HUCB-MSC treatment. The rapid decrease in intrarenal vascular endothelial growth factor (VEGF) following IRI was markedly mitigated by HUCB-MSC treatment. In inflammatory conditions simulated in a cell-culture experiment, VEGF secretion from HUCB-MSCs was substantially enhanced. VEGF inhibitor abolished the renoprotective effect of HUCB-MSCs after IRI. Flow cytometry analysis revealed the decreased infiltration of NKT cells and increased number of regulatory T cells in the postischemic kidneys. And, these effects of HUCB-MSCs on the kidney infiltrating mononuclear cells after IRI were attenuated by VEGF inhibitor. HUCB-MSCs attenuated renal injury in mice in the early injury phase following IRI, mainly by humoral effects and secretion of VEGF. Our results suggest a promising role for HUCB-MSCs in the treatment of renal IRI.</AbstractText>
                <CopyrightInformation>Copyright ?? 2013, American Journal of Physiology - Renal Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Jang</LastName>
                    <ForeName>Hye Ryoun</ForeName>
                    <Initials>HR</Initials>
                    <Affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Ji Hyeon</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kwon</LastName>
                    <ForeName>Ghee Young</ForeName>
                    <Initials>GY</Initials>
                    <Affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Jung Eun</ForeName>
                    <Initials>JE</Initials>
                    <Affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Huh</LastName>
                    <ForeName>Wooseong</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jin</LastName>
                    <ForeName>Hye Jin</ForeName>
                    <Initials>HJ</Initials>
                    <Affiliation>Biomedical Research Institute, MEDIPOST Co. Ltd.</Affiliation>
                </Author>
                <Author>
                    <LastName>Choi</LastName>
                    <ForeName>Soo Jin</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>Biomedical Research Institute, MEDIPOST Co. Ltd.</Affiliation>
                </Author>
                <Author>
                    <LastName>Oh</LastName>
                    <ForeName>Wonil</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Biomedical Research Institute, MEDIPOST Co. Ltd.</Affiliation>
                </Author>
                <Author>
                    <LastName>Oh</LastName>
                    <ForeName>Ha Young</ForeName>
                    <Initials>HY</Initials>
                    <Affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Yoon-Goo</ForeName>
                    <Initials>YG</Initials>
                    <Affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine ygkim26@skku.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Renal Physiol</MedlineTA>
            <NlmUniqueID>100901990</NlmUniqueID>
            <ISSNLinking>1522-1466</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">inflammation</Keyword>
            <Keyword MajorTopicYN="N">mesenchymal stem cells</Keyword>
            <Keyword MajorTopicYN="N">renal ischemia-reperfusion injury</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajprenal.00555.2013</ArticleId>
            <ArticleId IdType="doi">10.1152/ajprenal.00555.2013</ArticleId>
            <ArticleId IdType="pubmed">25143451</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143447</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1538-8514</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cancer therapeutics</Title>
                <ISOAbbreviation>Mol. Cancer Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Longitudinal time dependent effects of irradiation on multidrug resistance in a non-small lung cancer cell line.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">molcanther.0151.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Multi-drug resistance (MDR) in cancer is known to decrease the therapeutic efficacy of chemotherapy. The effects of irradiation on MDR in cancer cells remains unclear. Tc-99m methoxyisobutylisonitrile (MIBI) exhibits the same ATP-binding cassette (ABC) transporter kinetics as the chemotherapeutic compounds doxorubicin and cisplatin. In this study, we investigated the synergistic effects of chemotherapeutics and irradiation (0 Gy: C(control)-group; 3, 6, 9, 12 Gy: I(irradiation)-group) in the non-small lung cancer cell line, H1299 exhibiting MDR, on MIBI and doxorubicin ABC transporter kinetics, in vitro and in vivo, respectively. In vitro, inhibition of H1299 cell proliferation by irradiation was found to be irradiation dose dependent. The degree and duration of MDR inhibition in vitro in H1299 was also dose dependent. In the cells of both the C-group and 3 Gy I-group, no significant difference of MIBI accumulation was observed. In the 6 Gy I-group, a higher MIBI accumulation was observed at only 7 days after irradiation relative to the C-group. A higher MIBI accumulation in the 9, 12 Gy I-groups with a significant difference from the C-group was observed at 4 to 14 days after irradiation. A significant negative correlation between intracellular MIBI accumulation and cell replication was found. In vivo, high accumulation and retention of doxorubicin was observed in irradiated tumors in the H1299 xenograft mice group at 4 to 14 days after 9 Gy irradiation compared to the control mice group. These results provide evidence for a synergistic effect of concurrent chemotherapy and radiotherapy.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kono</LastName>
                    <ForeName>Yumiko</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Radiology, Kansai medical university kohnoy@hirakata.kmu.ac.jp.</Affiliation>
                </Author>
                <Author>
                    <LastName>Utsunomiya</LastName>
                    <ForeName>Keita</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Radiology, Kansai medical university.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kanno</LastName>
                    <ForeName>Shohei</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Radiology, Kansai Medicai University.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tanigawa</LastName>
                    <ForeName>Noboru</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Radiology, Kansai Medicai University.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Cancer Ther</MedlineTA>
            <NlmUniqueID>101132535</NlmUniqueID>
            <ISSNLinking>1535-7163</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1535-7163.MCT-14-0151</ArticleId>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-14-0151</ArticleId>
            <ArticleId IdType="pubmed">25143447</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143443</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1550-6606</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <ISOAbbreviation>J. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Fungal ??-Glucan, a Dectin-1 Ligand, Promotes Protection from Type 1 Diabetes by Inducing Regulatory Innate Immune Response.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">1400186</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">??-Glucans are naturally occurring polysaccharides in cereal grains, mushrooms, algae, or microbes, including bacteria, fungi, and yeast. Immune cells recognize these ??-glucans through a cell surface pathogen recognition receptor called Dectin-1. Studies using ??-glucans and other Dectin-1 binding components have demonstrated the potential of these agents in activating the immune cells for cancer treatment and controlling infections. In this study, we show that the ??-glucan from Saccharomyces cerevisiae induces the expression of immune regulatory cytokines (IL-10, TGF-??1, and IL-2) and a tolerogenic enzyme (IDO) in bone marrow-derived dendritic cells as well as spleen cells. These properties can be exploited to modulate autoimmunity in the NOD mouse model of type 1 diabetes (T1D). Treatment of prediabetic NOD mice with low-dose ??-glucan resulted in a profound delay in hyperglycemia, and this protection was associated with increase in the frequencies of Foxp3(+), LAP(+), and GARP(+) T cells. Upon Ag presentation, ??-glucan-exposed dendritic cells induced a significant increase in Foxp3(+) and LAP(+) T cells in in vitro cultures. Furthermore, systemic coadministration of ??-glucan plus pancreatic ?? cell Ag resulted in an enhanced protection of NOD mice from T1D as compared with treatment with ??-glucan alone. These observations demonstrate that the innate immune response induced by low-dose ??-glucan is regulatory in nature and can be exploited to modulate T cell response to ?? cell Ag for inducing an effective protection from T1D.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Karumuthil-Melethil</LastName>
                    <ForeName>Subha</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Surgery, University of Illinois at Chicago, Chicago, IL 60612;</Affiliation>
                </Author>
                <Author>
                    <LastName>Gudi</LastName>
                    <ForeName>Radhika</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Surgery, College of Medicine, Medical University of South Carolina, Charleston, SC 29425; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Johnson</LastName>
                    <ForeName>Benjamin M</ForeName>
                    <Initials>BM</Initials>
                    <Affiliation>Department of Microbiology and Immunology, College of Medicine, Medical University of South Carolina, Charleston, SC 29425.</Affiliation>
                </Author>
                <Author>
                    <LastName>Perez</LastName>
                    <ForeName>Nicolas</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Surgery, University of Illinois at Chicago, Chicago, IL 60612;</Affiliation>
                </Author>
                <Author>
                    <LastName>Vasu</LastName>
                    <ForeName>Chenthamarakshan</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Surgery, University of Illinois at Chicago, Chicago, IL 60612; Department of Surgery, College of Medicine, Medical University of South Carolina, Charleston, SC 29425; and Department of Microbiology and Immunology, College of Medicine, Medical University of South Carolina, Charleston, SC 29425 vasu@musc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Immunol</MedlineTA>
            <NlmUniqueID>2985117R</NlmUniqueID>
            <ISSNLinking>0022-1767</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jimmunol.1400186</ArticleId>
            <ArticleId IdType="doi">10.4049/jimmunol.1400186</ArticleId>
            <ArticleId IdType="pubmed">25143443</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143441</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1550-6606</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <ISOAbbreviation>J. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Survival and Differentiation of Pro-B and Pre-B Cells in the Bone Marrow Is Dependent on IL-7R?? Tyr449.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">1302925</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">IL-7 is critical for murine T and B cell development and survival and plays a significant role in lymphoblastic leukemia in both humans and mice. We evaluated the role of the IL-7R?? Tyr(449) cytoplasmic SH2-binding motif in IL-7-mediated B cell development using a knock-in mouse with a Tyr to Phe mutation (IL-7R??(449F/449F) mouse). IL-7R??(449F/449F) and IL-7R??(-/-) mice showed no defect in the number of pre-pro-B cells, although IL-7R??(449F/449F) mice had decreased Ebf1 in pre-pro-B cells and impairment in B cell-committed CLPs. We identified that IL-7R?? Tyr(449) was critical for both pro-B and pre-B stages of development in the bone marrow. IL-7R??(449F/449F) and IL-7R??(-/-) mice had comparable precursor B cell defects, indicating that signaling from the IL-7R?? required this motif. Although the defect in IL-7R??(449F/449F) pro-B cells was associated with loss of STAT5 activation and diminished expression of Mcl1, this was not rescued by overexpression of Bcl-2. IL-7R??(449F/449F) and IL-7R??(-/-) pre-B cells also showed defective cyto-Ig?? and CD25 expression, associated with reduced levels of Rag1, Rag2, and Irf4. Pre-B cells from IL-7R??(449F/449F) mice also failed to proliferate, perhaps as a result of the failure to rearrange Ig??. Our data suggest that IL-7R?? Tyr(449) was essential for IL-7R?? signaling in bone marrow B cell development and survival.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Patton</LastName>
                    <ForeName>Daniel T</ForeName>
                    <Initials>DT</Initials>
                    <Affiliation>Infection, Inflammation and Immunity Research Group, Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Plumb</LastName>
                    <ForeName>Adam W</ForeName>
                    <Initials>AW</Initials>
                    <Affiliation>Infection, Inflammation and Immunity Research Group, Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Abraham</LastName>
                    <ForeName>Ninan</ForeName>
                    <Initials>N</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2747-1246</Identifier>
                    <Affiliation>Infection, Inflammation and Immunity Research Group, Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada; and Department of Zoology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada ninan@mail.ubc.ca.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Immunol</MedlineTA>
            <NlmUniqueID>2985117R</NlmUniqueID>
            <ISSNLinking>0022-1767</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jimmunol.1302925</ArticleId>
            <ArticleId IdType="doi">10.4049/jimmunol.1302925</ArticleId>
            <ArticleId IdType="pubmed">25143441</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143434</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-3125</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cancer research : MCR</Title>
                <ISOAbbreviation>Mol. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>SIRT1 Inactivation Evokes Antitumor Activities in NSCLC through the Tumor Suppressor p27.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">molcanres.0239.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">P27Kip1 (CDKN1B) regulates cellular proliferation and senescence, and p27Kip1 deficiency in cancer is strongly correlated with poor prognosis of multiple cancer types. Understanding the mechanism of p27Kip1 loss in cancer and the consequences ofrestoring p27Kip1 levels is therefore critical for effective management during therapy. Here, SIRT1, a class III histone deacetylase (HDAC), is identified as an important regulator of p27Kip1 expression. Mechanistically, SIRT1 reduces p27Kip1 expression by decreasing p27Kip1 protein stability through the ubiquitin-proteasome pathway. In addition, SIRT1 silencing suppresses NSCLC proliferation and induces senescence in a p27Kip1-dependent manner. Furthermore, SIRT1 silencing dramatically suppresses tumor formation and proliferation in two distinct NSCLC xenograft mouse models. Collectively, these data not only demonstrate that SIRT1 is an important regulator of p27Kip1 but that SIRT inhibition induces senescence and anti-growth potential in lung cancer in vivo. Implications: SIRT1 is a key regulator of p27 protein levels and SIRT1 inhibition is a viable strategy for NSCLC therapy by means of p27 reactivation.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>Lijia</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Cancer Center and Department of Medicine, Boston University School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chiao</LastName>
                    <ForeName>Christine Y</ForeName>
                    <Initials>CY</Initials>
                    <Affiliation>Cancer Center and Department of Medicine, Boston University School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Enzer</LastName>
                    <ForeName>Katelyn Gail</ForeName>
                    <Initials>KG</Initials>
                    <Affiliation>Cancer Center and Department of Medicine, Boston University School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Stankiewicz</LastName>
                    <ForeName>Alexander John</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>The Department of Anatomy and Neurobiology, Boston University School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Faller</LastName>
                    <ForeName>Douglas V</ForeName>
                    <Initials>DV</Initials>
                    <Affiliation>Cancer Center and Department of Medicine, Boston University School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dai</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Cancer Center and Department of Medicine, Boston University School of Medicine yandai@bu.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Cancer Res</MedlineTA>
            <NlmUniqueID>101150042</NlmUniqueID>
            <ISSNLinking>1541-7786</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1541-7786.MCR-14-0239</ArticleId>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-14-0239</ArticleId>
            <ArticleId IdType="pubmed">25143434</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143394</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-2083</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human molecular genetics</Title>
                <ISOAbbreviation>Hum. Mol. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mutant huntingtin alters Tau phosphorylation and subcellular distribution.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ddu421</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Tau abnormalities play a central role in several neurodegenerative diseases, collectively known as tauopathies. In the present study, we examined whether mutant huntingtin, which causes Huntington's disease (HD), modifies Tau phosphorylation and subcellular localization using cell and mouse HD models. Initially, we used novel bimolecular fluorescence complementation (BiFC) assays in live cells to evaluate Tau interactions with either wild type (25QHtt) or mutant huntingtin (103QHtt). While 25QHtt and Tau interacted at the level of the microtubule network, 103QHtt and Tau interacted and formed &quot;ring-like&quot; inclusions localized in the vicinity of the microtubular organizing center (MTOC). Fluorescence recovery after photobleaching experiments also indicated that, whereas homomeric 103QHtt/103QHtt pairs rapidly re-entered into inclusions, heteromeric 103QHtt/Tau pairs remained excluded from the &quot;ring-like&quot; inclusions. Interestingly, in vitro Tau relocalization was associated to Tau hyperphosphorylation. Consistent with this observation, we found strong Tau hyperphosphorylation in brain samples from two different mouse models of HD, R6/2 and 140CAG knock-in. This was associated with a significant reduction in the levels of Tau phosphatases (PP1, PP2A and PP2B), with no apparent involvement of major Tau kinases. Thus, the present study strongly suggests that expression of mutant huntingtin leads to Tau hyperphosphorylation, relocalization, and sequestration through direct protein-protein interactions in inclusion-like compartments in the vicinity of the MTOC. Likewise, our data also suggests that Tau alterations may also contribute to HD pathogenesis.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Blum</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Universit?? Lille-Nord de France, UDSL, F-59000, Lille, France Inserm U837, Jean-Pierre Aubert Research Centre, IMPRT, F-59000, Lille France CHRU, F-59000, Lille, France david.blum@inserm.fr touteiro@gmail.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Herrera</LastName>
                    <ForeName>Federico</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Av. Prof. Egas Moniz, 1649-029 Lisboa.</Affiliation>
                </Author>
                <Author>
                    <LastName>Francelle</LastName>
                    <ForeName>Laetitia</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>CEA, DSV, I??BM, Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses F-92265, France CNRS, CEA URA 2210, Fontenay-aux-Roses F-92265, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mendes</LastName>
                    <ForeName>Tiago</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Av. Prof. Egas Moniz, 1649-029 Lisboa david.blum@inserm.fr touteiro@gmail.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Basquin</LastName>
                    <ForeName>Marie</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Universit?? Lille-Nord de France, UDSL, F-59000, Lille, France Inserm U837, Jean-Pierre Aubert Research Centre, IMPRT, F-59000, Lille France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Obriot</LastName>
                    <ForeName>H??l??ne</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Universit?? Lille-Nord de France, UDSL, F-59000, Lille, France Inserm U837, Jean-Pierre Aubert Research Centre, IMPRT, F-59000, Lille France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Demeyer</LastName>
                    <ForeName>Dominique</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Universit?? Lille-Nord de France, UDSL, F-59000, Lille, France Inserm U837, Jean-Pierre Aubert Research Centre, IMPRT, F-59000, Lille France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sergeant</LastName>
                    <ForeName>Nicolas</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Universit?? Lille-Nord de France, UDSL, F-59000, Lille, France Inserm U837, Jean-Pierre Aubert Research Centre, IMPRT, F-59000, Lille France CHRU, F-59000, Lille, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gerhardt</LastName>
                    <ForeName>Ellen</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Neurodegeneration and Restorative Research, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Goettingen, Waldweg 33, 37073 Goettingen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Brouillet</LastName>
                    <ForeName>Emmanuel</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>CEA, DSV, I??BM, Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses F-92265, France CNRS, CEA URA 2210, Fontenay-aux-Roses F-92265, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bu??e</LastName>
                    <ForeName>Luc</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Universit?? Lille-Nord de France, UDSL, F-59000, Lille, France Inserm U837, Jean-Pierre Aubert Research Centre, IMPRT, F-59000, Lille France CHRU, F-59000, Lille, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Outeiro</LastName>
                    <ForeName>Tiago F</ForeName>
                    <Initials>TF</Initials>
                    <Affiliation>Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Av. Prof. Egas Moniz, 1649-029 Lisboa Department of Neurodegeneration and Restorative Research, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Goettingen, Waldweg 33, 37073 Goettingen, Germany david.blum@inserm.fr touteiro@gmail.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Hum Mol Genet</MedlineTA>
            <NlmUniqueID>9208958</NlmUniqueID>
            <ISSNLinking>0964-6906</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ddu421</ArticleId>
            <ArticleId IdType="doi">10.1093/hmg/ddu421</ArticleId>
            <ArticleId IdType="pubmed">25143394</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143392</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-2083</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human molecular genetics</Title>
                <ISOAbbreviation>Hum. Mol. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dominant negative effect of polyglutamine expansion perturbs normal function of ataxin-3 in neuronal cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ddu422</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The physiological function of Ataxin-3 (ATXN3), a deubiquitylase (DUB) involved in Machado-Joseph Disease (MJD), remains elusive. In this study, we demonstrate that ATXN3 is required for neuronal differentiation and for normal cell morphology, cytoskeletal organization, proliferation and survival of SH-SY5Y and PC12 cells. This cellular phenotype is associated with increased proteasomal degradation of ITGA5 and reduced activation of integrin signaling, and is rescued by ITGA5 overexpression. Interestingly, silencing of ATXN3, overexpression of mutant versions of ATXN3 lacking catalytic activity or bearing an expanded polyglutamine (polyQ) tract led to partially overlapping phenotypes. In vivo analysis showed that both Atxn3 knockout and MJD transgenic mice had decreased levels of ITGA5 in the brain. Furthermore, abnormal morphology and reduced branching was observed both in cultured neurons expressing shRNA for ATXN3 and in those obtained from MJD mice. Our results show that ATXN3 rescues ITGA5 from proteasomal degradation in neurons and that polyQ expansion causes a partial loss of this cellular function, resulting in reduced integrin signaling and neuronal cytoskeleton modifications, which may be contributing to neurodegeneration.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Neves-Carvalho</LastName>
                    <ForeName>Andreia</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, 4710-057 Braga, Portugal ICVS/3B's - PT Government Associate Laboratory, Braga/Guimar??es, Portugal.</Affiliation>
                </Author>
                <Author>
                    <LastName>Logarinho</LastName>
                    <ForeName>Elsa</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Institute for Molecular and Cell Biology, University of Porto, Porto, Portugal.</Affiliation>
                </Author>
                <Author>
                    <LastName>Freitas</LastName>
                    <ForeName>Ana</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, 4710-057 Braga, Portugal ICVS/3B's - PT Government Associate Laboratory, Braga/Guimar??es, Portugal.</Affiliation>
                </Author>
                <Author>
                    <LastName>Duarte-Silva</LastName>
                    <ForeName>Sara</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, 4710-057 Braga, Portugal ICVS/3B's - PT Government Associate Laboratory, Braga/Guimar??es, Portugal.</Affiliation>
                </Author>
                <Author>
                    <LastName>do Carmo Costa</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Neurology, University of Michigan, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Silva-Fernandes</LastName>
                    <ForeName>Anabela</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, 4710-057 Braga, Portugal ICVS/3B's - PT Government Associate Laboratory, Braga/Guimar??es, Portugal.</Affiliation>
                </Author>
                <Author>
                    <LastName>Martins</LastName>
                    <ForeName>Margarida</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, 4710-057 Braga, Portugal ICVS/3B's - PT Government Associate Laboratory, Braga/Guimar??es, Portugal.</Affiliation>
                </Author>
                <Author>
                    <LastName>Serra</LastName>
                    <ForeName>Sofia Cravino</ForeName>
                    <Initials>SC</Initials>
                    <Affiliation>Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, 4710-057 Braga, Portugal ICVS/3B's - PT Government Associate Laboratory, Braga/Guimar??es, Portugal.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lopes</LastName>
                    <ForeName>Andr??</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, 4710-057 Braga, Portugal ICVS/3B's - PT Government Associate Laboratory, Braga/Guimar??es, Portugal.</Affiliation>
                </Author>
                <Author>
                    <LastName>Paulson</LastName>
                    <ForeName>Henry L</ForeName>
                    <Initials>HL</Initials>
                    <Affiliation>Department of Neurology, University of Michigan, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Heutink</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>German Center for Neurodegenerative Diseases (DZNE), T??bingen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Relvas</LastName>
                    <ForeName>Jo??o B</ForeName>
                    <Initials>JB</Initials>
                    <Affiliation>Institute for Molecular and Cell Biology, University of Porto, Porto, Portugal.</Affiliation>
                </Author>
                <Author>
                    <LastName>Maciel</LastName>
                    <ForeName>Patr??cia</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, 4710-057 Braga, Portugal ICVS/3B's - PT Government Associate Laboratory, Braga/Guimar??es, Portugal pmaciel@ecsaude.uminho.pt.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Hum Mol Genet</MedlineTA>
            <NlmUniqueID>9208958</NlmUniqueID>
            <ISSNLinking>0964-6906</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ddu422</ArticleId>
            <ArticleId IdType="doi">10.1093/hmg/ddu422</ArticleId>
            <ArticleId IdType="pubmed">25143392</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143383</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1083-351X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of biological chemistry</Title>
                <ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gene Targeting Study Reveals Unexpected Expression of Brain expressed X-linked 2 in Endocrine and Tissue Stem/progenitor Cells in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jbc.M114.580084</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Identification of genes specifically expressed in stem/progenitor cells is an important issue in developmental and stem cell biology. Genome-wide gene expression analyses in liver cells performed in the current study have revealed a strong expression of X-linked genes that include members of the Brain expressed X-linked (Bex) gene family in stem/progenitor cells. Bex family genes are expressed abundantly in the neural cells and have been suggested to play important roles in the development of nervous tissues. However, the physiological role of its individual members and the precise expression pattern outside the nervous system remained largely unknown. Here, we focused on Bex2 and examined its role and expression pattern by generating knock-in mice: the enhanced green fluorescence protein (EGFP) was inserted into the Bex2 locus. Bex2-deficiet mice were viable and fertile under laboratory growth conditions showing no obvious phenotypic abnormalities. Through immunohistochemical analysis and flow cytometry-based approach, we observed unique EGFP reporter expression patterns in endocrine and stem/progenitor cells of the liver, pyloric stomach, and hematopoietic system. Although Bex2 seems to play redundant roles in vivo, these results suggest the significance and potential applications of Bex2 in studies of endocrine and stem/progenitor cells.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, The American Society for Biochemistry and Molecular Biology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ito</LastName>
                    <ForeName>Keiichi</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>The University of Tokyo, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Yamazaki</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>The University of Tokyo, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Yamamoto</LastName>
                    <ForeName>Ryo</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>The University of Tokyo, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Tajima</LastName>
                    <ForeName>Yoko</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>The University of Tokyo, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Yanagida</LastName>
                    <ForeName>Ayaka</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>The University of Tokyo, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Kobayashi</LastName>
                    <ForeName>Toshihiro</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>NAKAUCHI Stem Cell and Organ Regeneration Project, Japan Science and Technology Agency, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Kato-Itoh</LastName>
                    <ForeName>Megumi</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>NAKAUCHI Stem Cell and Organ Regeneration Project, Japan Science and Technology Agency, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Kakuta</LastName>
                    <ForeName>Shigeru</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Graduate School of Agriculture and Life Sciences, the University of Tokyo, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Iwakura</LastName>
                    <ForeName>Yoichiro</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Tokyo University of Science, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Nakauchi</LastName>
                    <ForeName>Hiromitsu</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>The University of Tokyo, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Kamiya</LastName>
                    <ForeName>Akihide</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Tokai University, Japan kamiyaa@tokai-u.jp.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Biol Chem</MedlineTA>
            <NlmUniqueID>2985121R</NlmUniqueID>
            <ISSNLinking>0021-9258</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Brain expressed X-linked gene</Keyword>
            <Keyword MajorTopicYN="N">X-linked gene</Keyword>
            <Keyword MajorTopicYN="N">development</Keyword>
            <Keyword MajorTopicYN="N">endocrine cells</Keyword>
            <Keyword MajorTopicYN="N">gene expression</Keyword>
            <Keyword MajorTopicYN="N">gene knockout</Keyword>
            <Keyword MajorTopicYN="N">hematopoietic stem cells</Keyword>
            <Keyword MajorTopicYN="N">liver</Keyword>
            <Keyword MajorTopicYN="N">stem cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25143383</ArticleId>
            <ArticleId IdType="pii">M114.580084</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M114.580084</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143378</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1083-351X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of biological chemistry</Title>
                <ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inflammatory Monocytes Determine Endothelial Nitric Oxide Synthase Uncoupling and Nitro-oxidative Stress Induced by Angiotensin II.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jbc.M114.604231</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Endothelial nitric oxide synthase (eNOS) uncoupling and increased inducible NOS (iNOS) activity amplify vascular oxidative stress. The role of inflammatory myelomonocytic cells as mediators of these processes and their impact on tetrahydrobiopterin availability and function have not been defined yet. Angiotensin II (ATII, 1mg/kg/d, 7d) increased Ly6Chigh and CD11b+/iNOShigh leukocytes and upregulated levels of eNOS glutathionylation in aortas of C57BL/6 mice. Vascular iNOS dependent NO formation was increased, whereas eNOS dependent NO formation was decreased in aortas of ATII infused mice as assessed by electron paramagnetic resonance (EPR) spectroscopy. Diphteria toxin mediated ablation of lysozyme M positive (LysM+) monocytes in ATII-infused LysMiDTR transgenic mice prevented eNOS glutathionylation and eNOS derived L-NAME sensitive superoxide formation in the endothelial layer. ATII increased vascular guanosine triphosphate cyclohydrolase I (GTPCH) expression and biopterin synthesis in paralell, which was reduced in monocyte depleted LysMiDTR mice. Vascular tetrahydrobiopterin was increased by ATII infusion, but even higher in monocyte-depleted ATII infused mice, which was paralelled by a strong upregulation of dihydrofolate reductase expression. EPR spectroscopy revealed, that both vascular iNOS- and eNOS-dependent NO formation were normalized in ATII-infused mice following monocyte depletion. Additionally, deletion as well as pharmacologic inhibition of iNOS prevented ATII induced endothelial dysfunction. In summary, ATII induces an inflammatory cell dependent increase of iNOS, GTPCH, tetrahydrobiopterin, NO-formation and nitro-oxidative stress as well as eNOS uncoupling in the vessel wall, which can be prevented by ablation of LysM+ monocytes.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, The American Society for Biochemistry and Molecular Biology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kossmann</LastName>
                    <ForeName>Sabine</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>University Medical Center Mainz, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Hanhan</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>University Medical Center Mainz, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Steven</LastName>
                    <ForeName>Sebastian</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>University Medical Center Mainz, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Sch Oumlnfelder</LastName>
                    <ForeName>Tanja</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>University Medical Center Mainz, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Fraccarollo</LastName>
                    <ForeName>Daniela</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Hannover Medical School, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mikhed</LastName>
                    <ForeName>Yuliya</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>University Medical Center Mainz, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Br Aumlhler</LastName>
                    <ForeName>Melanie</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>University Medical Center Mainz, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Knorr</LastName>
                    <ForeName>Maike</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>University Medical Center Mainz, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Brandt</LastName>
                    <ForeName>Moritz</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>University Medical Center Mainz, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Karbach</LastName>
                    <ForeName>Susanne H</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>University Medical Center Mainz, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Becker</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>University Medical Center Mainz, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Oelze</LastName>
                    <ForeName>Matthias</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>University Medical Center Mainz, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Bauersachs</LastName>
                    <ForeName>Johann</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Hannover Medical School, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Widder</LastName>
                    <ForeName>Julian</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Hannover Medical School, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>M Uumlnzel</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>University Medical Center Mainz, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Daiber</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>University Medical Center Mainz, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Wenzel</LastName>
                    <ForeName>Philip</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>University Medical Center Mainz, Germany; wenzelp@uni-mainz.de.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Biol Chem</MedlineTA>
            <NlmUniqueID>2985121R</NlmUniqueID>
            <ISSNLinking>0021-9258</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">angiotensin II</Keyword>
            <Keyword MajorTopicYN="N">endothelial dysfunction</Keyword>
            <Keyword MajorTopicYN="N">inflammation</Keyword>
            <Keyword MajorTopicYN="N">monocyte</Keyword>
            <Keyword MajorTopicYN="N">nitric oxide synthase</Keyword>
            <Keyword MajorTopicYN="N">tetrahydrobiopterin (BH4)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25143378</ArticleId>
            <ArticleId IdType="pii">M114.604231</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M114.604231</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143376</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1541-6100</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of nutrition</Title>
                <ISOAbbreviation>J. Nutr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Short-Chain Fructo-oligosaccharide and Inulin Modulate Inflammatory Responses and Microbial Communities in Caco2-bbe Cells and in a Mouse Model of Intestinal Injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jn.114.195081</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Few studies have focused on the ability of prebiotics to prevent pathogen-induced cellular changes or alter the composition of the intestinal microbiota in complimentary relevant cell and animal models of inflammatory bowel disease. The objective of this study was to determine if pretreatment with inulin and a short-chain fructo-oligosaccharide (sc-FOS) prevents enterohemorrhagic Escherichia coli (EHEC) O157:H7 infection in Caco2-bbe epithelial cells and what effect 10% wt:v sc-FOS or inulin has on C57BL/6 mice under sham conditions or pretreatment with prebiotics before Citrobacter rodentium infection (10(8) colony-forming units). Actin rearrangement and tight junction protein (zona occludin-1) were examined with immunofluorescence. Barrier function was assessed by a fluorescent probe and by measuring transepithelial electrical resistance (TER). Alterations in cytokine gene expression and microbiome were assessed with quantitative reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization. Short-chain fatty acids (SCFAs) were measured by GC. sc-FOS added to monolayers altered actin polymerization without affecting TER or permeability to a fluorescein isothiocyanate (FITC) probe, whereas inulin increased TER (P &lt; 0.005) and altered actin arrangement without affecting FITC permeability. Neither prebiotic attenuated EHEC-induced decreases in barrier function. Prebiotics increased interleukin 10 (Il10) and transforming growth factor-?? (Tgf??) cytokine responses alone (P &lt; 0.05) or with EHEC O157:H7 infection (P &lt; 0.05) in vitro. Increases in tumor necrosis factor-?? (Tnf??) (P &lt; 0.05) and decreases in chemokine CXC motif ligand 8 (Cxcl8) (P &lt; 0.05) expression were observed with prebiotic treatment prior to EHEC infection. No differences were noted in barrier function or cytokine responses in the absence or presence of C. rodentium in vivo. Alterations in microbiome were evident at 6 d and 10 d postinfection in treatment groups, but a change in C. rodentium load was not observed. Inulin and sc-FOS (P &lt; 0.05) increased fecal SCFAs in the absence of infection. This study provides new insights as to how prebiotics act in complementary in vitro and in vivo models of intestinal injury.</AbstractText>
                <CopyrightInformation>?? 2014 American Society for Nutrition.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Johnson-Henry</LastName>
                    <ForeName>Kathene C</ForeName>
                    <Initials>KC</Initials>
                    <Affiliation>Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pinnell</LastName>
                    <ForeName>Lee J</ForeName>
                    <Initials>LJ</Initials>
                    <Affiliation>Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Waskow</LastName>
                    <ForeName>Alexandra M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Department of Chemistry and Biology, Ryerson University, Toronto, ON, Canada; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Irrazabal</LastName>
                    <ForeName>Thergiory</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Immunology, University of Toronto, Toronto, ON, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Martin</LastName>
                    <ForeName>Alberto</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Immunology, University of Toronto, Toronto, ON, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hausner</LastName>
                    <ForeName>Martina</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Chemistry and Biology, Ryerson University, Toronto, ON, Canada; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sherman</LastName>
                    <ForeName>Philip M</ForeName>
                    <Initials>PM</Initials>
                    <Affiliation>Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Nutr</MedlineTA>
            <NlmUniqueID>0404243</NlmUniqueID>
            <ISSNLinking>0022-3166</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jn.114.195081</ArticleId>
            <ArticleId IdType="doi">10.3945/jn.114.195081</ArticleId>
            <ArticleId IdType="pubmed">25143376</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143365</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1946-6242</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>6</Volume>
                    <Issue>250</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Science translational medicine</Title>
                <ISOAbbreviation>Sci Transl Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Denervation suppresses gastric tumorigenesis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>250ra115</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3009569</ELocationID>
            <Abstract>
                <AbstractText>The nervous system plays an important role in the regulation of epithelial homeostasis and has also been postulated to play a role in tumorigenesis. We provide evidence that proper innervation is critical at all stages of gastric tumorigenesis. In three separate mouse models of gastric cancer, surgical or pharmacological denervation of the stomach (bilateral or unilateral truncal vagotomy, or local injection of botulinum toxin type A) markedly reduced tumor incidence and progression, but only in the denervated portion of the stomach. Vagotomy or botulinum toxin type A treatment also enhanced the therapeutic effects of systemic chemotherapy and prolonged survival. Denervation-induced suppression of tumorigenesis was associated with inhibition of Wnt signaling and suppression of stem cell expansion. In gastric organoid cultures, neurons stimulated growth in a Wnt-mediated fashion through cholinergic signaling. Furthermore, pharmacological inhibition or genetic knockout of the muscarinic acetylcholine M3 receptor suppressed gastric tumorigenesis. In gastric cancer patients, tumor stage correlated with neural density and activated Wnt signaling, whereas vagotomy reduced the risk of gastric cancer. Together, our findings suggest that vagal innervation contributes to gastric tumorigenesis via M3 receptor-mediated Wnt signaling in the stem cells, and that denervation might represent a feasible strategy for the control of gastric cancer.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Association for the Advancement of Science.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Chun-Mei</ForeName>
                    <Initials>CM</Initials>
                    <Affiliation>Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7491, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hayakawa</LastName>
                    <ForeName>Yoku</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Division of Digestive and Liver Diseases, Columbia University College of Physicians and Surgeons, New York, NY 10032-3802, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kodama</LastName>
                    <ForeName>Yosuke</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7491, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muthupalani</LastName>
                    <ForeName>Sureshkumar</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Division of Comparative Medicine, Massachusetts Institute of Technology, Boston, MA 02139, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Westphalen</LastName>
                    <ForeName>Christoph B</ForeName>
                    <Initials>CB</Initials>
                    <Affiliation>Division of Digestive and Liver Diseases, Columbia University College of Physicians and Surgeons, New York, NY 10032-3802, USA. Medizinische Klinik III, Klinikum der Universit??t M??nchen, Campus Gro??hadern, 81377 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Andersen</LastName>
                    <ForeName>G??ran T</ForeName>
                    <Initials>GT</Initials>
                    <Affiliation>Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7491, Norway. Department of Surgery, St. Olavs University Hospital, Trondheim 7006, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Flatberg</LastName>
                    <ForeName>Arnar</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7491, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johannessen</LastName>
                    <ForeName>Helene</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7491, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Friedman</LastName>
                    <ForeName>Richard A</ForeName>
                    <Initials>RA</Initials>
                    <Affiliation>Biomedical Informatics Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Renz</LastName>
                    <ForeName>Bernhard W</ForeName>
                    <Initials>BW</Initials>
                    <Affiliation>Division of Digestive and Liver Diseases, Columbia University College of Physicians and Surgeons, New York, NY 10032-3802, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sandvik</LastName>
                    <ForeName>Arne K</ForeName>
                    <Initials>AK</Initials>
                    <Affiliation>Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7491, Norway. Department of Gastrointestinal and Liver Diseases, St. Olavs University Hospital, Trondheim 7006, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beisvag</LastName>
                    <ForeName>Vidar</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7491, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomita</LastName>
                    <ForeName>Hiroyuki</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu 501-1112, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hara</LastName>
                    <ForeName>Akira</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu 501-1112, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Quante</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>II. Medizinische Klinik, Klinikum rechts der Isar, Technische Universit??t M??nchen, M??nchen 81675, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Zhishan</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Pathology and Cell Biology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gershon</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                    <Affiliation>Department of Pathology and Cell Biology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaneko</LastName>
                    <ForeName>Kazuhiro</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Gastroenterology and Endoscopy Division, National Cancer Center Hospital East, Chiba 277-8577, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fox</LastName>
                    <ForeName>James G</ForeName>
                    <Initials>JG</Initials>
                    <Affiliation>Division of Comparative Medicine, Massachusetts Institute of Technology, Boston, MA 02139, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Timothy C</ForeName>
                    <Initials>TC</Initials>
                    <Affiliation>Division of Digestive and Liver Diseases, Columbia University College of Physicians and Surgeons, New York, NY 10032-3802, USA. duan.chen@ntnu.no tcw21@columbia.edu.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Duan</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7491, Norway. duan.chen@ntnu.no tcw21@columbia.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Sci Transl Med</MedlineTA>
            <NlmUniqueID>101505086</NlmUniqueID>
            <ISSNLinking>1946-6234</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">6/250/250ra115</ArticleId>
            <ArticleId IdType="doi">10.1126/scitranslmed.3009569</ArticleId>
            <ArticleId IdType="pubmed">25143365</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143358</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1529-7268</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biology of reproduction</Title>
                <ISOAbbreviation>Biol. Reprod.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Extra-Gonadal FSH Receptor: Is It Real?</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">biolreprod.114.124222</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">In this issue of Biology of Reproduction, Stilley and colleagues present their remarkable findings on FSHR expression in the human female reproductive tract and developing placenta and feto-placental defects in an Fshr mutant mouse model.Stilley JAW, Christensen DE, Dahlem KB, Guan R, Santillan DA, England SK, Al-Hendy A, Krirby PA, Segaloff DL. FSH Receptor (FSHR) Expression in Human Extra-gonadal Reproductive Tissues and the Developing Placenta, and the Impact of its Deletion on Pregnancy in Mice. Biol Reprod 2014; In Press. DOI: 10.1095/biolreprod.114.118562.</AbstractText>
                <CopyrightInformation>Copyright 2014 by The Society for the Study of Reproduction.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kumar</LastName>
                    <ForeName>T Rajendra</ForeName>
                    <Initials>TR</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biol Reprod</MedlineTA>
            <NlmUniqueID>0207224</NlmUniqueID>
            <ISSNLinking>0006-3363</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Endometrium</Keyword>
            <Keyword MajorTopicYN="N">Myometrium</Keyword>
            <Keyword MajorTopicYN="N">Ovary</Keyword>
            <Keyword MajorTopicYN="N">Pituitary/Pituitary hormones</Keyword>
            <Keyword MajorTopicYN="N">Placenta</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">biolreprod.114.124222</ArticleId>
            <ArticleId IdType="doi">10.1095/biolreprod.114.124222</ArticleId>
            <ArticleId IdType="pubmed">25143358</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143356</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1529-7268</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biology of reproduction</Title>
                <ISOAbbreviation>Biol. Reprod.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Retinoic Acid Biosynthesis Is Impaired in Human and Murine Endometriosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">biolreprod.114.119677</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Endometriosis is characterized by the presence of endometrial glands and stroma in extra-uterine sites. Our objective was to determine if endometriotic lesions (EL) from women with endometriosis have altered retinoid levels in comparison to their eutopic endometrium, and to test the hypothesis that defects in all-trans retinoic acid (ATRA) biosynthesis in EL is related to reduced expression of cellular retinol-binding protein type 1 (RBP1). Retinoids were evaluated by liquid chromatography-tandem mass spectrometry and high performance liquid chromatography in eutopic endometrial biopsies (EB) and EL from forty-two patients with pathologically confirmed endometriosis. ATRA levels were reduced, while retinol and retinyl ester concentrations were elevated in EL compared with EB tissue. Similar results were found in a mouse model of endometriosis that utilized GFP+ endometrial tissue injected into the peritoneum of syngeneic hosts to mimic retrograde menses. ATRA biosynthesis in vitro in retinol-treated primary human endometrial stromal cell (ESC) cultures derived from EL was reduced compared to ESC derived from patient-matched EB. Correspondingly, RBP1 expression was reduced in tissue and ESC derived from EL versus EB. Rbp1-/- mice showed reduced endometrial ATRA concentrations compared with wild-type, associated with loss of tissue organization and hypercellularity. These findings provide the first quantitative measurements of ATRA in human endometrium and endometriosis, demonstrating reduced ATRA in ectopic tissue and corresponding ESC cultures. Quantitation of retinoids in murine endometriosis and in Rbp1-/- mice supports the contention that impaired ATRA synthesis caused by reduced RBP1 promotes an &quot;endometriosis phenotype&quot; that enables cells to implant and grow at ectopic sites.</AbstractText>
                <CopyrightInformation>Copyright 2014 by The Society for the Study of Reproduction.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Pierzchalski</LastName>
                    <ForeName>Keely</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Taylor</LastName>
                    <ForeName>Robert N</ForeName>
                    <Initials>RN</Initials>
                </Author>
                <Author>
                    <LastName>Nezhat</LastName>
                    <ForeName>Ceana</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Jones</LastName>
                    <ForeName>Jace W</ForeName>
                    <Initials>JW</Initials>
                </Author>
                <Author>
                    <LastName>Napoli</LastName>
                    <ForeName>Joseph L</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Guixiang</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author>
                    <LastName>Kane</LastName>
                    <ForeName>Maureen A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author>
                    <LastName>Sidell</LastName>
                    <ForeName>Neil</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biol Reprod</MedlineTA>
            <NlmUniqueID>0207224</NlmUniqueID>
            <ISSNLinking>0006-3363</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Endometriosis</Keyword>
            <Keyword MajorTopicYN="N">Endometrium</Keyword>
            <Keyword MajorTopicYN="N">Female reproductive tract</Keyword>
            <Keyword MajorTopicYN="N">Retinoids</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">biolreprod.114.119677</ArticleId>
            <ArticleId IdType="doi">10.1095/biolreprod.114.119677</ArticleId>
            <ArticleId IdType="pubmed">25143356</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143355</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1529-7268</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biology of reproduction</Title>
                <ISOAbbreviation>Biol. Reprod.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Progressive Obesity Alters Ovarian Folliculogenesis with Impacts on Pro-Inflammatory and Steroidogenic Signaling in Female Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">biolreprod.114.121343</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Diet-induced obesity induces immune cell infiltration and inflammation in peri-ovarian adipose tissue and mRNA expression of inflammatory markers in ovarian tissue. Whether these changes are associated with obesity-related ovarian dysfunction remains unknown. In the present study, qRT-PCR and Western blot techniques were utilized to compare mRNA and protein abundance of ovarian immune cell and inflammation markers, along with NF-kappaB and steroidogenic pathway members in normal wild type non-agouti (a/a; lean) and lethal yellow mice (KK.CG-A(y)/J; obese) at 6, 12, 18 or 24 wk of age. Our data revealed that, beginning at 12 wk of age, NF-kappaB inflammatory signaling members were elevated (P &lt; 0.05) in obese females. Interestingly obesity had opposing and temporal effects on the steroidogenic enzyme pathway. Obesity decreased (P &lt; 0.05) STAR protein at 12, 18 and 24 wk of age. CYP11A1 and CYP19A1 proteins were increased (P &lt; 0.05) at 12 wk but decreased (P &lt; 0.05) at 18 and 24 wk. Interestingly, CYP19A1 was increased in lethal yellow mouse ovaries at 6 wk of age, potentially indicating early puberty onset. These data demonstrate that obesity alters expression of ovarian inflammatory and steroidogenic pathway genes in ways which could adversely affect ovarian function.</AbstractText>
                <CopyrightInformation>Copyright 2014 by The Society for the Study of Reproduction.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Nteeba</LastName>
                    <ForeName>Jackson</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Ganesan</LastName>
                    <ForeName>Shanthi</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Keating</LastName>
                    <ForeName>Aileen F</ForeName>
                    <Initials>AF</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biol Reprod</MedlineTA>
            <NlmUniqueID>0207224</NlmUniqueID>
            <ISSNLinking>0006-3363</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Estradiol/Estradiol receptor</Keyword>
            <Keyword MajorTopicYN="N">Follicular development</Keyword>
            <Keyword MajorTopicYN="N">Oocyte</Keyword>
            <Keyword MajorTopicYN="N">Ovary</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">biolreprod.114.121343</ArticleId>
            <ArticleId IdType="doi">10.1095/biolreprod.114.121343</ArticleId>
            <ArticleId IdType="pubmed">25143355</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143354</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1529-7268</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biology of reproduction</Title>
                <ISOAbbreviation>Biol. Reprod.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cellular Microenvironment Dictates Androgen Production by Murine Fetal Leydig Cells in Primary Culture.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">biolreprod.114.118570</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Despite recognition that fetal Leydig cells are the primary source of androgens in male embryos, the mechanisms by which steroidogenesis occurs within the developing testis remain unclear. A genetic approach was used to visualize and isolate fetal Leydig cells from remaining cells within developing mouse testes. Cyp11a1-Cre mice were bred to mT/mG dual reporter mice to target membrane-tagged enhanced green fluorescent protein (GFP) within steroidogenic cells while other cells expressed membrane-tagged tandem-dimer tomato red. Fetal Leydig cell identity was validated using double-labeled immunohistochemistry against GFP and steroidogenic enzyme 3betaHSD, and cells were successfully isolated as indicated by qPCR results from sorted cell populations. Because fetal Leydig cells must collaborate with neighboring cells to synthesize testosterone, we hypothesized that the fetal Leydig cell microenvironment defined their capacity for androgen production. Microfluidic culture devices were employed to measure androstenedione and testosterone production of fetal Leydig cells that were cultured in cell-cell contact within a mixed population, were isolated but remained in media contact via compartmentalized co-culture with other testicular cells, or were isolated and cultured alone. Results showed that fetal Leydig cells maintained their identity and steroidogenic activity for 3-5 days in primary culture. Microenvironment dictated proficiency of testosterone production. As expected, fetal Leydig cells produced androstenedione but not testosterone when cultured in isolation. More testosterone accumulated in media from mixed cultures than compartmentalized co-cultures initially; however, co-cultures maintained testosterone synthesis for a longer time. These data suggest that a combination of cell-cell contact and soluble factors constitute the ideal microenvironment for fetal Leydig cell activity in primary culture.</AbstractText>
                <CopyrightInformation>Copyright 2014 by The Society for the Study of Reproduction.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Carney</LastName>
                    <ForeName>Colleen M</ForeName>
                    <Initials>CM</Initials>
                </Author>
                <Author>
                    <LastName>Muszynski</LastName>
                    <ForeName>Jessica L</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author>
                    <LastName>Strotman</LastName>
                    <ForeName>Lindsay N</ForeName>
                    <Initials>LN</Initials>
                </Author>
                <Author>
                    <LastName>Lewis</LastName>
                    <ForeName>Samantha R</ForeName>
                    <Initials>SR</Initials>
                </Author>
                <Author>
                    <LastName>O'Connell</LastName>
                    <ForeName>Rachel L</ForeName>
                    <Initials>RL</Initials>
                </Author>
                <Author>
                    <LastName>Beebe</LastName>
                    <ForeName>David J</ForeName>
                    <Initials>DJ</Initials>
                </Author>
                <Author>
                    <LastName>Theberge</LastName>
                    <ForeName>Ashleigh B</ForeName>
                    <Initials>AB</Initials>
                </Author>
                <Author>
                    <LastName>Jorgensen</LastName>
                    <ForeName>Joan S</ForeName>
                    <Initials>JS</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biol Reprod</MedlineTA>
            <NlmUniqueID>0207224</NlmUniqueID>
            <ISSNLinking>0006-3363</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Androgens/Androgen receptor</Keyword>
            <Keyword MajorTopicYN="N">Fetal development</Keyword>
            <Keyword MajorTopicYN="N">Leydig cells</Keyword>
            <Keyword MajorTopicYN="N">Testis</Keyword>
            <Keyword MajorTopicYN="N">microfluidic device</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">biolreprod.114.118570</ArticleId>
            <ArticleId IdType="doi">10.1095/biolreprod.114.118570</ArticleId>
            <ArticleId IdType="pubmed">25143354</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143347</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1563</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Cell physiology</Title>
                <ISOAbbreviation>Am. J. Physiol., Cell Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A highly potent agonist to protease-activated receptor-2 (PAR2) reveals apical activation of the airway epithelium resulting in Ca2+-regulated ion conductance.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajpcell.00257.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The airway epithelium provides a barrier that separates inhaled air and its various particulates from the underlying tissues. It provides key physiological functions in both sensing the environment and initiating appropriate innate immune defenses to protect the lung. The protease-activated receptor-2 (PAR2) is expressed both apically and basolaterally throughout the airway epithelium. One consequence of basolateral PAR2 activation is the rapid, Ca(2+)-dependent ion flux that favors secretion in normally absorptive airway epithelium. However, roles for apically expressed PAR2 activation have not been demonstrated in part due to the lack of specific, high potency PAR2 ligands. In this study we used the newly developed PAR2 ligand 2at-LIGRLO(PEG3-Pam)-NH2, in combination with well-differentiated, primary cultured airway epithelial cells from wild type and PAR2 (-/-) mice to examine the physiological role of PAR2 in the conducting airway following apical activation. Using digital imaging microscopy of intracellular Ca(2+) concentration ([Ca(2+)]i) changes, we verified ligand potency on PAR2 in primary cultured airway cells. Examination of airway epithelial tissue in an Ussing chamber showed that apical activation of PAR2 by 2at-LIGRLO(PEG3-Pam)-NH2 resulted in a transient decrease in transepithelial resistance that was due to increased apical ion efflux. We determined pharmacologically that this increase in ion conductance was through Ca(2+)-activated Cl(-) (CaCC) and large conductance K(+) channels that were blocked with CaCC-inhibitor and clotrimazole, respectively. Stimulation of Cl(-) efflux via PAR2 activation at the airway epithelial surface would increase airway surface liquid that would aid in clearing the airway of noxious inhaled agents.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology - Cell Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sherwood</LastName>
                    <ForeName>Cara L</ForeName>
                    <Initials>CL</Initials>
                    <Affiliation>University of Arizona.</Affiliation>
                </Author>
                <Author>
                    <LastName>Daines</LastName>
                    <ForeName>Michael O</ForeName>
                    <Initials>MO</Initials>
                    <Affiliation>Arizona Respiratory Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Price</LastName>
                    <ForeName>Theodore J</ForeName>
                    <Initials>TJ</Initials>
                    <Affiliation>University of Texas at Dallas.</Affiliation>
                </Author>
                <Author>
                    <LastName>Vagner</LastName>
                    <ForeName>Josef</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>University of Arizona.</Affiliation>
                </Author>
                <Author>
                    <LastName>Boitano</LastName>
                    <ForeName>Scott</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Arizona Health Sciences Center sboitano@email.arizona.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Cell Physiol</MedlineTA>
            <NlmUniqueID>100901225</NlmUniqueID>
            <ISSNLinking>0363-6143</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">allergic asthma</Keyword>
            <Keyword MajorTopicYN="N">asthmagen</Keyword>
            <Keyword MajorTopicYN="N">ion conductance</Keyword>
            <Keyword MajorTopicYN="N">lipidated agonist</Keyword>
            <Keyword MajorTopicYN="N">protease-activated receptor-2</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajpcell.00257.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/ajpcell.00257.2014</ArticleId>
            <ArticleId IdType="pubmed">25143347</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143346</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1563</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Cell physiology</Title>
                <ISOAbbreviation>Am. J. Physiol., Cell Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Probiotic Bifidobacterium species Stimulate Human SLC26A3 Gene Function and Expression in Intestinal Epithelial Cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajpcell.00194.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">SLC26A3 or DRA (Down Regulated in Adenoma) plays a major role in mediating Cl- absorption in the mammalian intestine. Disturbances in DRA function and expression have been implicated in intestinal disorders such as congenital chloride diarrhea and gut inflammation. Our previous studies showed that increase in DRA function and expression by Lactobacillus acidophilus and its culture supernatant (CS) might underlie anti-diarrheal effects of this probiotic strain. However the effects of Bifidobacterium species, important inhabitants of human colon, on intestinal Cl-/HCO3- exchange activity are not known. Our current results demonstrated that CS derived from B. breve, B. infantis or B. bifidum increased the anion exchange activity (~ 1.8-2.4 fold) in Caco-2 cells. Consistent with the function, CS also increased the protein as well as mRNA levels of DRA (but not PAT-1). CS of all three species of Bifidobacteria increased DRA promoter activity (-1183/+114bp) in Caco-2 cells (1.5-1.8 fold). Further, the increase in DRA mRNA expression by CS of B. breve and B.infantis was blocked in the presence of transcription inhibitor, Actinomycin D (5??M) and ERK1/2 MAPK pathway inhibitor (U0126, 10??M). Administration of live B. breve, B. infantis and B. bifidum by oral gavage to mice for 24 h increased the DRA mRNA and protein levels in the colon. These data demonstrate an upregulation of DRA via activation of ERK1/2 pathway that may underlie potential anti-diarrheal effects of Bifidobacterium species.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology - Cell Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kumar</LastName>
                    <ForeName>Anoop</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>University of Illinois at Chicago.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hecht</LastName>
                    <ForeName>Cameron</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>University of Illinois at Chicago.</Affiliation>
                </Author>
                <Author>
                    <LastName>Priyamvada</LastName>
                    <ForeName>Shubha</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>University of Illinois at Chicago.</Affiliation>
                </Author>
                <Author>
                    <LastName>Anbazhagan</LastName>
                    <ForeName>Arivarasu N</ForeName>
                    <Initials>AN</Initials>
                    <Affiliation>University of Illinois at Chicago.</Affiliation>
                </Author>
                <Author>
                    <LastName>Alakkam</LastName>
                    <ForeName>Anas</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>University of Illinois at Chicago.</Affiliation>
                </Author>
                <Author>
                    <LastName>Borthakur</LastName>
                    <ForeName>Alip</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>University of Illinois at Chicago.</Affiliation>
                </Author>
                <Author>
                    <LastName>Alrefai</LastName>
                    <ForeName>Waddah A</ForeName>
                    <Initials>WA</Initials>
                    <Affiliation>University of Illinois at Chicago.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gill</LastName>
                    <ForeName>Ravinder K</ForeName>
                    <Initials>RK</Initials>
                    <Affiliation>University of Illinois at Chicago.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dudeja</LastName>
                    <ForeName>Pradeep K</ForeName>
                    <Initials>PK</Initials>
                    <Affiliation>Jesse Brown VA Medical Center/University of Illinois at Chicago pkdudeja@uic.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Cell Physiol</MedlineTA>
            <NlmUniqueID>100901225</NlmUniqueID>
            <ISSNLinking>0363-6143</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Anti-diarrheal</Keyword>
            <Keyword MajorTopicYN="N">Caco-2</Keyword>
            <Keyword MajorTopicYN="N">Cl absorption</Keyword>
            <Keyword MajorTopicYN="N">DRA</Keyword>
            <Keyword MajorTopicYN="N">upregulation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajpcell.00194.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/ajpcell.00194.2014</ArticleId>
            <ArticleId IdType="pubmed">25143346</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143340</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1556-679X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical and vaccine immunology : CVI</Title>
                <ISOAbbreviation>Clin. Vaccine Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Intranasal administration of BCG induces superior protection against an aerosol infection with Mycobacterium tuberculosis in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">CVI.00394-14</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Despite widespread usage of Mycobacterium bovis BCG, the only licensed vaccine against M. tuberculosis (TB), TB remains a global epidemic. To assess whether more direct targeting of the lung mucosa by respiratory immunization would enhance potency and longevity of BCG-induced anti-tuberculosis protective immunity, the long-term impact of intranasal (i.n.) BCG vaccination was compared to conventional subcutaneous (s.c.) immunization using a mouse model of pulmonary tuberculosis. Although significantly improved protection in the lung was seen at early time points (2 and 4 months post-vaccination) for i.n. BCG immunized mice, no differences in pulmonary protection were seen 8 and 10 months post-vaccination. In contrast, at all study periods, i.n. BCG vaccination induced significantly elevated protective splenic responses relative to s.c. immunization. At 5 of 9 time points, we observed a splenic protective response exceeding 1.9 log10 protection relative to the s.c. route. Furthermore, higher frequencies of CD4 T cells expressing IFN-?? and IFN-??/TNF-?? as well as CD8 T cells expressing IFN-?? were detected in the spleens of i.n. vaccinated mice. Using PCR arrays, significantly elevated levels of expression of IFN-??, IL-9, IL-11 and IL-21 were also seen in the spleens at 8 months after the respiratory BCG immunization. Overall, while i.n. BCG vaccination provided short-term enhancement of protection in the lung relative to s.c immunization, potent and extremely persistent splenic protective responses were seen for at least 10 months following respiratory immunization.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Derrick</LastName>
                    <ForeName>Steven C</ForeName>
                    <Initials>SC</Initials>
                    <Affiliation>Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, USA steven.derrick@fda.hhs.gov.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kolibab</LastName>
                    <ForeName>Kristopher</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Morris</LastName>
                    <ForeName>Sheldon L</ForeName>
                    <Initials>SL</Initials>
                    <Affiliation>Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Clin Vaccine Immunol</MedlineTA>
            <NlmUniqueID>101252125</NlmUniqueID>
            <ISSNLinking>1556-679X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">CVI.00394-14</ArticleId>
            <ArticleId IdType="doi">10.1128/CVI.00394-14</ArticleId>
            <ArticleId IdType="pubmed">25143340</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143333</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1752-8976</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of the renin-angiotensin-aldosterone system : JRAAS</Title>
                <ISOAbbreviation>J Renin Angiotensin Aldosterone Syst</ISOAbbreviation>
            </Journal>
            <ArticleTitle>ACE-inhibition increases podocyte number in experimental glomerular disease independent of proliferation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">1470320314543910</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this article is to test the effects of angiotensin-converting enzyme (ACE)-inhibition on glomerular epithelial cell number in an inducible experimental model of focal segmental glomerulosclerosis (FSGS).</AbstractText>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although ACE-inhibition has been shown to limit podocyte loss by enhancing survival, little is known about its effect on podocyte number following an abrupt decline in disease.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Experimental FSGS was induced with cytotoxic antipodocyte antibody. Following induction, groups were randomized to receive the ACE-inhibitor enalapril, the smooth muscle relaxant hydralazine (blood pressure control) or drinking water. Blood pressure, kidney function and histology were measured seven and 14 days following disease induction.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Both glomerulosclerosis and urinary albumin-to-creatinine ratio were less in the ACE-inhibition arm at day 14. At day 7 of disease, mean podocyte numbers were 26% and 29% lower in the enalapril and hydralazine arms, respectively, compared to normal mice in which no antibody was injected. At day 14, the mean podocyte number was only 18% lower in the enalapril arm, but was 39% lower in the hydralazine arm compared to normal mice. Podocyte proliferation did not occur at any time in any group. Compared to water- or hydralazine-treated mice with FSGS, the enalapril arm had a higher mean number of glomerular parietal epithelial cells that co-expressed the podocyte proteins WT-1 and synaptopodin, as well as phospho-ERK.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results show following an abrupt decline in podocyte number, the initiation of ACE-inhibition but not hydralazine, was accompanied by higher podocyte number in the absence of proliferation. This was accompanied by a higher number of parietal epithelial cells that co-express podocyte proteins. Increasing podocyte number appears to be accompanied by reduced glomerulosclerosis.</AbstractText>
                <CopyrightInformation>?? The Author(s) 2014.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Jiong</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Division of Nephrology, Department of Medicine, University of Washington School of Medicine, Washington Current address: Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yanez</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Biostatistics, School of Public Health, University of Washington, Washington.</Affiliation>
                </Author>
                <Author>
                    <LastName>Floege</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Division of Nephrology, Department of Medicine, University of Washington School of Medicine, Washington.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lichtnekert</LastName>
                    <ForeName>Julia</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Division of Nephrology, Department of Medicine, University of Washington School of Medicine, Washington.</Affiliation>
                </Author>
                <Author>
                    <LastName>Krofft</LastName>
                    <ForeName>Ronald D</ForeName>
                    <Initials>RD</Initials>
                    <Affiliation>Division of Nephrology, Department of Medicine, University of Washington School of Medicine, Washington.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Zhi-Hong</ForeName>
                    <Initials>ZH</Initials>
                    <Affiliation>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pippin</LastName>
                    <ForeName>Jeffrey W</ForeName>
                    <Initials>JW</Initials>
                    <Affiliation>Division of Nephrology, Department of Medicine, University of Washington School of Medicine, Washington.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shankland</LastName>
                    <ForeName>Stuart J</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>Division of Nephrology, Department of Medicine, University of Washington School of Medicine, Washington stuartjs@u.washington.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Renin Angiotensin Aldosterone Syst</MedlineTA>
            <NlmUniqueID>100971636</NlmUniqueID>
            <ISSNLinking>1470-3203</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Focal segmental glomerulosclerosis</Keyword>
            <Keyword MajorTopicYN="N">enalapril</Keyword>
            <Keyword MajorTopicYN="N">glomerulosclerosis</Keyword>
            <Keyword MajorTopicYN="N">parietal epithelial cell</Keyword>
            <Keyword MajorTopicYN="N">podocyte</Keyword>
            <Keyword MajorTopicYN="N">regeneration</Keyword>
            <Keyword MajorTopicYN="N">repair</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1470320314543910</ArticleId>
            <ArticleId IdType="doi">10.1177/1470320314543910</ArticleId>
            <ArticleId IdType="pubmed">25143333</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143325</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1752-8976</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of the renin-angiotensin-aldosterone system : JRAAS</Title>
                <ISOAbbreviation>J Renin Angiotensin Aldosterone Syst</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The effects of siRNA-silenced TRPC6 on podocyte autophagy and apoptosis induced by AngII.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">1470320314543724</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">the objective of this article is to evaluate the role of siRNA-silenced TRPC6 on podocyte autophagy and apoptosis induced by AngII.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">mouse podocyte cell lines were cultured in vitro. The apoptosis rates of each group were detected using flow cytometry. The expression of LC3-II protein and changes in distribution were detected by confocal laser, and the western blot protocol was employed for detection of protein expression of LC3-II.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">AngII-injured podocyte had a significant increase in apoptosis, while silencing TRPC6 could decrease the apoptosis induced by AngII. Autophagy remarkably increased after AngII injury. While silencing TRPC6 stabilized the autophagy expression, AngII could activate the autophagy of podocyte. Autophagy-associated protein LC3-II expression increased after AngII injury. The LC3-II mRNA and the protein level could be down regulated by 3-MA. The silencing of TRPC6 could stabilize the autophagy expression.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">the data suggest that AngII can lead to podocyte injury. Autophagy may have beneficial effects in preventing the progression of proteinuria. This study provides some new clues for further exploring the occurrence of podocyte injury and the development mechanism of proteinuria.</AbstractText>
                <CopyrightInformation>?? The Author(s) 2014.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Shengyou</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Pediatrics, Guangzhou First People's Hospital, affiliate to Guangzhou Medical University, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Pediatrics, Guangzhou First People's Hospital, affiliate to Guangzhou Medical University, China yuli828@yeah.net.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Renin Angiotensin Aldosterone Syst</MedlineTA>
            <NlmUniqueID>100971636</NlmUniqueID>
            <ISSNLinking>1470-3203</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">AngII</Keyword>
            <Keyword MajorTopicYN="N">Podocyte</Keyword>
            <Keyword MajorTopicYN="N">TRPC6</Keyword>
            <Keyword MajorTopicYN="N">apoptosis</Keyword>
            <Keyword MajorTopicYN="N">autophagy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1470320314543724</ArticleId>
            <ArticleId IdType="doi">10.1177/1470320314543724</ArticleId>
            <ArticleId IdType="pubmed">25143325</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143233</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-0851</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer immunology, immunotherapy : CII</Title>
                <ISOAbbreviation>Cancer Immunol. Immunother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Tumor progression occurs through the modulation of a number of physiological parameters, including the development of immunosuppressive mechanisms to prevent immune detection and response. Among these immune evasion mechanisms, the mobilization of myeloid-derived suppressor cells (MDSC) is a major contributor to the suppression of antitumor T-cell immunity. Patients with renal cell carcinoma (RCC) show increased MDSC, and methods are being explored clinically to reduce the prevalence of MDSC and/or inhibit their function. In the present study, we investigated the relationship between MDSC and the therapeutic potential of a TRAIL-encoding recombinant adenovirus (Ad5-TRAIL) in combination with CpG-containing oligodeoxynucleotides (Ad5-TRAIL/CpG) in an orthotopic mouse model of RCC. This immunotherapy effectively clears renal (Renca) tumors and enhances survival, despite the presence of a high frequency of MDSC in the spleens and primary tumor-bearing kidneys at the time of treatment. Subsequent analyses revealed that the CpG component of the immunotherapy was responsible for decreasing the frequency of MDSC in Renca-bearing mice; further, treatment with CpG modulated the phenotype and function of MDSC that remained after immunotherapy and correlated with an increased T-cell response. Interestingly, the CpG-dependent alterations in MDSC frequency and function did not occur in tumor-bearing mice complicated with diet-induced obesity. Collectively, these data suggest that in addition to its adjuvant properties, CpG also enhances antitumor responses by altering the number and function of MDSC.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>James</LastName>
                    <ForeName>Britnie R</ForeName>
                    <Initials>BR</Initials>
                    <Affiliation>Department of Urology, University of Minnesota, 3-125 CCRB, 2231 6th St. SE, Minneapolis, MN, 55455, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Anderson</LastName>
                    <ForeName>Kristin G</ForeName>
                    <Initials>KG</Initials>
                </Author>
                <Author>
                    <LastName>Brincks</LastName>
                    <ForeName>Erik L</ForeName>
                    <Initials>EL</Initials>
                </Author>
                <Author>
                    <LastName>Kucaba</LastName>
                    <ForeName>Tamara A</ForeName>
                    <Initials>TA</Initials>
                </Author>
                <Author>
                    <LastName>Norian</LastName>
                    <ForeName>Lyse A</ForeName>
                    <Initials>LA</Initials>
                </Author>
                <Author>
                    <LastName>Masopust</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author>
                    <LastName>Griffith</LastName>
                    <ForeName>Thomas S</ForeName>
                    <Initials>TS</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cancer Immunol Immunother</MedlineTA>
            <NlmUniqueID>8605732</NlmUniqueID>
            <ISSNLinking>0340-7004</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-014-1598-8</ArticleId>
            <ArticleId IdType="pubmed">25143233</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143196</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-904X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmaceutical research</Title>
                <ISOAbbreviation>Pharm. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Protective Effects of Calycosin Against CCl4-Induced Liver Injury with Activation of FXR and STAT3 in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Investigating the hepatoprotective effect of calycosin against acute liver injury in association with FXR activation and STAT3 phosphorylation.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The acute liver injury model was established by intraperitoneal injection of CCl4 in C57BL/6 mice. Serum alanine aminotransferase, aspartate aminotransferase, HE staining and TUNEL assay were used to identify the amelioration of the liver histopathological changes and hepatocytes apoptosis after calycosin treatment. ELISA kit and 5-bromo-2-deoxyuridine immunohistochemistry were used to measure the liver bile acid concentration and hepatocyte mitotic rate in vivo. The relation between calycosin and activation of FXR and STAT3 was comfirmed using the Luciferase assay, Molecular docking, Real-time PCR and Western Blot in vitro.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The liver histopathological changes, hepatocytes apoptosis, liver bile acid overload and hepatocyte mitosis showed significant changes after calycosin treatment. Calycosin promoted the expression of FXR target genes such as FoxM1B and SHP but the effect was reversed by FXR suppressor guggulsterone. Molecular docking results indicated that calycosin could be embedded into the binding pocket of FXR, thereby increasing the expressions of STAT3 tyrosine phosphorylation and its target genes, Bcl-xl and SOCS3.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Calycosin plays a critical role in hepatoprotection against liver injury in association with FXR activation and STAT3 phosphorylation.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Xinli</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, 9 West Section, Lvshun South Road, Lvshunkou District, Dalian, Liaoning, 116044, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Meng</LastName>
                    <ForeName>Qiang</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Changyuan</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Qi</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>Huijun</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Huo</LastName>
                    <ForeName>Xiaokui</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>Pengyuan</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Xiaobo</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Peng</LastName>
                    <ForeName>Jinyong</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Kexin</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Pharm Res</MedlineTA>
            <NlmUniqueID>8406521</NlmUniqueID>
            <ISSNLinking>0724-8741</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11095-014-1483-3</ArticleId>
            <ArticleId IdType="pubmed">25143196</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143173</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0376-2491</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>94</Volume>
                    <Issue>19</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Zhonghua yi xue za zhi</Title>
                <ISOAbbreviation>Zhonghua Yi Xue Za Zhi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Selective Laser Sintering-Produced porous titanium alloy scaffold for bone tissue engineering].</ArticleTitle>
            <Pagination>
                <MedlinePgn>1499-502</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the biocompatibility of SLS-produced titanium alloy scaffold in vitro and investigate the therapeutic effects in repairing segmental bone defects.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Porous titanium alloy scaffolds were produced by SLS and their surfaces were either left untreated or acid etched. In vitro, mouse pre-osteoblasts (MC3T3-E1 cells) were cultured on these 2 group scaffolds, and then cell proliferation and differentiation were examined after cell seeding. In vivo, bone defects were artificially made in 15 New Zealand rabbits and the porous titanium specimens were implanted into the radius of rabbits for 3 months. The regulating checks of X-ray were determined. The osteointegration of the implants was investigated by Micro-CT and histological examination at 12 weeks after surgery.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A gradual increase in cell-specific ALP synthesis by cells cultured in both groups was observed with longer culture time (14 d). ALP activity did not differ significantly between two groups (0.834 ?? 0.092 vs 0.815 ?? 0.081, P &gt; 0.05) . Both Micro-CT and the histological analysis indicated that the titanium alloy scaffolds had excellent ability to facilitate the osteointegration in vivo. The results were significantly different between the empty control and the 2 different surface modifications of SLS-implants (25.4% ?? 4.2% vs 23.6% ?? 8.4% vs 12.3% ?? 4.7%, P &lt; 0.05). Between the groups with implants, the number of bone points was not significantly different, irrespective of the surface treatment (25.4% ?? 4.2% vs 23.6% ?? 8.4%, P &gt; 0.05).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Selective Laser Sintering-Produced porous titanium alloy scaffold possessed admirable biocompatibility in vitro. It also could be contributed to the healing of long tulular bone defect. The porous Ti6Al4V implant not only reduced the stress-shielding but also exerted appropriate osteoconductive properties.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ding</LastName>
                    <ForeName>Ran</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Orthorpaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Zhihong</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Orthorpaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Guixing</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Orthorpaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China. Email: qguixing@126.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Gui</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Orthorpaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Hai</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Orthorpaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Su</LastName>
                    <ForeName>Xinlin</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Orthorpaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yin</LastName>
                    <ForeName>Bo</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Orthorpaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Shuo</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Orthorpaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qi</LastName>
                    <ForeName>Bing</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Orthorpaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Zhonghua Yi Xue Za Zhi</MedlineTA>
            <NlmUniqueID>7511141</NlmUniqueID>
            <ISSNLinking>0376-2491</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25143173</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143155</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1742-4658</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The FEBS journal</Title>
                <ISOAbbreviation>FEBS J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Non-neuronal acetylcholine as an endogenous regulator of proliferation and differentiation of Lgr5-positive stem cells in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1111/febs.12974</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Non-neuronal acetylcholine (non-neuronal ACh) is predicted to function as a local cell signaling molecule. However, the physiological significance of the synthesis of non-neuronal ACh in the intestine remains unclear. Here, experiments using crypt-villus organoids that lack nerve and immune cells in culture led us to suggest that endogenous ACh is synthesized in the intestinal epithelium to evoke growth and differentiation of the organoids through activation of muscarinic ACh receptors (mAChRs). The extracts of the cultured organoids exhibit a noticeable capacity for ACh synthesis that is sensitive to a potent inhibitor of choline acetyltransferase (ChAT). Imaging mass spectrometry (IMS) reveals distribution of endogenous ACh that is localized in the epithelial layer in mouse small intestinal epithelium in vivo, suggesting that there are non-neuronal resources of ACh. Treatment of organoids with carbachol down-regulates growth of organoids and expression of marker genes for epithelial cells. On the other hand, antagonists for mAChRs enhances growth and differentiation of organoids, indicating involvement of mAChRs in regulating proliferation and differentiation of Lgr5-positive stem cells. Collectively, our data provide evidence that endogenous ACh released from intestinal epithelium maintains homeostasis of intestinal epithelial cell growth and differentiation via mAChRs in mice. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Takahashi</LastName>
                    <ForeName>Toshio</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Suntory Foundation for Life Sciences, Bioorganic Research Institute, Osaka, 618-8503, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ohnishi</LastName>
                    <ForeName>Hiroe</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Sugiura</LastName>
                    <ForeName>Yuki</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Honda</LastName>
                    <ForeName>Kurara</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Suematsu</LastName>
                    <ForeName>Makoto</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Kawasaki</LastName>
                    <ForeName>Takashi</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Deguchi</LastName>
                    <ForeName>Tomonori</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Fujii</LastName>
                    <ForeName>Takeshi</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Orihashi</LastName>
                    <ForeName>Kaoru</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Hippo</LastName>
                    <ForeName>Yoshitaka</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Watanabe</LastName>
                    <ForeName>Takehiro</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Yamagaki</LastName>
                    <ForeName>Tohru</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Yuba</LastName>
                    <ForeName>Shunsuke</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>FEBS J</MedlineTA>
            <NlmUniqueID>101229646</NlmUniqueID>
            <ISSNLinking>1742-464X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cholinergic system</Keyword>
            <Keyword MajorTopicYN="N">Gut</Keyword>
            <Keyword MajorTopicYN="N">Lgr5</Keyword>
            <Keyword MajorTopicYN="N">Organoid</Keyword>
            <Keyword MajorTopicYN="N">non-neuronal acetylcholine</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1111/febs.12974</ArticleId>
            <ArticleId IdType="pubmed">25143155</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143127</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1440-1827</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>64</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pathology international</Title>
                <ISOAbbreviation>Pathol. Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Therapeutic effects of exon skipping and losartan on skeletal muscle of mdx mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>388-96</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/pin.12190</ELocationID>
            <Abstract>
                <AbstractText>Various attempts have been made to find treatments for Duchenne muscular dystrophy (DMD) patients. Exon skipping is one of the promising technologies for DMD treatment by restoring dystropin protein, which is one of the muscle components. It is well known that losartan, an angiotensin II type1 receptor blocker, promotes muscle regeneration and differentiation by lowering the level of transforming growth factor-beta1 signaling. In this study, we illustrated the combined effects of exon skipping and losartan on skeletal muscle of mdx mice. We supplied mdx mice with losartan for 2 weeks before exon skipping treatment. The losartan with the exon skipping group showed less expression of myf5 than the losartan treated group. Also the losartan with exon skipping group recovered normal muscle architecture, in contrast to the losartan group which still showed many central nuclei. However, the exon skipping efficiency and the restoration of dystrophin protein were lower in the losartan with exon skipping group compared to the exon skipping group. We reveal that losartan promotes muscle regeneration and shortens the time taken to restore normal muscle structure when combined with exon skipping. However, combined treatment of exon skipping and losartan decreases the restoration of dystrophin protein meaning decrease of exon skipping efficiency.</AbstractText>
                <CopyrightInformation>?? 2014 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Eun-Joo</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>College of Veterinary Medicine, School of Medicine, Kyungpook National University, Daegu, Korea; Stem Cell Therapeutic Research Institute, School of Medicine, Kyungpook National University, Daegu, Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Ah-Young</ForeName>
                    <Initials>AY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Eun-Mi</ForeName>
                    <Initials>EM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Myeong-Mi</ForeName>
                    <Initials>MM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Min</LastName>
                    <ForeName>Chang-Woo</ForeName>
                    <Initials>CW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kang</LastName>
                    <ForeName>Kyung-Ku</ForeName>
                    <Initials>KK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Jin-Kyu</ForeName>
                    <Initials>JK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hwang</LastName>
                    <ForeName>Meeyul</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kwon</LastName>
                    <ForeName>Soon-Hak</ForeName>
                    <Initials>SH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tremblay</LastName>
                    <ForeName>Jacques P</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeong</LastName>
                    <ForeName>Kyu-Shik</ForeName>
                    <Initials>KS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Australia</Country>
            <MedlineTA>Pathol Int</MedlineTA>
            <NlmUniqueID>9431380</NlmUniqueID>
            <ISSNLinking>1320-5463</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">combined effect</Keyword>
            <Keyword MajorTopicYN="N">exon skipping</Keyword>
            <Keyword MajorTopicYN="N">losartan</Keyword>
            <Keyword MajorTopicYN="N">mdx mice</Keyword>
            <Keyword MajorTopicYN="N">muscle regeneration</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1111/pin.12190</ArticleId>
            <ArticleId IdType="pubmed">25143127</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143122</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1559-0305</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular biotechnology</Title>
                <ISOAbbreviation>Mol. Biotechnol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Production of a Plant-Derived Immunogenic Protein Targeting ApoB100 and CETP: Toward a Plant-Based Atherosclerosis Vaccine.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">In an effort to initiate the development of a plant-based vaccination model against atherosclerosis, a cholera toxin B subunit (CTB)-based chimeric protein was designed to target both ApoB100 and CETP epitopes associated with immunotherapeutic effects in atherosclerosis. Epitopes were fused at the C-terminus of CTB to yield a protein called CTB:p210:CETPe. A synthetic gene coding for CTB:p210:CETPe was successfully transferred to tobacco plants with no phenotypic alterations. Plant-derived CTB:p210:CETPe was expressed and assembled in the pentameric form. This protein retained the target antigenic determinants, as revealed by GM1-ELISA and Western blot analyses. Higher expresser lines reached recombinant protein accumulation levels up to 10????g/g fresh weight in leaf tissues and these lines carry a single insertion of the transgene as determined by qPCR. Moreover, when subcutaneously administered, the biomass from these CTB:p210:CETPe-producing plants was able to elicit humoral responses in mice against both ApoB100 and CETP epitopes and human serum proteins. These findings evidenced for the first time that atherosclerosis-related epitopes can be expressed in plants retaining immunogenicity, which opens a new path in the molecular farming field for the development of vaccines against atherosclerosis.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Salazar-Gonzalez</LastName>
                    <ForeName>Jorge Alberto</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>Laboratorio de Biofarmac??uticos Recombinantes, Facultad de Ciencias Qu??micas, Universidad Aut??noma de San Luis Potos??, Av. Dr. Manuel Nava 6, 78210, San Luis Potos??, SLP, Mexico.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rosales-Mendoza</LastName>
                    <ForeName>Sergio</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Romero-Maldonado</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Monreal-Escalante</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author>
                    <LastName>Uresti-Rivera</LastName>
                    <ForeName>Edith Elena</ForeName>
                    <Initials>EE</Initials>
                </Author>
                <Author>
                    <LastName>Ba??uelos-Hern??ndez</LastName>
                    <ForeName>Bernardo</ForeName>
                    <Initials>B</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Biotechnol</MedlineTA>
            <NlmUniqueID>9423533</NlmUniqueID>
            <ISSNLinking>1073-6085</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12033-014-9793-6</ArticleId>
            <ArticleId IdType="pubmed">25143122</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143031</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1471-2954</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>281</Volume>
                    <Issue>1792</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                        <Day>7</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Proceedings. Biological sciences / The Royal Society</Title>
                <ISOAbbreviation>Proc. Biol. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nasal aerodynamics protects brain and lung from inhaled dust in subterranean diggers, Ellobius talpinus.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1098/rspb.2014.0919</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">20140919</ELocationID>
            <Abstract>
                <AbstractText>Inhalation of air-dispersed sub-micrometre and nano-sized particles presents a risk factor for animal and human health. Here, we show that nasal aerodynamics plays a pivotal role in the protection of the subterranean mole vole Ellobius talpinus from an increased exposure to nano-aerosols. Quantitative simulation of particle flow has shown that their deposition on the total surface of the nasal cavity is higher in the mole vole than in a terrestrial rodent Mus musculus (mouse), but lower on the olfactory epithelium. In agreement with simulation results, we found a reduced accumulation of manganese in olfactory bulbs of mole voles in comparison with mice after the inhalation of nano-sized MnCl2 aerosols. We ruled out the possibility that this reduction is owing to a lower transportation from epithelium to brain in the mole vole as intranasal instillations of MnCl2 solution and hydrated nanoparticles of manganese oxide MnO ?? (H2O)x revealed similar uptake rates for both species. Together, we conclude that nasal geometry contributes to the protection of brain and lung from accumulation of air-dispersed particles in mole voles.</AbstractText>
                <CopyrightInformation>?? 2014 The Author(s) Published by the Royal Society. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Moshkin</LastName>
                    <ForeName>M P</ForeName>
                    <Initials>MP</Initials>
                    <Affiliation>Institute of Cytology and Genetics, Siberian Branch of RAS, Novosibirsk 630090, Russia Department of Physiology, Novosibirsk State University, Novosibirsk 630090, Russia Department of Zoology and Animal Ecology, Tomsk State University, Tomsk 634050, Russia mmp@bionet.nsc.ru.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Petrovski</LastName>
                    <ForeName>D V</ForeName>
                    <Initials>DV</Initials>
                    <Affiliation>Institute of Cytology and Genetics, Siberian Branch of RAS, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akulov</LastName>
                    <ForeName>A E</ForeName>
                    <Initials>AE</Initials>
                    <Affiliation>Institute of Cytology and Genetics, Siberian Branch of RAS, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Romashchenko</LastName>
                    <ForeName>A V</ForeName>
                    <Initials>AV</Initials>
                    <Affiliation>Institute of Cytology and Genetics, Siberian Branch of RAS, Novosibirsk 630090, Russia Design Technological Institute of Digital Techniques, Siberian Branch of RAS, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gerlinskaya</LastName>
                    <ForeName>L A</ForeName>
                    <Initials>LA</Initials>
                    <Affiliation>Institute of Cytology and Genetics, Siberian Branch of RAS, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ganimedov</LastName>
                    <ForeName>V L</ForeName>
                    <Initials>VL</Initials>
                    <Affiliation>Khristianovich Institute of Theoretical and Applied Mechanics, Siberian Branch of RAS, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muchnaya</LastName>
                    <ForeName>M I</ForeName>
                    <Initials>MI</Initials>
                    <Affiliation>Khristianovich Institute of Theoretical and Applied Mechanics, Siberian Branch of RAS, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sadovsky</LastName>
                    <ForeName>A S</ForeName>
                    <Initials>AS</Initials>
                    <Affiliation>Khristianovich Institute of Theoretical and Applied Mechanics, Siberian Branch of RAS, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koptyug</LastName>
                    <ForeName>I V</ForeName>
                    <Initials>IV</Initials>
                    <Affiliation>International Tomographic Center, Siberian Branch of RAS, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Savelov</LastName>
                    <ForeName>A A</ForeName>
                    <Initials>AA</Initials>
                    <Affiliation>International Tomographic Center, Siberian Branch of RAS, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Troitsky</LastName>
                    <ForeName>S Yu</ForeName>
                    <Initials>SY</Initials>
                    <Affiliation>Boreskov Institute of Catalysis, Siberian Branch of RAS, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moshkn</LastName>
                    <ForeName>Y M</ForeName>
                    <Initials>YM</Initials>
                    <Affiliation>Department of Biochemistry, Erasmus Medical Center, Dr. Molewaterplein 50, Rotterdam 3015GE, The Netherlands.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bukhtiyarov</LastName>
                    <ForeName>V I</ForeName>
                    <Initials>VI</Initials>
                    <Affiliation>Boreskov Institute of Catalysis, Siberian Branch of RAS, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kolchanov</LastName>
                    <ForeName>N A</ForeName>
                    <Initials>NA</Initials>
                    <Affiliation>Institute of Cytology and Genetics, Siberian Branch of RAS, Novosibirsk 630090, Russia Department of Physiology, Novosibirsk State University, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sagdeev</LastName>
                    <ForeName>R Z</ForeName>
                    <Initials>RZ</Initials>
                    <Affiliation>International Tomographic Center, Siberian Branch of RAS, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fomin</LastName>
                    <ForeName>V M</ForeName>
                    <Initials>VM</Initials>
                    <Affiliation>Khristianovich Institute of Theoretical and Applied Mechanics, Siberian Branch of RAS, Novosibirsk 630090, Russia.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Proc Biol Sci</MedlineTA>
            <NlmUniqueID>101245157</NlmUniqueID>
            <ISSNLinking>0962-8452</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Ellobius</Keyword>
            <Keyword MajorTopicYN="N">Mus</Keyword>
            <Keyword MajorTopicYN="N">adaptation to dust</Keyword>
            <Keyword MajorTopicYN="N">nanoparticles</Keyword>
            <Keyword MajorTopicYN="N">nasal aerodynamics</Keyword>
            <Keyword MajorTopicYN="N">subterranean rodents</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">rspb.2014.0919</ArticleId>
            <ArticleId IdType="doi">10.1098/rspb.2014.0919</ArticleId>
            <ArticleId IdType="pubmed">25143031</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143004</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1758-535X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The journals of gerontology. Series A, Biological sciences and medical sciences</Title>
                <ISOAbbreviation>J. Gerontol. A Biol. Sci. Med. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Recovery of Indicators of Mitochondrial Biogenesis, Oxidative Stress, and Aging With (-)-Epicatechin in Senile Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">glu131</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">There is evidence implicating oxidative stress (OS) as the cause of the deleterious effects of aging. In this study, we evaluated the capacity of the flavanol (-)-epicatechin (Epi) to reduce aging-induced OS and restore mitochondrial biogenesis, as well as, structural and functional endpoints in aged mice. Senile (S; 26-month-old) C57BL/6 male mice were randomly assigned to receive either water (vehicle) or 1mg/kg of Epi via oral gavage (twice daily) for 15 days. Young (Y; 6-month-old) mice were used as controls. In S brain, kidney, heart, and skeletal muscle (compared with Y animals) an increase in OS was observed as evidenced by increased protein-free carbonyls and decreased reduced glutathione levels as well as sirtuin 3, superoxide dismutase 2, catalase, thioredoxin and glutathione peroxidase protein levels. Well-recognized factors (eg, sirtuin 1) that regulate mitochondrial biogenesis and mitochondrial structure- and/or function-related endpoints (eg, mitofilin and citrate synthase) protein levels were also reduced in S organs. In contrast, the aging biomarker senescence-associated ??-galactosidase was increased in S compared with Y animals, and Epi administration reduced levels towards those observed in Y animals. Altogether, these data suggest that Epi is capable of shifting the biology of S mice towards that of Y animals.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Moreno-Ulloa</LastName>
                    <ForeName>Aldo</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Medicine, University of California, San Diego, La Jolla, California, USA . Secci??n de Estudios de Posgrado e Investigaci??n, Escuela Superior de Medicina, Instituto Polit??cnico Nacional, Mexico .Instituto de Bioqu??mica M??dica Leopoldo De M??is, CCS, UFRJ, Rio de Janeiro, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nogueira</LastName>
                    <ForeName>Leonardo</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Medicine, University of California, San Diego, La Jolla, California, USA .</Affiliation>
                </Author>
                <Author>
                    <LastName>Rodriguez</LastName>
                    <ForeName>Alonso</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Medicine, University of California, San Diego, La Jolla, California, USA .</Affiliation>
                </Author>
                <Author>
                    <LastName>Barboza</LastName>
                    <ForeName>Jonathan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Medicine, University of California, San Diego, La Jolla, California, USA .</Affiliation>
                </Author>
                <Author>
                    <LastName>Hogan</LastName>
                    <ForeName>Michael C</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>Department of Medicine, University of California, San Diego, La Jolla, California, USA .</Affiliation>
                </Author>
                <Author>
                    <LastName>Ceballos</LastName>
                    <ForeName>Guillermo</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Secci??n de Estudios de Posgrado e Investigaci??n, Escuela Superior de Medicina, Instituto Polit??cnico Nacional, Mexico .Instituto de Bioqu??mica M??dica Leopoldo De M??is, CCS, UFRJ, Rio de Janeiro, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Villarreal</LastName>
                    <ForeName>Francisco</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Medicine, University of California, San Diego, La Jolla, California, USA .</Affiliation>
                </Author>
                <Author>
                    <LastName>Ramirez-Sanchez</LastName>
                    <ForeName>Israel</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Department of Medicine, University of California, San Diego, La Jolla, California, USA . Secci??n de Estudios de Posgrado e Investigaci??n, Escuela Superior de Medicina, Instituto Polit??cnico Nacional, Mexico .Instituto de Bioqu??mica M??dica Leopoldo De M??is, CCS, UFRJ, Rio de Janeiro, Brazil. israel.ramirez14@hotmail.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Gerontol A Biol Sci Med Sci</MedlineTA>
            <NlmUniqueID>9502837</NlmUniqueID>
            <ISSNLinking>1079-5006</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">(???)-Epicatechin</Keyword>
            <Keyword MajorTopicYN="N">Mitochondrial biogenesis</Keyword>
            <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
            <Keyword MajorTopicYN="N">Senescence-associated ??-galactosidase.</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">glu131</ArticleId>
            <ArticleId IdType="doi">10.1093/gerona/glu131</ArticleId>
            <ArticleId IdType="pubmed">25143004</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143000</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-0215</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of cancer. Journal international du cancer</Title>
                <ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>microRNA-155 Deficiency Enhances the Recruitment and Functions of Myeloid-Derived Suppressor Cells in Tumor Microenvironment and Promotes Solid Tumor Growth.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/ijc.29151</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Immune cells in tumor microenvironment play a prominent role in tumor progression and metastasis. MicroRNA-155 (miR-155) represents an important player in innate and adaptive immunity by regulating differentiation, maturation and activation of macrophages, dendritic cells, B cells and T cells. However, the role of miR-155 expression in immune cells in solid tumor development is less elucidated. Our current study showed that both B16-F10 melanoma and Lewis lung carcinoma (LLC) tumors grew much faster in bic/miR-155 knockout (miR-155(-/-) ) mice along with an increase of myeloid-derived suppressor cells (MDSCs) accumulation in tumors, compared to that in wild-type mice. Bone marrow transplantation study showed that bone marrow miR-155 deficiency could replicate the above tumor-promoting phenotype. In vitro study demonstrated that tumor-infiltrating miR-155(-/-) MDSCs showed greater migration ability and expressed higher level of multiple chemokines. Furthermore, we found that the level of HIF-1??, a direct target of miR-155, was increased in miR-155 deficient MDSCs, and that the increased HIF-1?? up-regulated CXCL1, CXCL3 and CXCL8 expression in MDSCs, contributing to the enhanced recruitment of miR-155(-/-) MDSCs to the tumors. Moreover, miR-155(-/-) MDSCs showed enhanced immunosuppressive and pro-angiogenic capacities. Taken together, our study, for the first time, demonstrated that miR-155 deficiency promoted solid tumor growth through increasing the recruitment of MDSCs to tumor microenvironment and enhancing the tumor-promoting functions of the recruited MDSCs. Thus, upregulating miR-155 expression in MDSCs may be developed as a therapeutic approach to halt tumor development. ?? 2014 Wiley Periodicals, Inc.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 UICC.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Junfeng</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, SC, 29209; Centre for Stem Cell Research and Application, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yu</LastName>
                    <ForeName>Fang</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Jia</LastName>
                    <ForeName>Xuemei</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Iwanowycz</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Yuzheng</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Shiang</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Ai</LastName>
                    <ForeName>Walden</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author>
                    <LastName>Fan</LastName>
                    <ForeName>Daping</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Int J Cancer</MedlineTA>
            <NlmUniqueID>0042124</NlmUniqueID>
            <ISSNLinking>0020-7136</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">HIF-1??</Keyword>
            <Keyword MajorTopicYN="N">MDSCs</Keyword>
            <Keyword MajorTopicYN="N">chemokines</Keyword>
            <Keyword MajorTopicYN="N">microRNA-155</Keyword>
            <Keyword MajorTopicYN="N">tumor growth</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29151</ArticleId>
            <ArticleId IdType="pubmed">25143000</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25142975</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2045-2322</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>4</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Scientific reports</Title>
                <ISOAbbreviation>Sci Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genetic evidence suggests that Spata22 is required for the maintenance of Rad51 foci in mammalian meiosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6148</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/srep06148</ELocationID>
            <Abstract>
                <AbstractText>Meiotic nodules are the sites of double-stranded DNA break repair. Rpa is a single-stranded DNA-binding protein, and Rad51 is a protein that assists in the repair of DNA double strand breaks. The localisation of Rad51 to meiotic nodules before the localisation of Rpa in mice introduces the issue of whether Rpa is involved in presynaptic filament formation during mammalian meiosis. Here, we show that a protein with unknown function, Spata22, colocalises with Rpa in meiotic nodules in rat spermatocytes. In spermatocytes of Spata22-deficient mutant rats, meiosis was arrested at the zygotene-like stage, and a normal number of Rpa foci was observed during leptotene- and zygotene-like stages. The number of Rad51 foci was initially normal but declined from the leptotene-like stage. These results suggest that both formation and maintenance of Rpa foci are independent of Spata22, and the maintenance, but not the formation, of Rad51 foci requires Spata22. We propose a possible model of presynaptic filament formation in mammalian meiosis, which involves Rpa and Spata22.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ishishita</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Division of Bioscience, Graduate School of Environmental Earth Science, Hokkaido University, North 10 West 8, Kita-ku, Sapporo 060-0810, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsuda</LastName>
                    <ForeName>Yoichi</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Laboratory of Animal Genetics, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8601, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kitada</LastName>
                    <ForeName>Kazuhiro</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Division of Bioscience, Graduate School of Science, Hokkaido University, North 10 West 8, Kita-ku, Sapporo 060-0810, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Sci Rep</MedlineTA>
            <NlmUniqueID>101563288</NlmUniqueID>
            <ISSNLinking>2045-2322</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">srep06148</ArticleId>
            <ArticleId IdType="doi">10.1038/srep06148</ArticleId>
            <ArticleId IdType="pubmed">25142975</ArticleId>
            <ArticleId IdType="pmc">PMC4139951</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142974</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-2180</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Carcinogenesis</Title>
                <ISOAbbreviation>Carcinogenesis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>FOXA2 suppresses the metastasis of hepatocellular carcinoma partially through matrix metalloproteinase-9 inhibition.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">bgu180</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The transcription factor forkhead box A2 (FOXA2) is a member of the hepatocyte nuclear factor family and plays an important role in liver development and metabolic homeostasis, but its role in the metastasis of hepatocellular carcinoma (HCC) has not been evaluated. In this study, we found that the expression of FOXA2 was decreased in 68.1% (49/72) of human HCC tissues compared with their paired noncancerous adjacent tissues. Clinicopathological analysis revealed that reduced FOXA2 expression was correlated with aggressive characteristics (venous invasion, poor differentiation, high TNM grade). FOXA2 level was even lower in portal vein tumor thrombus compared with primary tumor tissues and correlated with epithelial-mesenchymal transition in HCC cells. Overexpression of FOXA2 inhibited migration and invasion of Focus cells, while knockdown of FOXA2 in HepG2 showed the opposite effect. Moreover, upregulation of FOXA2 suppressed HCC metastasis to bone, brain and lung in two distinct mouse models. Finally, we proved that FOXA2 repressed the transcription of matrix metalloproteinase (MMP)-9 and exerted its anti-metastasis effect partially through downregulation of MMP-9. In conclusion, our findings indicate that FOXA2 plays a critical role in HCC metastasis and may serve as a novel therapeutic target for HCC.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Jian</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>Chang-Peng</ForeName>
                    <Initials>CP</Initials>
                    <Affiliation>Department of Internal Medicine, Chinese PLA 531 Hospital, Tonghua 134000, Jilin, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Ping-Fang</ForeName>
                    <Initials>PF</Initials>
                    <Affiliation>Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Qian</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ning</LastName>
                    <ForeName>Bei-Fang</ForeName>
                    <Initials>BF</Initials>
                    <Affiliation>Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Qing</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Jiao</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shi</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xie</LastName>
                    <ForeName>Wei-Fen</ForeName>
                    <Initials>WF</Initials>
                    <Affiliation>Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China weifenxie@medmail.com.cn.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Carcinogenesis</MedlineTA>
            <NlmUniqueID>8008055</NlmUniqueID>
            <ISSNLinking>0143-3334</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">FOXA2</Keyword>
            <Keyword MajorTopicYN="N">MMP-9</Keyword>
            <Keyword MajorTopicYN="N">hepatocellular carcinoma</Keyword>
            <Keyword MajorTopicYN="N">metastasis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">bgu180</ArticleId>
            <ArticleId IdType="doi">10.1093/carcin/bgu180</ArticleId>
            <ArticleId IdType="pubmed">25142974</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142968</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-9645</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European heart journal</Title>
                <ISOAbbreviation>Eur. Heart J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ehu319</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary treatment targets. Epidemiological studies propose HDL-C as a possible candidate. Cholesteryl ester transfer protein (CETP) transfers cholesteryl esters from atheroprotective HDL to atherogenic (V)LDL. The CETP inhibitor anacetrapib decreases (V)LDL-C by ???15-40% and increases HDL-C by ???40-140% in clinical trials. We evaluated the effects of a broad dose range of anacetrapib on atherosclerosis and HDL function, and examined possible additive/synergistic effects of anacetrapib on top of atorvastatin in APOE*3Leiden.CETP mice.</AbstractText>
                <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Mice were fed a diet without or with ascending dosages of anacetrapib (0.03; 0.3; 3; 30 mg/kg/day), atorvastatin (2.4 mg/kg/day) alone or in combination with anacetrapib (0.3 mg/kg/day) for 21 weeks. Anacetrapib dose-dependently reduced CETP activity (-59 to -100%, P &lt; 0.001), thereby decreasing non-HDL-C (-24 to -45%, P &lt; 0.001) and increasing HDL-C (+30 to +86%, P &lt; 0.001). Anacetrapib dose-dependently reduced the atherosclerotic lesion area (-41 to -92%, P &lt; 0.01) and severity, increased plaque stability index and added to the effects of atorvastatin by further decreasing lesion size (-95%, P &lt; 0.001) and severity. Analysis of covariance showed that both anacetrapib (P &lt; 0.05) and non-HDL-C (P &lt; 0.001), but not HDL-C (P = 0.76), independently determined lesion size.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Anacetrapib dose-dependently reduces atherosclerosis, and adds to the anti-atherogenic effects of atorvastatin, which is mainly ascribed to a reduction in non-HDL-C. In addition, anacetrapib improves lesion stability.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>K??hnast</LastName>
                    <ForeName>Susan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Gaubius Laboratory, TNO, Metabolic Health Research, Zernikedreef 9, 2333 CK, PO Box 2215, 2301 CE, Leiden, The Netherlands Department of Cardiology, LUMC, Leiden, The Netherlands Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>van der Tuin</LastName>
                    <ForeName>Sam J L</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands Department of Endocrinology and Metabolic Diseases, LUMC, Leiden, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>van der Hoorn</LastName>
                    <ForeName>Jos?? W A</ForeName>
                    <Initials>JW</Initials>
                    <Affiliation>Gaubius Laboratory, TNO, Metabolic Health Research, Zernikedreef 9, 2333 CK, PO Box 2215, 2301 CE, Leiden, The Netherlands Department of Cardiology, LUMC, Leiden, The Netherlands Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>van Klinken</LastName>
                    <ForeName>Jan B</ForeName>
                    <Initials>JB</Initials>
                    <Affiliation>Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands Department of Human Genetics, LUMC, Leiden, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Simic</LastName>
                    <ForeName>Branko</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Center for Molecular Cardiology, Campus Schlieren, University of Zurich, Zurich, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pieterman</LastName>
                    <ForeName>Elsbet</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Gaubius Laboratory, TNO, Metabolic Health Research, Zernikedreef 9, 2333 CK, PO Box 2215, 2301 CE, Leiden, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Havekes</LastName>
                    <ForeName>Louis M</ForeName>
                    <Initials>LM</Initials>
                    <Affiliation>Gaubius Laboratory, TNO, Metabolic Health Research, Zernikedreef 9, 2333 CK, PO Box 2215, 2301 CE, Leiden, The Netherlands Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands Department of Endocrinology and Metabolic Diseases, LUMC, Leiden, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Landmesser</LastName>
                    <ForeName>Ulf</ForeName>
                    <Initials>U</Initials>
                    <Affiliation>University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>L??scher</LastName>
                    <ForeName>Thomas F</ForeName>
                    <Initials>TF</Initials>
                    <Affiliation>University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Willems van Dijk</LastName>
                    <ForeName>Ko</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands Department of Endocrinology and Metabolic Diseases, LUMC, Leiden, The Netherlands Department of Human Genetics, LUMC, Leiden, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rensen</LastName>
                    <ForeName>Patrick C N</ForeName>
                    <Initials>PC</Initials>
                    <Affiliation>Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands Department of Endocrinology and Metabolic Diseases, LUMC, Leiden, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jukema</LastName>
                    <ForeName>J Wouter</ForeName>
                    <Initials>JW</Initials>
                    <Affiliation>Department of Cardiology, LUMC, Leiden, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Princen</LastName>
                    <ForeName>Hans M G</ForeName>
                    <Initials>HM</Initials>
                    <Affiliation>Gaubius Laboratory, TNO, Metabolic Health Research, Zernikedreef 9, 2333 CK, PO Box 2215, 2301 CE, Leiden, The Netherlands hans.princen@tno.nl.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur Heart J</MedlineTA>
            <NlmUniqueID>8006263</NlmUniqueID>
            <ISSNLinking>0195-668X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Anacetrapib</Keyword>
            <Keyword MajorTopicYN="N">Atherosclerosis</Keyword>
            <Keyword MajorTopicYN="N">Atorvastatin</Keyword>
            <Keyword MajorTopicYN="N">Cholesteryl ester transfer protein</Keyword>
            <Keyword MajorTopicYN="N">HDL function</Keyword>
            <Keyword MajorTopicYN="N">HDL-cholesterol</Keyword>
            <Keyword MajorTopicYN="N">Non-HDL-cholesterol</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ehu319</ArticleId>
            <ArticleId IdType="doi">10.1093/eurheartj/ehu319</ArticleId>
            <ArticleId IdType="pubmed">25142968</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142911</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2202</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC neuroscience</Title>
                <ISOAbbreviation>BMC Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Simultaneous monitoring of cerebral metal accumulation in an experimental model of Wilson's disease by laser ablation inductively coupled plasma mass spectrometry.</ArticleTitle>
            <Pagination>
                <MedlinePgn>98</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neuropsychiatric affection involving extrapyramidal symptoms is a frequent component of Wilson's disease (WD). WD is caused by a genetic defect of the copper (Cu) efflux pump ATPase7B. Mouse strains with natural or engineered transgenic defects of the Atp7b gene have served as model of WD. These show a gradual accumulation and concentration of Cu in liver, kidneys, and brain. However, still little is known about the regional distribution of Cu inside the brain, its influence on other metals and subsequent pathophysiological mechanisms. We have applied laser ablation inductively coupled plasma mass spectrometry and performed comparative metal bio-imaging in brain sections of wild type and Atp7b null mice in the age range of 11-24 months. Messenger RNA and protein expression of a panel of inflammatory markers were assessed using RT-PCR and Western blots of brain homogenates.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We could confirm Cu accumulation in brain parenchyma by a factor of two in WD (5.5 mug g-1 in the cortex) vs. controls (2.7 mug g-1) that was already fully established at 11 months. In the periventricular regions (PVR) known as structures of prominent Cu content, Cu was reduced in turn by a factor of 3. This corroborates the view of the PVR as efflux compartments with active transport of Cu into the cerebrospinal fluid. Furthermore, the gradient of Cu increasing downstream the PVR was relieved. Otherwise the architecture of Cu distribution was essentially maintained. Zinc (Zn) was increased by up to 40% especially in regions of high Cu but not in typical Zn accumulator regions, a side effect due to the fact that Zn is to some degree a substrate of Cu-ATPases. The concentrations of iron (Fe) and manganese (Mn) were constant throughout all regions assessed. Inflammatory markers TNF-alpha, TIMP-1 and the capillary proliferation marker alpha-SMA were increased by a factor of 2-3 in WD.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study confirmed stable cerebral Cu accumulation in parenchyma and discovered reduced Cu in cerebrospinal fluid in Atp7b null mice underlining the diagnostic value of micro-local analytical techniques.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Boaru</LastName>
                    <ForeName>Sorina Georgiana</ForeName>
                    <Initials>SG</Initials>
                </Author>
                <Author>
                    <LastName>Merle</LastName>
                    <ForeName>Uta</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author>
                    <LastName>Uerlings</LastName>
                    <ForeName>Ricarda</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Zimmermann</LastName>
                    <ForeName>Astrid</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Weiskirchen</LastName>
                    <ForeName>Sabine</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Matusch</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Stremmel</LastName>
                    <ForeName>Wolfgang</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author>
                    <LastName>Weiskirchen</LastName>
                    <ForeName>Ralf</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>BMC Neurosci</MedlineTA>
            <NlmUniqueID>100966986</NlmUniqueID>
            <ISSNLinking>1471-2202</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1471-2202-15-98</ArticleId>
            <ArticleId IdType="doi">10.1186/1471-2202-15-98</ArticleId>
            <ArticleId IdType="pubmed">25142911</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142875</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1757-7012</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Wiley interdisciplinary reviews. RNA</Title>
                <ISOAbbreviation>Wiley Interdiscip Rev RNA</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CLP1 as a novel player in linking tRNA splicing to neurodegenerative disorders.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/wrna.1255</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Defects in RNA metabolic pathways are well-established causes for neurodegenerative disorders. Several mutations in genes involved in pre-messenger RNA (pre-mRNA) and tRNA metabolism, RNA stability and protein translation have been linked to motor neuron diseases. Our study on a mouse carrying a catalytically inactive version of the RNA kinase CLP1, a component of the tRNA splicing endonuclease complex, revealed a neurological disorder characterized by progressive loss of lower spinal motor neurons. Surprisingly, mutant mice accumulate a novel class of tRNA-derived fragments. In addition, patients with homozygous missense mutations in CLP1 (R140H) were recently identified who suffer from severe motor-sensory defects, cortical dysgenesis and microcephaly, and exhibit alterations in transfer RNA (tRNA) splicing. Here, we review functions of CLP1 in different RNA pathways and provide hypotheses on the role of the tRNA splicing machinery in the generation of tRNA fragments and the molecular links to neurodegenerative disorders. We further immerse the biology of tRNA splicing into topics of (t)RNA metabolism and oxidative stress, putting forward the idea that defects in tRNA processing leading to tRNA fragment accumulation might trigger the development of neurodegenerative diseases. For further resources related to this article, please visit the WIREs website. Conflict of interest: The authors have declared no conflicts of interest for this article.</AbstractText>
                <CopyrightInformation>?? 2014 John Wiley &amp; Sons, Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Weitzer</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>IMBA, Institute of Molecular Biotechnology of the Academy of Sciences, Vienna, Austria.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hanada</LastName>
                    <ForeName>Toshikatsu</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Penninger</LastName>
                    <ForeName>Josef M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author>
                    <LastName>Martinez</LastName>
                    <ForeName>Javier</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Wiley Interdiscip Rev RNA</MedlineTA>
            <NlmUniqueID>101536955</NlmUniqueID>
            <ISSNLinking>1757-7004</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/wrna.1255</ArticleId>
            <ArticleId IdType="pubmed">25142875</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142864</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-4644</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cellular biochemistry</Title>
                <ISOAbbreviation>J. Cell. Biochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Reduction of Myeloid-derived Suppressor Cells and Lymphoma Growth by a Natural Triterpenoid.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/jcb.24946</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Lymphoma is a potentially life threatening disease. The goal of this study was to investigate the therapeutic potential of a natural triterpenoid, Ganoderic acid A (GA-A) in controlling lymphoma growth both in vitro and in vivo. Here, we show that GA-A treatment induces caspase-dependent apoptotic cell death characterized by a dose-dependent increase in active caspases 9 and 3, up-regulation of pro-apoptotic BIM and BAX proteins, and a subsequent loss of mitochondrial membrane potential with release of cytochrome c. In addition to GA-A's anti-growth activity, we show that lower doses of GA-A enhance HLA class II-mediated antigen presentation and CD4+ T cell recognition of lymphoma in vitro. The therapeutic relevance of GA-A treatment was also tested in vivo using the EL4 syngeneic mouse model of metastatic lymphoma. GA-A-treatment significantly prolonged survival of EL4 challenged mice and decreased tumor metastasis to the liver, an outcome accompanied by a marked down-regulation of STAT3 phosphorylation, reduction myeloid-derived suppressor cells (MDSCs), and enhancement of cytotoxic CD8+ T cells in the host. Thus, GA-A not only selectively induces apoptosis in lymphoma cells, but also enhances cell-mediated immune responses by attenuating MDSCs, and elevating Ag presentation and T cell recognition. The demonstrated therapeutic benefit indicates that GA-A is a candidate for future drug design for the treatment of lymphoma. J. Cell. Biochem. ?? 2014 Wiley Periodicals, Inc.</AbstractText>
                <CopyrightInformation>?? 2014 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Radwan</LastName>
                    <ForeName>Faisal F Y</ForeName>
                    <Initials>FF</Initials>
                    <Affiliation>Department of Microbiology and Immunology, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425; Hollings Cancer Center, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425; Children's Research Institute, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hossain</LastName>
                    <ForeName>Azim</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>God</LastName>
                    <ForeName>Jason M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author>
                    <LastName>Leaphart</LastName>
                    <ForeName>Nathan</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Elvington</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Nagarkatti</LastName>
                    <ForeName>Mitzi</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Tomlinson</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Haque</LastName>
                    <ForeName>Azizul</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Cell Biochem</MedlineTA>
            <NlmUniqueID>8205768</NlmUniqueID>
            <ISSNLinking>0730-2312</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apoptosis</Keyword>
            <Keyword MajorTopicYN="N">Caspases</Keyword>
            <Keyword MajorTopicYN="N">HLA class II proteins</Keyword>
            <Keyword MajorTopicYN="N">Lymphoma</Keyword>
            <Keyword MajorTopicYN="N">Mitochondria</Keyword>
            <Keyword MajorTopicYN="N">STAT3</Keyword>
            <Keyword MajorTopicYN="N">T cells</Keyword>
            <Keyword MajorTopicYN="N">Triterpenoid</Keyword>
            <Keyword MajorTopicYN="N">myeloid-derived suppressor cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.24946</ArticleId>
            <ArticleId IdType="pubmed">25142864</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25142835</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2045-2322</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>4</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Scientific reports</Title>
                <ISOAbbreviation>Sci Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sapodilla Plum (Achras sapota) Induces Apoptosis in Cancer Cell Lines and Inhibits Tumor Progression in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6147</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/srep06147</ELocationID>
            <Abstract>
                <AbstractText>Intake of fruits rich in antioxidants in daily diet is suggested to be cancer preventive. Sapota is a tropical fruit grown and consumed extensively in several countries including India and Mexico. Here we show that methanolic extracts of Sapota fruit (MESF) induces cytotoxicity in a dose-dependent manner in cancer cell lines. Cell cycle analysis suggested activation of apoptosis, without arresting cell cycle progression. Annexin V-propidium iodide double-staining demonstrated that Sapota fruit extracts potentiate apoptosis rather than necrosis in cancer cells. Loss of mitochondrial membrane potential, upregulation of proapoptotic proteins, activation of MCL-1, PARP-1, and Caspase 9 suggest that MESF treatment leads to activation of mitochondrial pathway of apoptosis. More importantly, we show that MESF treatment leads to significant inhibition of tumor growth and a 3-fold increase in the life span of tumor bearing animals compared to untreated tumor mice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Srivastava</LastName>
                    <ForeName>Mrinal</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biochemistry, Indian Institute of Science, Bangalore 560 012, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hegde</LastName>
                    <ForeName>Mahesh</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biochemistry, Indian Institute of Science, Bangalore 560 012, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chiruvella</LastName>
                    <ForeName>Kishore K</ForeName>
                    <Initials>KK</Initials>
                    <Affiliation>Department of Biochemistry, Indian Institute of Science, Bangalore 560 012, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koroth</LastName>
                    <ForeName>Jinsha</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Institute of Bioinformatics and Applied Biotechnology, Electronics City, Bangalore 560 100, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bhattacharya</LastName>
                    <ForeName>Souvari</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Biochemistry, Indian Institute of Science, Bangalore 560 012, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choudhary</LastName>
                    <ForeName>Bibha</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Institute of Bioinformatics and Applied Biotechnology, Electronics City, Bangalore 560 100, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Raghavan</LastName>
                    <ForeName>Sathees C</ForeName>
                    <Initials>SC</Initials>
                    <Affiliation>Department of Biochemistry, Indian Institute of Science, Bangalore 560 012, India.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Sci Rep</MedlineTA>
            <NlmUniqueID>101563288</NlmUniqueID>
            <ISSNLinking>2045-2322</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">srep06147</ArticleId>
            <ArticleId IdType="doi">10.1038/srep06147</ArticleId>
            <ArticleId IdType="pubmed">25142835</ArticleId>
            <ArticleId IdType="pmc">PMC4139949</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142712</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1364-6753</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neurogenetics</Title>
                <ISOAbbreviation>Neurogenetics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genes and Gene Networks Implicated in Aggression Related Behaviour.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Aggressive behaviour is a major cause of mortality and morbidity. Despite of moderate heritability estimates, progress in identifying the genetic factors underlying aggressive behaviour has been limited. There are currently three genetic mouse models of high and low aggression created using selective breeding. This is the first study to offer a global transcriptomic characterization of the prefrontal cortex across all three genetic mouse models of aggression. A systems biology approach has been applied to transcriptomic data across the three pairs of selected inbred mouse strains (Turku Aggressive (TA) and Turku Non-Aggressive (TNA), Short Attack Latency (SAL) and Long Attack Latency (LAL) mice and North Carolina Aggressive (NC900) and North Carolina Non-Aggressive (NC100)), providing novel insight into the neurobiological mechanisms and genetics underlying aggression. First, weighted gene co-expression network analysis (WGCNA) was performed to identify modules of highly correlated genes associated with aggression. Probe sets belonging to gene modules uncovered by WGCNA were carried forward for network analysis using ingenuity pathway analysis (IPA). The RankProd non-parametric algorithm was then used to statistically evaluate expression differences across the genes belonging to modules significantly associated with aggression. IPA uncovered two pathways, involving NF-kB and MAPKs. The secondary RankProd analysis yielded 14 differentially expressed genes, some of which have previously been implicated in pathways associated with aggressive behaviour, such as Adrbk2. The results highlighted plausible candidate genes and gene networks implicated in aggression-related behaviour.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Malki</LastName>
                    <ForeName>Karim</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>King's College London, MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, London, UK, karim.malki@kcl.ac.uk.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pain</LastName>
                    <ForeName>Oliver</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author>
                    <LastName>Du Rietz</LastName>
                    <ForeName>Ebba</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author>
                    <LastName>Tosto</LastName>
                    <ForeName>Maria Grazia</ForeName>
                    <Initials>MG</Initials>
                </Author>
                <Author>
                    <LastName>Paya-Cano</LastName>
                    <ForeName>Jose</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Sandnabba</LastName>
                    <ForeName>Kenneth N</ForeName>
                    <Initials>KN</Initials>
                </Author>
                <Author>
                    <LastName>de Boer</LastName>
                    <ForeName>Sietse</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Schalkwyk</LastName>
                    <ForeName>Leonard C</ForeName>
                    <Initials>LC</Initials>
                </Author>
                <Author>
                    <LastName>Sluyter</LastName>
                    <ForeName>Frans</ForeName>
                    <Initials>F</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neurogenetics</MedlineTA>
            <NlmUniqueID>9709714</NlmUniqueID>
            <ISSNLinking>1364-6745</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10048-014-0417-x</ArticleId>
            <ArticleId IdType="pubmed">25142712</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142617</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1743-2928</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Redox report : communications in free radical research</Title>
                <ISOAbbreviation>Redox Rep.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Circadian (about 24-hour) variation in malondialdehyde content and catalase activity of mouse erythrocytes.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Lipid peroxidation is a part of normal metabolism that may cause biological molecule damage leading to the formation of several specific metabolites that include aldehydes of variable chains, such as malondialdehyde (MDA). These biological effects are controlled in vivo by a wide spectrum of enzymatic and non-enzymatic defense mechanisms among which catalase (CAT) is considered as an important regulator of oxidative stress. The present study aimed to investigate the possible relationship between the temporal patterns of the formation of MDA and the activity of CAT in the erythrocytes of mice. Twenty-four-hour studies were performed on male Swiss albino mice, 12 weeks old, synchronized to a 12:12 light: dark cycle for 3 weeks. Different and comparable groups of animals (n??=??10) were sacrificed at an interval of 4 hours (1, 5, 9, 13, 17, and 21 hours after light onset (HALO)). The levels of erythrocyte MDA concentration and CAT activity both significantly (analysis of variance: F??=??6.4, P??&lt;??0.002) varied according to the time of sampling under non-stressed conditions. The characteristics of the waveform describing the temporal patterns differed between the two studied variables, e.g. MDA content showing one peak (???21 HALO) and CAT activity showing three peaks (???9, 17, and 21 HALO). Cosinor analysis revealed a significant (adjusted Cosinor: P???????0.018) circadian (?? ??? 24 hours) rhythm in MDA level and no statistically significant rhythmicity in CAT activity. The differences and the absence of correlation between the curve patterns of erythrocyte MDA content and CAT activity under physiological conditions are hypothesized to explain that variation in lipid peroxidation may depend on several factors. Moreover, the identification of peak/trough levels of MDA accumulation in erythrocytes may reflect the degree of oxidative stress in these blood cells. In addition, the observed significant time-of-day effect suggests that, in both clinical and scientific settings, appropriate comparison of MDA production and CAT activity levels can only be achieved on data obtained at the same time of day.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sani</LastName>
                    <ForeName>Mamane</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Sebai</LastName>
                    <ForeName>Hichem</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>N??ziha</LastName>
                    <ForeName>Ghanem-Boughanmi</ForeName>
                    <Initials>GB</Initials>
                </Author>
                <Author>
                    <LastName>Boughattas</LastName>
                    <ForeName>Naceur A</ForeName>
                    <Initials>NA</Initials>
                </Author>
                <Author>
                    <LastName>Ben-Attia</LastName>
                    <ForeName>Mossadok</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Redox Rep</MedlineTA>
            <NlmUniqueID>9511366</NlmUniqueID>
            <ISSNLinking>1351-0002</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Catalase</Keyword>
            <Keyword MajorTopicYN="N">Circadian rhythm</Keyword>
            <Keyword MajorTopicYN="N">Erythrocyte</Keyword>
            <Keyword MajorTopicYN="N">Malondialdehyde</Keyword>
            <Keyword MajorTopicYN="N">Mouse</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1179/1351000214Y.0000000102</ArticleId>
            <ArticleId IdType="pubmed">25142617</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142614</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1549-4918</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Stem cells (Dayton, Ohio)</Title>
                <ISOAbbreviation>Stem Cells</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Controlling and monitoring stem cell safety in vivo in an experimental rodent model.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/stem.1819</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Adult stem cells have been investigated increasingly over the past years for multiple applications. Although they have a more favorable safety profile compared to pluripotent stem cells, they are still capable of self-renewal and differentiate into several cell types. We investigated the behavior of Oct4 positive (Oct4(+) ) and Oct4 negative (Oct4(-) ) murine or rat bone marrow (BM) derived stem cells in the healthy brain of syngeneic mice and rats. Engraftment of mouse and rat Oct4 positive BM-derived hypoblast like stem cells (m/rOct4(+) BM-HypoSC's) resulted in yolk-sac tumor formation in the healthy brain which were monitored longitudinally using magnetic resonance imaging (MRI) and bioluminescence imaging (BLI). Contrast enhanced MRI confirmed the disruption of the blood brain barrier (BBB). In contrast, m/r Oct4 negative BM derived multipotent adult progenitor cells (m/rOct4(-) BM-MAPC's) did not result in mass formation after engraftment into the brain. mOct4(+) BM-HypoSC's and mOct4(-) BM-MAPC's were transduced to express enhanced green fluorescent protein (eGFP), firefly luciferase (fLuc) and herpes simplex virus - thymidine kinase (HSV - tk) to follow up suicide gene expression as a potential 'safety switch' for tumor forming stem cells by multi - modal imaging. Both cell lines were eradicated efficiently in vivo by ganciclovir (GCV) administration indicating successful suicide gene expression in vivo, as assessed by MRI, BLI and histology. The use of suicide genes to prevent tumor formation is in particular of interest for therapeutic approaches where stem cells are used as vehicles to deliver therapeutic genes. Stem Cells 2014.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 AlphaMed Press.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Leten</LastName>
                    <ForeName>Cindy</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Biomedical MRI, Department of Imaging and Pathology, KU Leuven, Leuven, 3000, Belgium; Molecular Small Animal Imaging Center, KU Leuven, 3000, Leuven, Belgium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Roobrouck</LastName>
                    <ForeName>Valerie D</ForeName>
                    <Initials>VD</Initials>
                </Author>
                <Author>
                    <LastName>Struys</LastName>
                    <ForeName>Tom</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Burns</LastName>
                    <ForeName>Terry C</ForeName>
                    <Initials>TC</Initials>
                </Author>
                <Author>
                    <LastName>Dresselaers</LastName>
                    <ForeName>Tom</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Velde</LastName>
                    <ForeName>Greetje Vande</ForeName>
                    <Initials>GV</Initials>
                </Author>
                <Author>
                    <LastName>Santermans</LastName>
                    <ForeName>Jeanine</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Lo Nigro</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Ibrahimi</LastName>
                    <ForeName>Abdelilah</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Gijsbers</LastName>
                    <ForeName>Rik</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Eggermont</LastName>
                    <ForeName>Kristel</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Lambrichts</LastName>
                    <ForeName>Ivo</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author>
                    <LastName>Verfaillie</LastName>
                    <ForeName>Catherine M</ForeName>
                    <Initials>CM</Initials>
                </Author>
                <Author>
                    <LastName>Himmelreich</LastName>
                    <ForeName>Uwe</ForeName>
                    <Initials>U</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Stem Cells</MedlineTA>
            <NlmUniqueID>9304532</NlmUniqueID>
            <ISSNLinking>1066-5099</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.1819</ArticleId>
            <ArticleId IdType="pubmed">25142614</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142608</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-5514</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of virology</Title>
                <ISOAbbreviation>J. Virol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">JVI.01643-14</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Infections with Marburg (MARV) and Ebola virus (EBOV) cause severe hemorrhagic fever in humans and non-human primates (NHPs) with fatality rates up to 90%. A number of experimental vaccine and treatment platforms have previously been shown to be protective against EBOV infection. However, the rate of development for prophylactics and therapeutics against MARV has been slower in comparison, possibly because a small animal model is not widely available. Here we report the development of a mouse model for studying the pathogenesis of MARV Angola (MARV/Ang), the most virulent strain of MARV. Infection with the wild-type virus does not cause disease in mice, but the adapted virus (MARV/Ang-MA) recovered from liver homogenates after 24 serial passages in severe combined immunodeficient (SCID) mice caused severe disease when administered intranasally (IN) or intraperitoneally (IP). The LD50 was determined to be 0.015 TCID50 MARV/Ang-MA in SCID mice, and IP infection at a dose of 1000 x LD50 resulted in death between 6-8 days post-infection (dpi) in SCID mice. Similar results were obtained with immunocompetent BALB/c and C57BL/6 mice challenged IP with 2000 x LD50 of MARV/Ang-MA. Virological and pathological analyses in MARV/Ang-MA infected BALB/c mice revealed that the associated pathology was reminiscent of observations made in NHPs with MARV/Ang. MARV/Ang-MA infected mice showed most of the clinical hallmarks observed with Marburg hemorrhagic fever, including lymphopenia, thrombocytopenia, marked liver damage and uncontrolled viremia. Virus titers reached 10(8) TCID50/ml in the blood, and between 10(6-10) TCID50/g tissue in the intestines, kidney, lungs, brain, spleen, and liver. This model provides an important tool to screen candidate vaccines and therapeutics against MARV infections.</AbstractText>
                <AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">The Angola strain of Marburg virus (MARV/Ang) was responsible for the largest outbreak ever documented for Marburg viruses. At a 90% fatality rate, it is similar to Ebola virus, which makes it one of the most lethal viruses known to humans. There are currently no approved interventions for Marburg virus, in part because a small animal model that is vulnerable to MARV/Ang infection is not available to screen and test potential vaccines and therapeutics in a quick and economical manner. To address this need, we have adapted MARV/Ang so that it causes illness in mice resulting in death. The signs of disease in these mice are reminiscent of wild-type MARV/Ang infections in humans and nonhuman primates. We believe this will be of help in accelerating the development of life-saving measures against Marburg virus infections.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Qiu</LastName>
                    <ForeName>Xiangguo</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada xiangguo.qiu@phac-aspc.gc.ca.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wong</LastName>
                    <ForeName>Gary</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Audet</LastName>
                    <ForeName>Jonathan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cutts</LastName>
                    <ForeName>Todd</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Applied Biosafety and Research Program, JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Niu</LastName>
                    <ForeName>Yulian</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Molecular PathoBiology, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Booth</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Molecular PathoBiology, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kobinger</LastName>
                    <ForeName>Gary P</ForeName>
                    <Initials>GP</Initials>
                    <Affiliation>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada Department of Immunology, University of Manitoba, Winnipeg, MB, Canada Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA gary.kobinger@phac-aspc.gc.ca.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Virol</MedlineTA>
            <NlmUniqueID>0113724</NlmUniqueID>
            <ISSNLinking>0022-538X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">JVI.01643-14</ArticleId>
            <ArticleId IdType="doi">10.1128/JVI.01643-14</ArticleId>
            <ArticleId IdType="pubmed">25142608</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142603</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-5514</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of virology</Title>
                <ISOAbbreviation>J. Virol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immunodeficient Mouse Models with Different Disease Profiles by in vivo Infection with the Same Clinical Isolate of Enterovirus 71.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">JVI.00692-14</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Like poliovirus, severe infection with enterovirus 71 (EV71) can cause neuropathology. Unlike poliovirus, EV71 is often associated with hand, foot, and mouth disease (HFMD). Here, we established three mouse models for experimental infection with the same clinical isolate of EV71. The NOD/SCID mouse model is unique in developing skin rash, an HFMD-like symptom. While the NOD/SCID model developed limb paralysis and death at near 100% efficiency, the interferon-gamma receptor knockout (ifngr KO) and the stat-1 knockout mice exhibited paralysis and death rates near 78% and 30%, respectively. Productive infection with EV71 depends on viral dose, host age, and inoculation routes. Infectious EV71, and VP1-specific RNA and protein in muscle, brain, and spinal cord, were compared side-by-side between NOD/SCID and stat-1 models before, during, and after disease onset. Spleen fibrosis and muscle degeneration are common in NOD/SCID and stat-1 models. Main differences between these two models include their disease manifestations and cytokine/chemokine profiles. Pathology of the NOD/SCID model includes 1) inflammation and expression of viral VP1 antigen in muscle; 2) increased neutrophils and decreased eosinophils and lymphocytes; 3) hair loss and skin rash. Characteristic pathology of the stat-1 model includes 1) a strong tropism of EV71 for central nervous system; 2) detection of VP1 protein in the Purkinje layer of cerebellar cortex, pons, brainstem, and spinal cord; 3) amplification of microglial cells; 4) dystrophy of intestinal villi. Our comparative studies on these new models by oral or intraperitoneal (i.p.) infection underscored the contribution of host immunity, including interferon-gamma receptor, to EV71 pathogenesis.</AbstractText>
                <AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">In the past decade, enterovirus 71 (EV71) has emerged as a major threat to the public health in the Asia-Pacific regions. Disease manifestations include subclinical infection, common cold-like syndromes, hand-foot-and-mouth disease (HFMD), uncomplicated brainstem encephalitis, severe dysregulated autonomic nerve system, fatal pulmonary edema, and cardiopulmonary collapse. To date, no effective vaccine or treatment is available. A user-friendly and widely accessible animal model for researching EV71 infection and pathogenesis is urgently needed by the global community, both academia and industry.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Liao</LastName>
                    <ForeName>Chun-Che</ForeName>
                    <Initials>CC</Initials>
                    <Affiliation>Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liou</LastName>
                    <ForeName>An-Ting</ForeName>
                    <Initials>AT</Initials>
                    <Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan Taiwan International Graduate Program (TIGP) in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chang</LastName>
                    <ForeName>Ya-Shu</ForeName>
                    <Initials>YS</Initials>
                    <Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Szu-Yao</ForeName>
                    <Initials>SY</Initials>
                    <Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chang</LastName>
                    <ForeName>Chih-Shin</ForeName>
                    <Initials>CS</Initials>
                    <Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Chien-Kuo</ForeName>
                    <Initials>CK</Initials>
                    <Affiliation>Institute of Immunology, National Taiwan University, Taipei 100, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kung</LastName>
                    <ForeName>John T</ForeName>
                    <Initials>JT</Initials>
                    <Affiliation>Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tu</LastName>
                    <ForeName>Pang-Hsien</ForeName>
                    <Initials>PH</Initials>
                    <Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yu</LastName>
                    <ForeName>Ya-Yen</ForeName>
                    <Initials>YY</Initials>
                    <Affiliation>Section of Clinical Virology and Molecular Diagnosis, Department of Laboratory Medicine, Changhua Christian Hospital, Changhua, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lin</LastName>
                    <ForeName>Chi-Yung</ForeName>
                    <Initials>CY</Initials>
                    <Affiliation>Section of Clinical Virology and Molecular Diagnosis, Department of Laboratory Medicine, Changhua Christian Hospital, Changhua, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lin</LastName>
                    <ForeName>Jen-Shiou</ForeName>
                    <Initials>JS</Initials>
                    <Affiliation>Section of Clinical Virology and Molecular Diagnosis, Department of Laboratory Medicine, Changhua Christian Hospital, Changhua, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shih</LastName>
                    <ForeName>Chiaho</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan Taiwan International Graduate Program (TIGP) in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, Taiwan cshih@ibms.sinica.edu.tw.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Virol</MedlineTA>
            <NlmUniqueID>0113724</NlmUniqueID>
            <ISSNLinking>0022-538X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">JVI.00692-14</ArticleId>
            <ArticleId IdType="doi">10.1128/JVI.00692-14</ArticleId>
            <ArticleId IdType="pubmed">25142603</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142599</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-5514</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of virology</Title>
                <ISOAbbreviation>J. Virol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">JVI.01930-14</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Relatively little is known about the extent of the polyclonal antibody (PAb) repertoire elicited by HSV glycoproteins during natural infection and how these antibodies affect virus neutralization. Here, we examined IgGs from ten HSV-seropositive individuals originally classified as high or low virus shedders. All PAbs neutralized virus to varying extents. We determined which HSV entry glycoproteins these PAbs were directed against: glycoproteins gB, gD and gC were recognized by all sera but fewer reacted against gH/gL. We previously characterized multiple mouse monoclonal antibodies (MAbs) and mapped those with high neutralizing activity to the crystal structures of gD, gB and gH/gL. We used a biosensor competition assay to determine whether there were corresponding human antibodies to those epitopes. All ten samples had neutralizing IgGs to gD epitopes but there were variations in which epitopes were seen in individual samples. Surprisingly, only three samples contained neutralizing IgGs to gB epitopes. To further dissect the nature of these IgGs, we developed a method to select out gD- and gB-specific IgGs from four representative sera via affinity chromatography, allowing us to determine the contribution of antibodies against each glycoprotein to the overall neutralization capacity of the serum. In two cases, gD and gB accounted for all of the neutralizing activity against HSV-2, with a modest amount of HSV-1 neutralization directed against gC. In the other two samples, the dominant response was to gD.</AbstractText>
                <AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Antibodies targeting functional epitopes on HSV entry glycoproteins mediate HSV neutralization. Virus neutralizing epitopes have been defined and characterized using murine monoclonal antibodies. However, it is largely unknown whether these same epitopes are targeted by the humoral response to HSV infection in humans. We have shown that during natural infection, virus-neutralizing antibodies are principally directed against gD and gB and to a lesser extent, gC. While several key HSV neutralizing epitopes within gD and gB are commonly targeted by human serum IgG, others fail to induce consistent responses. These data are particularly relevant to the design of future HSV vaccines.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cairns</LastName>
                    <ForeName>Tina M</ForeName>
                    <Initials>TM</Initials>
                    <Affiliation>Department of Microbiology, School of Dental Medicine tmcairns@dental.upenn.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Zhen-Yu</ForeName>
                    <Initials>ZY</Initials>
                    <Affiliation>Department of Microbiology, School of Dental Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Whitbeck</LastName>
                    <ForeName>J Charles</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Department of Microbiology, School of Dental Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>de Leon</LastName>
                    <ForeName>Manuel Ponce</ForeName>
                    <Initials>MP</Initials>
                    <Affiliation>Department of Microbiology, School of Dental Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lou</LastName>
                    <ForeName>Huan</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Microbiology, School of Dental Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wald</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Krummenacher</LastName>
                    <ForeName>Claude</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Eisenberg</LastName>
                    <ForeName>Roselyn J</ForeName>
                    <Initials>RJ</Initials>
                    <Affiliation>Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cohen</LastName>
                    <ForeName>Gary H</ForeName>
                    <Initials>GH</Initials>
                    <Affiliation>Department of Microbiology, School of Dental Medicine.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Virol</MedlineTA>
            <NlmUniqueID>0113724</NlmUniqueID>
            <ISSNLinking>0022-538X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">JVI.01930-14</ArticleId>
            <ArticleId IdType="doi">10.1128/JVI.01930-14</ArticleId>
            <ArticleId IdType="pubmed">25142599</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142598</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-5514</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of virology</Title>
                <ISOAbbreviation>J. Virol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Residue 82 of the Chikungunya Virus E2 Attachment Protein Modulates Viral Dissemination and Arthritis in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">JVI.01672-14</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that has reemerged to cause profound epidemics of fever, rash, and arthralgia throughout sub-Saharan Africa, Southeast Asia, and the Caribbean. Like other arthritogenic alphaviruses, mechanisms of CHIKV pathogenesis are not well defined. Using the attenuated CHIKV strain 181/25 and virulent strain AF15561, we identified a residue in the E2 viral attachment protein that is a critical determinant of viral replication in cultured cells and pathogenesis in vivo. Viruses containing an arginine at E2 residue 82 displayed enhanced infectivity in mammalian cells but reduced infectivity in mosquito cells and diminished virulence in a mouse model of CHIKV disease. Mice inoculated with virus containing an arginine at this position exhibited reduced swelling at the site of inoculation with a concomitant decrease in the severity of necrosis in joint-associated tissues. Viruses containing a glycine at E2 residue 82 produced higher titers in the spleen and serum at early times postinfection. Using wildtype and glycosaminoglycan (GAG)-deficient Chinese hamster ovary (CHO) cell lines and soluble GAGs, we found that an arginine at residue 82 conferred greater dependence on GAGs for infection of mammalian cells. These data suggest that CHIKV E2 interactions with GAGs diminish dissemination to lymphoid tissue, establishment of viremia, and activation of inflammatory responses early in infection. Collectively, these results suggest a function for GAG utilization in regulating CHIKV tropism and host responses that contribute to arthritis.</AbstractText>
                <AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">CHIKV is a reemerging alphavirus of global significance with high potential to spread into new, immunologically na??ve populations. The severity of CHIKV disease, particularly its propensity for chronic musculoskeletal manifestations, emphasizes the need for identification of genetic determinants that dictate CHIKV virulence in the host. To better understand mechanisms of CHIKV pathogenesis, we probed the function of an amino acid polymorphism in the E2 viral attachment protein using a mouse model of CHIKV musculoskeletal disease. In addition to influencing glycosaminoglycan utilization, we identified roles for this polymorphism in differential infection of mammalian and mosquito cells and targeting of CHIKV to specific tissues within infected mice. These studies demonstrate a correlation between CHIKV tissue tropism and virus-induced pathology modulated by a single polymorphism in E2, which in turn illuminates potential targets for vaccine and antiviral drug development.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ashbrook</LastName>
                    <ForeName>Alison W</ForeName>
                    <Initials>AW</Initials>
                    <Affiliation>Departments of Pathology, Microbiology, and Immunology Elizabeth B. Lamb Center for Pediatric Research , Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Burrack</LastName>
                    <ForeName>Kristina S</ForeName>
                    <Initials>KS</Initials>
                    <Affiliation>Department of Microbiology , University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Silva</LastName>
                    <ForeName>Laurie A</ForeName>
                    <Initials>LA</Initials>
                    <Affiliation>Elizabeth B. Lamb Center for Pediatric Research , Vanderbilt University School of Medicine, Nashville, Tennessee, USA Pediatrics.</Affiliation>
                </Author>
                <Author>
                    <LastName>Montgomery</LastName>
                    <ForeName>Stephanie A</ForeName>
                    <Initials>SA</Initials>
                    <Affiliation>Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Heise</LastName>
                    <ForeName>Mark T</ForeName>
                    <Initials>MT</Initials>
                    <Affiliation>Departments of Genetics and Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Morrison</LastName>
                    <ForeName>Thomas E</ForeName>
                    <Initials>TE</Initials>
                    <Affiliation>Department of Microbiology , University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dermody</LastName>
                    <ForeName>Terence S</ForeName>
                    <Initials>TS</Initials>
                    <Affiliation>Departments of Pathology, Microbiology, and Immunology Elizabeth B. Lamb Center for Pediatric Research , Vanderbilt University School of Medicine, Nashville, Tennessee, USA Pediatrics terry.dermody@vanderbilt.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Virol</MedlineTA>
            <NlmUniqueID>0113724</NlmUniqueID>
            <ISSNLinking>0022-538X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">JVI.01672-14</ArticleId>
            <ArticleId IdType="doi">10.1128/JVI.01672-14</ArticleId>
            <ArticleId IdType="pubmed">25142598</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142586</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-5514</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of virology</Title>
                <ISOAbbreviation>J. Virol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gammaherpesvirus Latency Differentially Impacts The Generation Of Primary Versus Secondary Memory CD8+T Cells During Subsequent Infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">JVI.02106-14</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Unlike laboratory animals, humans are infected with multiple pathogens, including the highly prevalent herpesviruses. The purpose of these studies was to determine the effect of gammaherpesvirus latency on T cell number and differentiation during subsequent heterologous viral infections. Mice were first infected with murine gammaherpesvirus 68 (MHV68), a model of Epstein-Barr virus (EBV) infection, and then after latency was established, they were challenged with the Armstrong strain of lymphocytic choriomeningitis virus (LCMV). The initial replication of LCMV was lower in latently infected mice and the maturation of dendritic cells was abated. Although the number of LCMV-specific effector CD8(+) T cells was not altered, they were skewed to a memory phenotype. In contrast, LCMV-specific effector CD4(+) T cells were increased in latently infected mice compared to those infected solely with LCMV. When the memory phase was reached, latently infected mice had a LCMV-specific memory T cell pool that was increased relative to that found in singly infected mice. Importantly, LCMV-specific memory CD8(+) T cells had decreased CD27 and increased KLRG1 expression. Upon secondary challenge, LCMV-specific secondary effector CD8(+) T cells expanded and cleared the infection. But, the LCMV-specific secondary memory CD8(+) T cell pool was decreased in latently infected animals, abrogating the boosting effect normally observed following rechallenge. Taken together these results demonstrate ongoing gammaherpesvirus latency affects the number and phenotype of primary versus secondary memory CD8(+) T cells during acute infection.</AbstractText>
                <AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">CD8(+) T cells are critical for the clearance of intracellular pathogens including viruses, certain bacteria and tumors. However, current models for memory CD8(+) T cell differentiation are derived from pathogen-free laboratory mice challenged with a single pathogen or vaccine vector. Unlike laboratory animals, all humans are infected with multiple acute and chronic pathogens, including the highly prevalent herpesviruses Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex viruses (HSV), and varicella zoster virus (VZV). The purpose of these studies was to determine the effect of gammaherpesvirus latency on T cell number and differentiation during subsequent heterologous viral infections. We observed that ongoing gammaherpesvirus latency affects the number and phenotype of primary versus secondary memory CD8(+) T cells during acute infection. These results suggest that unlike pathogen free laboratory mice, infection or immunization of latently infected humans may result in the generation of T cells with limited potential for long-term protection.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Barton</LastName>
                    <ForeName>Erik S</ForeName>
                    <Initials>ES</Initials>
                    <Affiliation>Department of Microbiology and Immunology, Wake Forest University School of Medicine Winston-Salem, NC 27157, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rajkarnikar</LastName>
                    <ForeName>Sujana</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Microbiology and Immunology, Wake Forest University School of Medicine Winston-Salem, NC 27157, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Langston</LastName>
                    <ForeName>P Kent</ForeName>
                    <Initials>PK</Initials>
                    <Affiliation>Department of Microbiology and Immunology, Wake Forest University School of Medicine Winston-Salem, NC 27157, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Price</LastName>
                    <ForeName>Madeline J</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>Department of Microbiology and Immunology, Wake Forest University School of Medicine Winston-Salem, NC 27157, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Grayson</LastName>
                    <ForeName>Jason M</ForeName>
                    <Initials>JM</Initials>
                    <Affiliation>Department of Microbiology and Immunology, Wake Forest University School of Medicine Winston-Salem, NC 27157, USA jgrayson@wfubmc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Virol</MedlineTA>
            <NlmUniqueID>0113724</NlmUniqueID>
            <ISSNLinking>0022-538X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">JVI.02106-14</ArticleId>
            <ArticleId IdType="doi">10.1128/JVI.02106-14</ArticleId>
            <ArticleId IdType="pubmed">25142586</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142581</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-5514</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of virology</Title>
                <ISOAbbreviation>J. Virol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immunogenicity studies of proteins forming the T4 phage head surface.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">JVI.02043-14</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Advances in phage therapy and novel applications of phages in biotechnology encourage interest in phage impact on human and animal immunity. Here we present comparative studies of immunogenic properties of T4 phage head surface proteins gp23*, gp24*, Hoc and Soc, both as elements of the phage capsid and as isolated agents. Studies comprise evaluation of specific antibodies in the human population, analysis of the proteins' impact on the primary and secondary response in mice, as well as the effect of specific antibodies on phage antibacterial activity in vitro and in vivo in mice. In humans, natural antibodies specific to T4-like phages were abundant (81% of investigated sera). Among those, significantly elevated levels of IgG antibodies only against major head protein (gp23*) were found, which probably reflected cross-reactions of T4 with antibodies induced by other T4-like phages. Both IgM and IgG antibodies were induced mostly by gp23* and Hoc, while weak (gp24*) and very weak (Soc) reactivity of other head proteins was noticed. Thus, T4 head proteins that markedly contribute to immunological memory to the phage are: highly antigenic outer capsid protein (Hoc) and major capsid protein (gp23*). Specific anti-gp23* and anti-Hoc antibodies substantially decreased T4 phage activity in vitro and to some extent in vivo. Cooperating with antibodies, the immune complement system also contributed to annihilating phages.</AbstractText>
                <AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Current descriptions of phage immunogenicity and its biological consequences are still vague and incomplete thus the central problem of this work is timely and may have strong practical implications. Here, is presented the very first observation of bacteriophage proteins contribution to immunological memory of the phage. Understanding of interactions between phages and mammalian immunology may help in biotechnological adaptations of phages for therapeutic requirements as well as for better appreciation of phage ecology and their role in the biosphere.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>D??browska</LastName>
                    <ForeName>Krystyna</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland dabrok@iitd.pan.wroc.pl.</Affiliation>
                </Author>
                <Author>
                    <LastName>Miernikiewicz</LastName>
                    <ForeName>Paulina</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Piotrowicz</LastName>
                    <ForeName>Agnieszka</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hodyra</LastName>
                    <ForeName>Katarzyna</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Owczarek</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lecion</LastName>
                    <ForeName>Dorota</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ka??mierczak</LastName>
                    <ForeName>Zuzanna</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Letarov</LastName>
                    <ForeName>Andrey</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Winogradsky Institute of Microbiology, RAS, Moscow, Russia.</Affiliation>
                </Author>
                <Author>
                    <LastName>G??rski</LastName>
                    <ForeName>Andrzej</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland Institute of Transplantology, Medical University of Warsaw, Warsaw, Poland.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Virol</MedlineTA>
            <NlmUniqueID>0113724</NlmUniqueID>
            <ISSNLinking>0022-538X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">JVI.02043-14</ArticleId>
            <ArticleId IdType="doi">10.1128/JVI.02043-14</ArticleId>
            <ArticleId IdType="pubmed">25142581</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
